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Preface 
The number of applications of synthetic biomaterials continues to expand. One 
particularly interesting new development concerns the use of injectable polymeric 
biomaterials, e.g., to correct wrinkles and lips, to treat lipoatrophy in AIDS patients, or 
to treat acne scars. Injection of synthetic biomaterials is also used to treat stress urinary 
incontinence, or vesicoureteral reflux, for vocal cord augmentation, and in various 
embolization strategies, such as those aimed at blockage of tumor-feeding arteries, or 
uterine fibroids. The increase in use of injectable biomaterials has coincided with 
improved imaging techniques, so that minimally invasive treatment of patients has 
become more reliable and safe. Imaging of the injected biomaterials is important to 
control the treatment procedure in real time, to avoid complications and to assess 
therapeutic success. Minimally invasive approaches have set new standards for the 
physico-chemical characteristics of the injectable materials, in so far that they have to 
be easily detectable by clinically available imaging techniques, like X-ray or magnetic 
resonance imaging (MRI). The standard polymeric biomaterials that have been used for 
injection purposes are dominated by inert materials that are poorly visible with standard 
imaging techniques. 
This thesis focuses in particular on the development of new injectable biomaterials that 
combine intrinsic X-ray visibility with a biofunctionality.  
 
Stress Urinary Incontinence 
In 2003, the International Continence Society committee on terminology presented a 
well-considered set of definitions for lower urinary tract functions and dysfunctions. 
The committee defined stress urinary incontinence as follows: 
 
Stress urinary incontinence (SUI) is the complaint of involuntary leakage on effort or 
exertion, or sneezing or coughing [1]. 
 
Incontinence, i.e., the complaint of involuntary leakage of urine, has been known as 
long as written records are being made. Already in the 2nd millennium BC, the 
Egyptians described a series of recipes and treatments for incontinence [2,3]. 
Nowadays, more than 200 million people worldwide live with incontinence. A major 
subset of these patients, approximately 35%, suffers from so-called stress urinary 
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incontinence. SUI is a bladder storage problem in which the strength of the muscles 
(urethral sphincter) that help to control urination is reduced. The sphincter is not able to 
prevent urine flow when there is increased pressure from the abdomen. The disease is 
usually caused by weakening of the pelvic floor muscles that support the bladder and 
urethra or because of malfunction of the urethral sphincter (intrinsic sphincter 
deficiency). The weakness may be caused by prior injury to the urethral area, child 
birth, neurological injury, medications, or after surgery. 
 
 
Figure 1. Front view of bladder. a) Strong sphincter and pelvic muscles keep the urethra closed. 
b) Weak muscles result in urine leakage. 
 
SUI is the most common type of urinary incontinence in women. Studies have shown 
about 50% of all women have occasional urinary incontinence. At least 10% have 
frequent incontinence, and approximately 20% of women over age 75 experience daily 
urinary incontinence. One has to realize that these data represent only the portion of 
women who chose to discuss their symptoms. Owing to embarrassment and other 
factors, fewer than half of the women seek treatment or talk to a physician [4]. 
Therefore, SUI is an important medical and societal problem. More than 65% of the 
treatment-seeking SUI patients in 14 European countries reported that they were 
moderately to extremely bothered by the symptoms [5]. For instance, the impact of SUI 
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on sexual activity in women is considerable, since the disease can lead to sexual anxiety 
[6,7]. Furthermore, numerous women avoid sport activities [8]. 
The etiology of SUI is well investigated. The most important risks are: being female, 
age [9-11], childbirth, smoking, obesity, and chronic coughing (e.g., as a result of 
bronchitis and asthma). SUI is most prevalent in white Caucasian women [12,13]. 
Childbirth increases the risk of SUI drastically. The prevalence of SUI in parous women 
is much higher than in nulliparous women, since pelvic floor injuries are common 
during vaginal delivery [14,15]. Menopause is associated with aging of patients, and it 
has been shown that postmenopausal women have higher frequency of SUI, compared 
to peri- and pre-menopausal women [16,17]. Also, women whose mothers and older 
sisters are incontinent have an increased risk of acquiring SUI themselves [18,19]. 
Smoking, which is associated with decreased collagen synthesis, is believed to cause 
weakening of the pelvic floor’s supportive muscles [20]. The association between SUI 
and obesity is probably a consequence of the fact that excess weight places extra 
pressure on the pelvic floor, compromising the outlet [21]. 
It seems logical to suppose, that physically fit woman have a strong pelvic floor as a 
result of their regular training, thus have less chance of obtaining urinary incontinence 
problems. But this does not correspond to the facts. Sports involving high impact 
activities such as gymnastics, track and field, and some ball games also pose a 
significant risk to develop urinary incontinence problems [22,23]. Tea drinkers are at 
slightly higher risk for all types of incontinence. A decrease of fluid intake can result in 
improvement of SUI. Intake of caffeine containing beverages has no important effect on 
SUI [24]. Diabetic and pre-diabetic woman have twice the prevalence of stress urinary 
incontinence, compared with healthy woman [25]. 
 
Treatment of SUI 
In 1948 Arnold Kegel introduced pelvic floor muscle training (PFMT) for management 
of SUI [26]. The aim of these exercises, which may actually root in Chinese Taoism, is 
to strengthen the muscles which support the urethra, bladder sphincter muscles, via 
permanent elevation of the levator plate into a higher location inside the pelvis, 
increased muscle volume, strengthened connective tissue in the muscles, strengthened 
bony connections, and more effective recruiting of motor neurons [27]. Long-term 
results of PFMT program are unclear. Symptoms tend to worsen on the long run and 
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women then prefer alternative treatments [28]. Another considerable argument against 
this method is the conviction that PFMT must be done permanently. But because of the 
lack of risk and relatively small cost, PFMT is recommended by health professionals as 
a first-line therapy [29]. 
Pharmacological treatment of SUI has been attempted, but with moderate success. The 
mixed serotonin/noradrenaline reuptake inhibitor Duloxetine was used. Duloxetine was 
believed to increase the strength of urethral sphincter contraction and to increase 
bladder outlet resistance, thereby, prevent accidental urine leakage. However, 
Duloxetine has a wide spectrum of severe side effects, which led to denial of approval 
by the US Food and Drug administration [30-35].  
There are also surgical interventions, which have been practiced for decades. In 1996 
Ulmstein first introduced tension-free vaginal tape (TVT), used as a sling [36]. This 
procedure is performed through a small vaginal and two small abdominal incisions. 
TVT involves placing a narrow strip of synthetic material around the middle of the 
urethra. Surgical intervention of SUI has been associated with some serious 
complications like perforation of the bladder [37], excessive bleeding [38], erosion of 
the sling into the vagina or urinary tract [39-41], and infection. Urethral erosion is 
dependent on the biomechanical and mesh properties of the tape, as well as on surgical 
technique. Complications result in pain and worsening of SUI symptoms [42-45]. When 
the implanted biomaterial meshes extrude from the tissue, infection is almost 
unavoidable and the sling has to be removed. Furthermore, bone anchors used in SUI 
surgery can be associated with pubic osteomyelitis and osteitis pubis. In such cases, 
surgical removal and aggressive treatment with long-term antibiotics is required [46,47]. 
 
Modern minimally invasive therapies for SUI 
During the last two decades, less invasive procedures, aimed at achieving high long-
term cure rates for SUI, have been developed. Most successful are peri-urethral 
injections of a so-called bulking agent. This technique led to very good results, 
especially for the elderly patients, for women who have undergone multiple failed 
procedures, or after radiotherapy where the urethra may have become fixed and scarred.  
From the perspective of biomaterials science, these developments are particularly 
interesting. A variety of different bulking agents have been used; the most commonly 
used materials are cross-linked bovine collagen (Contigen), polydimethylsiloxane 
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(PDMS, Macroplastique), ethylene vinyl alcohol copolymer (Tegress), 
polytetrafluoroethylene (PTFE, Urethrin), carbon-coated zirconiumdioxide beads 
(Durasphere), calcium hydroxylapatite (Coaptite), and dextranomer/hyaluronic acid 
copolymer. Bulking agents are injected carefully in the periurethral tissue. The goal is 
urethral coaptation during the storage of urine, maintenance of that coaptation during 
periods of increased abdominal pressure, and improving sphincter closure.  
 
 
Figure 2. Front view of bladder. a) Urethra with weak muscles results in urine leakage.   b) 
Complete coaptation of the urethra, which is achieved by injection of the bulking agent around 
the urethra. 
 
Degradable bulking agents such as autologous fat tend to relieve symptoms, but have 
comparatively low efficiency and disappointing long-term results. In addition, some 
side-effects were reported, such as granuloma formation, obstructive mass formation, 
urine retention and fat embolism [48-55].  
Ethylene vinyl alcohol copolymer suspended in DMSO (Tegress) was evaluated as 
embolic agent, but was also approved as a bulking agent for treatment of SUI. Recent 
studies not only demonstrated that Tegress may be less efficacious than reported in 
FDA trials, but also that a significant percentage of patients experienced serious 
complications like urethral erosion [56,57]. Injection of solid polydimethylsiloxane 
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(silicone rubber) particles proved to have moderate success, with approximately half of 
the patients being cured after 24 months [58-60]. Furthermore, the misplacement or 
injection of too many silicon particles leads to complications, caused by the invisibility 
of the particles [61,62]. 
Polytetrafluoroethylene paste is a resin with very high molecular weight and high 
viscosity. The material is composed of small particles and has been used to treat SUI 
since 1964. In spite of this, PTFE is not approved in the United States for treatment of 
incontinence, because of dangerous complications, such as distant migration, 
periurethral abscess, urethral diverticulum, urethral granuloma formation, and even 
increased tumor risk [63-66]. 
Durasphere® is composed pyrolitic carbon-coated zirconium oxide beads suspended in 
water–based carrier gel containing beta-glucan. Pyrolytic carbon is inert and 
biocompatible, and is used in implantable medical devices, including replacement heart 
valves [67]. One of the potential advantages is its very low immunogenicity. 
Durasphere® particles are relatively large, 200-500 µm, and radiopaque, which is useful 
for tracing after injection. Durasphere® is non-degradable, therefore concerns were 
raised over long-term durability [68]. In spite of promising clinical data, Durasphere® 
demonstrated some serious complications, among which migration from implantation 
site is the most dangerous one. The obvious dislocation from the implantation site was 
shown in animal studies [69]. Six months after injection of carbon coated beads with 
diameter of 251 to 300 µm, significant migration of these beads was observed into local 
and distant lymph nodes, as well as into the urethral mucosa. The exact reason for bead 
migration remains unclear [70]. Durasphere® injection may result in long-term outlet 
obstruction, which can cause voiding dysfunction, permanent urinary retention and 
periurethral mass formation [71-73]. Urethral prolapse is an uncommon condition, but 
some cases have been described [74]. The long-term efficacy of Durasphere® injection 
is low. At 18 months follow up in 70 patients only 13% of patients considered 
themselves cured, 52.2% improved and 34.7% failed [75]. Another study demonstrated 
that Durasphere® remained effective in 35%, 33%, and 21% of patients at 12, 24, and 36 
months respectively [76]. 
Synthetic calcium hydroxylapatite (CaHa) spheres suspended in a water-based gel 
carrier is a sterile, radiopaque, non-pyrogenic, semi-solid, cohesive implant. It is known 
as Coaptite and Radiesse. Coaptite is used for treatment of SUI and Radiasse is used for 
Chapter 1 
 16
the correction of facial lypoatrophy in HIV patients [77,78]. They differ in size range of 
the microspheres. 
Theoretically, injected CaHa spheres have to form a scaffold for developing soft tissue 
that will gradually replace the gel carrier. For integration in the surrounding tissue, 
fibroblasts have to attach and grow on the surface of the spheres, resulting in anchoring 
at the injection site. Coaptite had promising results beforehand [79]. Nevertheless, the 
implant also has shortcomings. The histology of injected CaHa microspheres 
demonstrated, that microspheres become deformed, appearing irregular, and start being 
adsorbed at 9 months, likely because of enzymatic breakdown of the calcium 
hydroxylapatite [80]. Furthermore, it looks as if CaHa microspheres migrate away from 
the injection site. This migration may result in periureteral fibrosis, ureteric obstruction 
and subsequent renal loss [81]. Moreover, granulomatous reaction can lead to urethral 
prolapse, as early as 3 months after the transurethral injection of calcium 
hydroxylapatite [82]. 
 
Embolization therapy 
Embolization is defined as “therapeutic introduction of various substances into the 
circulation to occlude vessels, either to arrest or prevent hemorrhaging, to devitalize a 
structure, tumor, or organ by occluding its blood supply, or to reduce blood flow to an 
arteriovenous malformation” [83].  
Closure of a target artery can be achieved by use of different embolic agents such as 
synthetic microparticles, pellets, glues, or platinum coils [84,85]. This technique, also 
known as embolotherapy, leads to obstruction of arterial blood flow. Injected particles 
act in the same way as thrombotic emboli [86-90].  
The field of interventional radiology routinely uses artificial microparticles and live-
imaging techniques to specifically block arteries and starve targeted tissues from 
oxygen and nutrients. For this, a catheter is inserted and maneuvered to the target vessel 
that has to be embolized, i.e., blocked. Subsequently, the embolic particles are injected 
into the flowing blood and become stuck in the vessel, blocking the blood flow to the 
downstream tissue.  
Embolotherapy is used in a variety of treatments of: (i) tumors, varicoceles, and organ 
ablation; (ii) hemorrhages, e.g., pelvic, posttraumatic, epistaxis, and hemoptysis; (iii) 
vascular anomalies, e.g., venous, lymphatic, arteriovenous malformations. Also the 
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treatment of inoperable tumors is among the applications of embolotherapy. Tumors 
that lie deep in the brain are an obvious target for embolotherapy although one has to 
keep in mind that such interventions are often more palliative.  
 
 
Figure 3. Overview of different applications of embolization therapy. 
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Furthermore, benign tumors like uterine fibroids can be treated by embolizing the 
feeding artery as an alternative to the common hysterectomy. So in this case 
embolotherapy is a minimally invasive alternative to surgery. Another application of 
embolic particles is the treatment of hemoptysis, i.e., severe bleeding because of trauma 
or of infections in the lungs, e.g., pneumonia can cause heavy bleeding. Embolization in 
such cases is used to stop lethal blood loss of the patient [85, 91-98]. 
 
Embolization of tumors 
Embolotherapy is a new minimally invasive technique for the treatment of solid tumors. 
The embolization is performed pre-operatively, to shrink the tumor and prevent 
excessive blood-loss, or as a palliative treatment of unoperable tumors. The benign 
uterus tumors in women, called uterine fibroids (UF), will be discussed to explain tumor 
embolization in further detail. 
UF consist mainly of smooth muscles and large amounts of extracellular matrix 
containing collagen, fibronectin, and proteoglycan. UF are also called fibromyomas, 
leiomyomas or myomas. They are very common and clinically apparent in about 25% of 
women, but because many commonly used imaging techniques lack resolution, the true 
prevalence may be as high as 77% [99]. 
 
 
Figure 4. Front view of uterus: a) healthy uterus; b) uterus with fibroids. 
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UF can cause abnormal uterine bleeding, resulting in iron-deficiency anemia, 
dysmenorrhea and non-cyclic pelvic pain [100-103]. The enlarging pelvic mass 
contributes to urinary problems and constipation [104-106]. UF are also associated with 
an increased risk of complications during pregnancy, and with infertility [107,108]. In 
other words UF have significant impact on the quality of life of women [109]. 
Even there are no systematic estimates of the total healthcare and productivity-loss costs 
attributable to uterine fibroid, the high cost of procedures used to treat (up $11,839 per 
procedure) was reported [110].  
Interestingly, race is an important risk factor for UF. Black women are more likely than 
white women to have uterine fibroids, are more likely to have multiple fibroid tumors 
too. Black women are also younger at diagnosis than white [111,112]. 
The prevalence of UF definitely increases with age with a peak around the menopause 
and decreases after menopause. However, UF are present in the sixth, seventh, and even 
the eighth decade [113,114]. First-degree relatives of women with UF have a 2.5 times 
increased risk of developing myomas. Furthermore, cytogenetic, molecular and 
epidemiological data strongly suggest a genetic component in the etiology of fibroids 
[115,116]. Body mass index and weight gain exhibit a complex relation with risk of UF. 
This can be supposed that women with greater upper body obesity have decreased sex 
hormone-binding globulin levels, altered estrogen metabolism and some other such 
factors, which may promote tumor development [117]. 
There are also several factors that surprisingly decrease the risk for UF among which 
are smoking, pregnancy, and exercise [99]. This does not mean that smoking is an 
advised therapy in the prevention of UF, or can be used as an excuse for smoking. 
Treatment of UF is relatively crude; surgical removal of the uterus, hysterectomy, is the 
most common method. In the US only, approximately 600,000 hysterectomies are 
performed annually, with uterine fibroids accounting for approximately 40% of all 
hysterectomies [118]. Especially for younger women, hysterectomy means that the 
possibility for child birth is gone and this may have serious psychological effects. Also, 
hysterectomy often does not relieve symptoms in several women, and some women 
reported new symptoms, such as hot flashes, weight gain, and depression [119,120].  
Myomectomy is the surgical removal of uterine fibroids with preservation of the uterus. 
This is an invasive surgical technique, which can be performed in several different ways 
depending upon the size, number and location of the UF. There are three approaches to 
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myomectomy: abdominal, laparoscopic, and hysteroscopic. Despite preserving fertility, 
myomectomy has complications. Most common complications of myomectomy are 
damage and infections of surrounding organs; damage, weakening and scaring of 
womb, which can lead to complications during the pregnancy such as rupturing the 
womb wall; bleeding, that can lead to full hysterectomy [121-123]. 
Medications for uterine fibroids do not eliminate fibroids, but may shrink them. Target 
hormones regulate menstrual cycle, treating symptoms such as heavy menstrual 
bleeding and pelvic pressure. The most commonly reported adverse effects of 
progesterone receptor modulators were headache, abdominal pain, nausea, dizziness, 
and metrorrhagia [124]. Side effects such as muscle cramps, acne, fluid retention, 
unwanted hair growth, weight gain, and deeper voice can occur during androgen therapy 
[125].  
 
 
Figure 5. Angiographic catheter is introduced into the femoral artery through the small opening 
in the groin. Microspheres are injected into the artery that is supplying the fibroids and block 
these arteries. 
  
An alternative treatment of uterine fibroids is called embolotherapy. This means that the 
feeding arteries to the fibroids are blocked by localized injection of microparticles. As a 
consequence, the fibroids will become devoid of oxygen and nutrients. The mass of the 
UF will diminish over time and the symptoms will thus be reduced. The interventional 
radiologist has the choice of a number of synthetic microparticles that can be used for 
the embolotherapy.  
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These particles are however not ideal because: i) they are not visible under standard 
clinical conditions (X-ray); ii) they are irregular in shape and size; iii) they are inert and 
the interaction with the surrounding tissue is unpredictable. The lack of radiopacity, i.e., 
X-ray visibility forces the interventional radiologist to guess how much particles have 
been injected and where these end up. Therefore the currently used microparticles are 
mixed with liquid contrast agent to at least get some idea of where the injected particles 
end up. Also, in this way reverse flow, and unwanted embolization distant from the 
intended site, can be avoided. The current embolization-microparticles are irregular in 
shape. This may lead to obstruction in the catheter and incomplete embolization, leaking 
blood to the down-stream tissues. In practice microspheres are the ideal embolic 
particles. After embolization the microparticles induce a reaction from the surrounding 
tissue. Severe inflammatory reactions are in general undesirable, and also angiogenesis, 
formation of collateral vessels is surely not wanted. The preferred tissue reaction would 
be inertia, leaving the down-stream tissues devoid of oxygen and nutrients. 
 
Aim of thesis  
The research described in this thesis set out to achieve improvements over the injectable 
polymeric biomaterials that are currently in clinical use. Most of the commercially 
available particulate injectables are composed of inert polymers. These materials are 
radiolucent, i.e., the particles are invisible on X-ray images. Obviously, this hampers 
their retrieval once they have been injected in the body. Note that other imaging 
techniques, notably magnetic resonance imaging, are also of limited use for localization 
of small polymer particles. Some commercially available injectable particles are 
radiopaque; the most important example is DuraSphere®. These particles consist of 
ZrO2. For DuraSphere®, however, the advantage of the X-ray visibility is 
counterbalanced by the fact that the particles have a high density (around 6 g/cm3). 
Presumably, the high density of DuraSphere® particles is responsible for the fact that 
these particles have a tendency to migrate from the site of injection [70]. Our key 
hypothesis was that methacrylate copolymers that contain covalently bound iodine 
would offer a promising approach to injectable particles that uniquely combine: 
adequate radiopacity, spherical shape, a high level of biocompatibility and a density 
which is comparable to the density of soft tissues. This approach is a logical extension 
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of previous work from the laboratory on polymeric biomaterials featuring intrinsic 
radiopacity, on the basis of incorporation of covalently bound iodine [126,127,128]. 
We chose to focus on poly(methacrylate) copolymers, since these already find 
widespread use as implant biomaterials. Radiopacity was introduced through either 
monomer 2-[4,-iodobenzoyloxy] ethyl methacrylate (4-IEMA), or monomer 2-
[2’,3’,5’,-triiodobenzoyloxy] ethyl methacrylate (2,3,5-TIEMA), shown in Figure 6 and 
7, respectively. Note that these monomers have a reactive methacrylate group on one 
side, and an iodine-bearing aromatic ring on the other side. Both monomers were 
copolymerized with methyl methacrylate, 2-hydroxy ethyl methacrylate or N-
vinylpyrrollidinone, always in temperature-controlled free-radical polymerization 
reactions. 
O
O
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Figure 6. 4IEMA 
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Figure 7. 2,3,5-TIEMA. 
 
We have become familiar with the copolymer materials that are produced in such 
reactions. For instance, an animal study demonstrated that these radiopaque materials 
are stable in vivo over a long period of time (2 years) [129]. In one case, an official CE-
certification for an implant medical device that was based on an iodine-containing 
copolymer was awarded. Through the use of different co-monomers, it proved possible 
to manipulate the properties of the resulting copolymers. This is especially valuable 
with regard to hydrophilicity an aqueous swelling. Completely new hydrogel 
biomaterials, which combine radiopacity and controlled uptake of water, 
biocompatibility, and surprisingly high resistance to fatigue, emerged form this work.  
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Preparation of microspheres with the desired properties proved to be possible. Two 
routes of preparation were explored: solvent evaporation and suspension 
polymerization; each proved effective after careful optimization of several essential 
parameters. We further investigated the biocompatibility of these particles, both in vitro 
and in vivo. Finally, we added and additional functionality through chemical 
modification of the surface of the radiopaque spheres. A method was explored to attach 
proteins, such as thrombin and collagen. In the case of thrombin, we found that the 
enzyme retains its activity, at least partially, after immobilization.  
Chapter 2 describes the first production of small microspheres using the 2,3,5-TIEMA 
monomer. For this, copolymer was produced in bulk, dissolved in an organic solvent, 
and dripped slowly in a stirred aqueous solution containing a stabilizing agent to obtain 
small droplets. Upon evaporation of the solvent, small microspheres were obtained that 
are visible under standard clinical X-ray conditions (mammography). A prerequisite for 
all injectable biomaterials is their biocompatibility. The iodine-containing microspheres 
were shown to be devoid of any cytotoxicity in vitro. 
Biocompatibility was further investigated in Chapter 3 where we studied the behavior of 
the microspheres in rats over a period of 3 months. Both subcutaneous and 
intramuscular injection of the microspheres, suspended in collagen, demonstrated the 
microspheres to be nicely biocompatible. 
Chapter 4 describes a different method of obtaining X-ray visible microspheres. 
Suspension polymerization results in microspheres that are more uniform and the 
control over size and shape are improved. Furthermore, the problem of the inert surface 
of the microspheres is tackled in this chapter. Heating of the microspheres in strong 
alkaline environment results in the formation of carboxylic groups on the surface, which 
can be used to anchor active protein. The addition of protein on the surface may be of 
importance to anchor the spheres more strongly in the tissue, preventing the problem of 
microsphere migration.  
In Chapter 5 this biofunctionalization is improved by addition of methacrylic acid in the 
suspension polymerization, resulting in microspheres with surface carboxylic groups. 
This method is more controllable than the one described in Chapter 4. As an example, 
active thrombin, the key enzyme in blood coagulation, was coupled to the spheres in 
order to enhance embolization therapy. The clotting of blood upon mechanical closure 
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of e.g., a tumor-feeding artery or a severely bleeding artery, may lead to faster and more 
stable closure of the blood vessel.  
In Chapter 6 biofunctionalization was achieved by the synthesis of microspheres with 
surface aldehyde groups. Coupling of collagen should result in improved adhesion of 
cells and ultimately better anchoring of microspheres in surrounding tissue. 
In Chapter 7, the synthesis of a different sort of microspheres is described. The X-ray 
visible microspheres are designed to slowly swell in aqueous environment. This has 
several advantages for embolotherapy. First of all these microspheres are compressible, 
which can avoid microspheres getting stuck in the catheter. Also the microspheres could 
potentially anchor themselves tightly in the artery by swelling in situ and blocking 
blood-flow completely. 
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Abstract 
The copolymer of methyl methacrylate (MMA) and 2-[2’,3’,5’-triiodobenzoyl]oxoethyl 
methacrylate (1), ratio 3:1 (mass/mass) was prepared via a free-radical polymerization 
in bulk. The copolymer (Mw = 97.9 kD and Mn = 41.5 kD) was dissolved in chloroform 
and subsequently transformed into beads with a diameter in the micrometer range, using 
a solvent evaporation technique. The resulting microbeads were characterized by 
different techniques, including NMR spectroscopy, differential scanning calorimetry, 
gel permeation chromatography, and scanning electron microscopy. The latter technique 
was used as the basis for statistical analysis of the bead size. Typically, an average 
diameter of 96 µm and a standard deviation of 21 µm were obtained. The beads were 
also subjected to some preliminary test regarding cytotoxicity. The copolymer of MMA 
and 1 contains covalently bound iodine. Therefore, the material is intrinsically 
radiopaque, i.e., capable of adsorbing X-radiation while no contrast additive is needed. 
Our interest in these microspheres stems primarily from their possible utility as 
injectable and afterward traceable (radiopaque) bulking agents, e.g., for use in urology 
for the treatment of female stress incontinence due to sphincter deficiency. As a first test 
into this direction, a sample of the microbeads was mixed with ethylene glycol, and the 
resulting suspension was studied with respect to injectability and radiopacity. The 
results suggest that the radiopaque microbeads may provide access to improved bulking 
agents. Further modification of the surface may be necessary in order to suppress the 
migratory aptitude of the radiopaque polymeric microspheres in vivo. 
 
Introduction 
Polymeric beads with a diameter in the micrometer range find use in various medical 
applications, such as bone dements (powder fraction) [1], in local delivery of drugs [2], 
and in treatment of female stress urinary incontinence [3,4]. Medical microspheres 
usually consist of poly(methyl methacrylate) (PMMA), poly(lactic acid-co-glycolic 
acid), poly(tetrafluoroethylene) (PTFE), or silicone rubbers. A particularly important 
application of microspheres relates to their use as so-called bulking agents; the 
microspheres are injected via a syringe, usually as a suspension in a collagen solution. It 
is known that injected microspheres have a tendency to migrate, depending on their 
size. It is believed that beads with a diameter > 80 µm are unlikely to migrate [5], but it 
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remains unclear how other factors (such as the exact site of the injection) might 
influence their migratory aptitude. 
Herein, we report the preparation of new polymeric microspheres with clear X-ray 
visibility (radiopacity). In principle, this feature offers the advantage that injected beads 
can be detected through X-ray fluoroscopy, not only shortly after the injection but also 
on the long term [6]. Microspheres consisting of PMMA, PTFE, or silicon rubbers are 
radiolucent, i.e., invisible on the X-ray image. The practical utility of microspheres with 
X-ray visibility lies in the fact that the clinician can assess possible migration in a direct 
manner. This information may provide guidance in cases where a second injection of 
bulking agent is necessary (repeated treatment). 
The microspheres which are described in this work are made out of a polymer that 
belongs to the poly(methacrylate) family. A copolymer of methyl methacrylate (MMA) 
and a methacrylate that contains covalently bound iodine in the side chain was used. 
The copolymer features intrinsic radiopacity; i.e., it has the capacity to absorb X-
radiation while no radiopaque additive is used. Biomaterials of this type have proven 
biocompatibility and stability in vivo [6], which may explain the increased interest in 
these biomaterials over the last years [7]. The copolymer used in this work was 
synthesized from MMA and 2-[2’,3’,5’-triiodobenzoyl]oxoethyl methacrylate (1), via a 
free-radical polymerization in bulk. We report synthesis and physicochemical analysis 
of the copolymer with ratio MMA:1 = 3:1 (mass:mass).  
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Furthermore, we describe a reproducible procedure, based on a solvent evaporation, for 
transformation of the crude materials into microspheres with a mean diameter of 
approximately 96 µm and a standard deviation of 21 µm. Size and size distribution 
could be varied, and the most important process parameters to accomplish this were 
identified. In addition, it is shown that the microspheres have clear X-ray visibility after 
injection in a realistic model system. Furthermore, the microspheres were tested with 
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respect to their biocompatibility in vitro. Finally, it is discussed that these microspheres 
are potentially useful as bulking agents which can be traced by X-ray fluoroscopy, after 
their implantation, e.g., for treatment of stress urinary incontinence. 
 
Materials and Methods 
Materials 
All materials were purchased from Sigma/Aldrich/Fluka chemicals, Acros Organics, 
and Invitrogen. MMA was distilled at atmospheric pressure and stored at -20 ºC. 2-
Hydroxyethyl methacrylate (HEMA) was distilled under reduced pressure (13 mbar) 
and stored at -20 ºC. Tetrahydrofuran (THF), dichloromethane, and triethylamine (TEA) 
were distilled from calcium hydride and stored over either 3 Å molecular sieves (THF, 
dichloromethane) or potassiumhydroxide pellets (TEA). 
 
Synthesis of 2-[2’,3’,5’-triiodobenzoyl]oxoethyl methacrylate (1)  
At room temperature, thionyl chloride (19.00 g, 159,70 mmol) was added dropwise to a 
magnetically stirred solution of 2,3,5-triiodobenzoic acid (40.00 g, 80.13 mmol) in 300 
mL of anhydrous THF. After completion of the addition, the reaction mixture was 
heated, refluxed (30 min), and then allowed to cool to ambient temperature. All volatiles 
were removed under reduced pressure (stench!). The residue, 2,3,5-triiodobenzoyl 
chloride, was dissolved in 450 mL of anhydrous dichloromethane. The solution was 
magnetically stirred and cooled to -5 ºC, and a solution of HEMA (11.47 g, 88.14 
mmol) and TEA (32.43 g, 320.52 mmol) in 50 mL of anhydrous dichloromethane was 
added dropwise. After the addition was completed, the ice bath was removed, and 
stirring was continued for 1 h at room temperature. Then, the reaction mixture was 
again cooled -5 ºC, and water (approximately 150 mL) was added carefully. The 
reaction mixture was transferred into a separatory funnel, and the organic layer was 
separated. The organic layer was washed with 0.1 M sodium bicarbonate (once) and 
with brine (twice), dried over MgSO4, filtered, and concentrated. The crude product was 
recrystallized from hexane/ethanol to afford 1 as a white solid in 77% yield, mp 95.5 ºC. 
1H NMR (CDCl3): δ 1.95 (s, 3H, CH3), 4.48 (d, 2H, CH2CH2), 4.57 (d, 2H, CH2CH2), 
5.61 (s, 1H, CH2=C), 6.16 (s, 1H, CH2=C), 7.73 (s, 1H, arom), 8.29 (s, 1H arom). 13C 
NMR (CDCl3): δ 18.67, 62.24, 64.23, 94.02, 106.96, 113.78, 126.75, 135.99, 137.44, 
141.15, 149.13, 165.85, 167.24. 1H and 13C NMR spectra were recorded at 399.6 and 
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100.6 MHz, respectively, on a Varian Unity-Plus spectrometer using deuterated 
chloroform as the solvent. Tetramethylsilane was used as the internal standard (δ = 0.00 
ppm). 
 
Polymerization  
A 500 mL round-bottom flask was charged with 1 (10.00 g, 16.34 mmol) and MMA 
(30.00 g, 299.64 mmol), dibenzoyl peroxide (BPO, 1.2 mol%, 0.92 g, 3.80 mmol) as 
initiator, and N,N-dimethyl-p-toluidine (0.13 mL, 0.91 mmol) as accelerator. Monomers 
1 and MMA were miscible at room temperature in the mass:mass ratio 1:3; further 
increase of the content of 1 resulted in a inhomogeneous mixture and, hence, a 
nonhomogeneous copolymer. The flask was placed in a thermostated oil bath, equipped 
with a programmable time-temperature control system (PM LAUDA, Könogshausen, 
Germany). The temperature profile as show in table 1 was run. The procedure afforded 
the copolymer as an amber-like solid. The procedure involves relatively slow 
polymerization at 60 ºC, and subsequent thermal treatment at 80 and 100 ºC. It is our 
experience that this temperature profile results in high conversions (typically >95%). 
Presently, a conversion of approximately 96% was achieved, as judged by 1H NMR of 
the crude polymer. Remnants of unreacted MMA and 1 were still present, vide infra. 
 
Table 1. Temperature Profile for the Polymerization 
temperature (ºC) time (h) temperature (ºC) time (h) 
1) heat to 60 0.5 5) heat to 100 1.0 
2) maintain at 60 8.0 6) maintain at 100 4.0 
3) heat to 80 1.0 7) cool down to 40 2.0 
4) maintain at 80 4.0   
 
Preparation of microspheres  
The copolymer was dissolved in chloroform (150 mg/mL). The solution was added 
dropwise to a mechanically stirred (500 rpm) solution of 12 g of detergent (Dubro, 
Proctor & Gamble) in 2 L of distilled water. Other detergents tried were Triton, Tween 
(both nonionic detergents) and sodium dodecyl sulfate (anionic). 
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Figure 1. Overall proton NMR spectrum (δ 9.0 to -0.5 ppm) of a sample of the radiopaque 
microspheres, after redissolution in deuterated chloroform. The spectrum provides evidence for 
the composition and purity of the material. A and B are expansions of the spectral regions δ 6.65-
4.20 and 8.65-7.55 ppm. The two broadened singlet peaks in A correspond with the methylene 
protons of iodine-containing elements in the polymer chain. The two broadened singlet peaks in B 
correspond with the aromatic protons in the same elements. Assignments of the resonances in the 
overall spectra are as follows: a, sharp singlet of CHCl3 traces in the solvent; b, pendant OCH3 
groups; c, methylene protons in the polymer chain; d, singlet due to trace of water in the solvent; 
e, pendant CH3 groups; f, tetramethylsilane (reference, δ = 0 ppm). 
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No microspheres were obtained with Triton X-100 (poly-(oxyehtylene)(10)-
isooctylhexyl ether (CAS # 92046-34-9), 4-(C8H17)C6H4C6H10(OCH2CH2)nOH (n = 
10)), or Tween 20 (poly(oxyethylene)(20) sorbitan monolaureate (CAS # 9005-64-5)), 
and sodium dodecyl sulfate performed less satisfactorily, as compared to Dubro. 
Stirring was continued overnight at room temperature to remove the chloroform (fume 
hood). Then, stirring was stopped and the microspheres were allowed to precipitate. The 
microspheres were thoroughly washed with water (2x), ethanol (3x) and water (3x). The 
microspheres were transferred into a 100-mL round-bottom flask and dried by 
lyophilization. Yield: 76%. 1H NMR (CDCl3): δ 0.71-2.10 (aliphatic H), 3.59 (OMe), 
5.30 and 4.52 (methylene H), 7,81 and 8.36 (aromatic H) see Figure 1. 
 
Scanning Electron Microscopy (SEM)  
Morphology and size of the microspheres were characterized using SEM (RJ Lee 
PSEM75, Goffin Meyvis, Etten Leur, The Netherlands). The microspheres were stuck 
on an aluminum stub with double-face adhesive carbon tape. The stubs were coated 
under vacuum for 2 min with a thin layer of gold and examined at an accelerating 
voltage of 20 kV. Three different windows of view were chosen, and approximately 300 
spheres were included in each determination of average size and size distribution. 
 
Differential Scanning Calorimetry (DSC)  
Samples (approximately 14 mg) placed in aluminum pans were analyzed with a Perkin-
Elmer-DSC-7 instrument at a heating rate of 10 deg/min. Each sample was heated 
beyond the glass transition temperature, cooled rapidly, and heated again. The data 
presented were collected during the second heating scan. The glass transition 
temperature was taken as the midpoint of the heat capacity change. Indium and gallium 
were used as standards for temperature calibration. 
 
Gel Permeation Chromatography (GPC) 
GPC was performed using a Water Wisp autoinjection apparatus (Millipore Corp., 
Milford, MA), equipped with 105, 104, and 103 µ-Styragel (Alltech, Deerfield, IL). THF 
was used as the mobile phase at a flow rate of 1.0 mL/min. Detection was based on UV 
(UV 440, ambient conditions) at 254 nm and reflective index (RI 410, 40 ºC). 
Calibration was against a series of polystyrene standards (580 to 6 x 106 Da). We realize 
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that use of these standards does not provide an accurate measure of MW and MN of our 
copolymer, which will have a different “molecular density” as compared to polystyrene 
(i.e., different Mark-Houwink constant). Nonetheless, the experiment values for MW and 
MN, as derived from the GP chromatograms and using the polystyrene standards, allow 
us to conclude that the copolymer was a mixture of genuine macromolecules (vide 
infra). 
 
X-ray Visibility  
The radiopacity of the microspheres was tested in a realistic model, under routine 
hospital conditions. First, a suspension of microspheres in ethylene glycol was made 
(500 mg of microspheres/1.00 mL of ethylene glycol). The suspension was transferred 
into a 2-mL syringe. A chicken leg, purchased in a local supermarket, was used as a 
model. The microsphere suspension was injected into the soft tissue, and the model was 
examined with a Philips Optimus Z75C radiodiagnostic system. 
 
Cytotoxicity  
Microspheres were sterilized with UV light for 15 min and subsequently incubated for 
48 h in culture medium at 37 ºC. Culture medium used was Dulbecco’s modification of 
eagle medium/F-12 nutrient mix containing Glutamax-I and supplemented with 10% 
fetal bovine serum and antibiotic/antimycotic solution (1x). Mouse 3T3 fibroblasts were 
inoculated into a 96-well tissue culture plate (TCP) at a density of approximately 103 
cells/well. The cells were cultured to semi-confluence, in an incubator at 37 ºC and 5% 
CO2 at high (near 100%) humidity for 3 days. The incubated microspheres were placed 
in the wells in such a way that estimated 15-20% coverage of the total area by the 
spheres was achieved. The remaining extract medium, 100 µL, was separately added to 
the cells. TCP was used as a negative control, and latex was used as a positive control. 
Cells were cultured for another 3 days. Then, the medium was removed and replaced 
with culture medium containing thiazolyl blue (MTT, 0.5 mg/mL). The cells were 
cultured for 1-2 h, the medium was removed, and the formed precipitated formazan was 
dissolved in dimethyl sulfoxide (DMSO). The absorbance of the samples was 
determined using a microtiter plate reader at 550 nm. 
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Direct Cell Contact Assay  
Mouse 3T3 cells were inoculated into a 24-well TCP at a density of approximately 25 x 
103 cells/well. The same culture medium as described above was used. The cells were 
incubated at 37 ºC and 5% CO2 overnight. When the cells were semi-confluent, a 
suspension of the microspheres in culture medium (50 µg/mL) was added to the cells. 
Cells were cultured for another 4 days and examined with light microscopy. Pictures 
were taken. Light microscopy was performed on a Leica DM-IL inverted microscope 
equipped with a Sony DSC-70 digital camera. 
 
Results and Discussion 
The two-step synthesis of 1, starting from 2,3,5-triiodobenzoic acid and HEMA, 
proceeded smoothly and with satisfactory overall yield (77%). The subsequent free-
radical copolymerization of 1 and MMA was run in bulk, using dibenzoyl peroxide and 
N,N-dimethyl-p-toluidine as radical initiator and accelerator, respectively. 1H NMR 
analysis of the crude product revealed that the conversion was approximately 95%. Both 
unreacted MMA and 1 were present, as judged by four singlet resonances in the spectral 
region δ 6.2-5.5 ppm. 
The key step in the preparation of the microspheres was the dropwise addition of the 
copolymer-in-chloroform solution to the stirred solution of detergent in water. Upon 
falling in the turbulent aqueous medium, each drop of the copolymer solution is split 
into numerous smaller droplets. These are stabilized by the detergent. Continuous 
stirring results in evaporation of the chloroform. Several experimental parameters were 
found to influence the average size and the size distribution of the microspheres. The 
concentration of the polymer-in-chloroform solution was set at 15 g/100mL. This 
resulted in microspheres with average diameter of 96 µm, and a standard deviation of 21 
µm (vide infra). At lower concentrations, the average diameter became smaller (e.g., 25 
µm (6 µm standard deviation) at 5 g/100mL). At higher concentrations, the procedure 
failed in most cases; a clump of polymer then attached to the rotor blade. Another 
important parameter, although less sensitive, was the speed of stirring. The optimal 
speed was found to be 500 rpm. Slower stirring resulted in broader size distributions, 
whereas faster stirring was practically impossible. A third important parameter was the 
height from which each drop fell into the detergent solution: this height was fixed at 
approximately 10 cm. With respect to the detergent, it was found that the most 
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satisfactory results were obtained with the commercial household detergent Dubro, at a 
concentration of 6 g/L. After a series of test experiments, the other experimental 
parameters were chosen as follows: 2 L of detergent solution in a 4-L conical glass 
vessel, addition of 100 mL of the copolymer solution, time of addition 30 min. 
The microspheres precipitated readily when stirring was stopped (typically 18 h after 
the addition). Workup consisted of several washing steps, including three washings with 
alcohol to remove monomer remnants, and lyophilization. 1H NMR analysis of the 
microspheres showed the absence of free monomer (Figure 1). GPC analysis showed 
that the microspheres consist of genuine macromolecular structures with MW = 97.8 kD 
and MN = 41.5 kD, i.e., polydispersity = 2.4. We realize that these numbers must be 
treated with caution, as a series of polystyrenes was used for GPC calibration, and the 
Mark-Houwink constants for our copolymer and polystyrene are most likely different.  
 
 
Figure 2. Typical scanning electron micrograph of microspheres as obtained by the solvent 
evaporation technique. 
 
Nonetheless, we can safely conclude that the copolymer consists of a mixture of 
genuine macromolecules with a relatively small polydispersity. DSC showed a clear 
glass transition at 104 ºC. Figure 2 shows a SEM micrograph of a typical batch of 
microspheres. Size distributions of all different batches were derived from the SEM 
pictures, by measuring all microspheres in several arbitrarily chosen windows of view. 
Approximately 300 microspheres were incorporated in each analysis. The data were 
sorted into 10 µm intervals. Figure 3 shows a histogram that compiles the results of a 
Injectable Polymeric Microspheres with X-ray visibility   
 41
typical size analysis, showing an average diameter of 96 µm, and a standard deviation of 
21 µm. 
 Figure 3. Size distribution, as measured for a typical batch of microspheres. The data were 
derived from several independent scanning electron micrographs of the same synthetic batch
. 
 
A pilot experiment was conducted in order to check whether the microspheres have 
adequate radiopacity. A suspension of microspheres (500 mg) in ethylene glycol (1.0 
mL) was made and transferred into a 2-mL syringe.  
 
 
Figure 4. Demonstration of the X-ray visibility of injected microspheres, in a representative 
model, a chicken leg as purchased in a local supermarket: (A) X-ray image before the injection 
(filled syringe); (B) X-ray image after the injection. Note that the injected suspension is imaged as 
clearly as the femur and tibia. 
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A fresh chicken leg, purchased in a local supermarket, was used as a realistic model 
which allowed us to compare the X-ray visibility of (i) the microspheres after injection 
in the soft tissue, and (ii) the chicken femur and tibia. Figure 4 shows the X-ray images 
of the chicken leg before (left) and after (right) injection of the microspheres. The 
images of Figure 4 were recorded under normal clinical conditions in equipment that is 
routinely used for the detection of breast tumors. 
The injected microspheres show excellent visibility, as judged by an experienced 
radiologist. It was also established that comparable microspheres of PTFE, PMMA, or 
silicone rubber are practically invisible under the same experimental conditions. 
Two different experiments were done in order to investigate the in vitro 
biocompatibility of the microspheres.  
 
Figure 5. Survival percentage of the mouse 3T3 fibroblast cells in the MTT test. 
 
First, the MTT test was performed, using mouse 3T3 fibroblast cells. Defining adhered 
cell density onto tissue-culture-polystyrene as 100%, it was found that the adhered cell 
density is 88% and 95%, in contrast with the extract and microspheres, respectively 
(Figure 5). 
Second, the growth of mouse 3T3 cells in direct contact with microspheres was 
monitored. After 4 days, the cells formed a confluent layer on the bottom of the well, as 
is shown in Figure 6. Moreover, cells appear to cover parts of the surface of the 
microspheres (arrows), which may be interpreted as additional proof for the non-
cytotoxicity of the material. 
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Figure 6. Light microscopic image of microspheres, after 4 days of incubation with 3T3 mouse 
fibroblast cells. The cells adhere not only to the bottom of the well (polystyrene) but also to some 
of the microspheres, indicating that the material is not cytotoxic. 
 
In 1992, Jayakrishnan and Thanoo already described polymeric iodine-containing 
radiopaque microspheres which are similar to ours [7a,b]. They reported on copolymers 
of (i), the HEMA-ester of iothalamic acid (IEH) and HEMA, and (ii), triiodophenyl 
methacrylate (TIPM) and HEMA [7a]. These copolymers were converted into beads 
with large diameter (mostly >1 mm), also through the solvent evaporation method. The 
monomer IEH has a bulky side chain, which was held responsible for the observation 
that copolymerization of IEH and MMA did not produce a high-molecular-weight 
copolymer. The monomer TIPM has its iodine-containing aromatic ring very close to 
the reactive double bond, which may explain why the copolymerization TIPM + MMA 
also failed. It is for this reason, that Jayakrishnan and Thanoo restricted themselves to 
copolymers based on HEMA [7a]. These microspheres have a slightly hydrophilic 
nature, and it must be assumed that they will absorb some water and become softer after 
implantation. This is undesirable as far as the application as a bulking agent is 
concerned. While Jayakrishnan and Thanoo observed that copolymerization of IEH or 
TIPM with MMA is troublesome, we have now found that the copolymerization MMA 
+ 1 proceeds smoothly. The resulting microspheres consist of hydrophobic building 
blocks exclusively. Therefore, they will retain their hardness after implantation. 
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We anticipate that the present microspheres can be helpful in the search for an improved 
treatment of female stress urinary incontinence, caused by intrinsic sphincter deficiency. 
Several injectable bulking agents have been developed specifically for this purpose, but 
their use is still associated with significant drawbacks and complications. Microparticles 
of PTFE, formulated in a paste, have been used with reasonable success, but the safety 
of this material is uncertain for two reasons: (i) the tendency of PTFE microbeads to 
migrate away from the implantation site to lymph nodes, lungs, and brain [8] and (ii) the 
risk for granuloma formation (sometimes called “Teflonoma”) [9]. Silicone rubber 
particles, suspended in hydrogel, appear to work better than PTFE. Distant migration 
was found, but only for particles smaller than 70 µm [5,10]. The long-term risks of 
silicone microbeads are unknown [3a]. Biological materials, such as cross-linked bovine 
collagen or autologous fat, are biodegradable, and therefore the initial bulking effect is 
usually lost on the long-term. A very promising new injectable bulking agent, consisting 
of biocompatible and non-immunogenic zirconium dioxide beads with a coating of 
pyrolytic carbon (Durasphere®) was introduced recently [3b,11]. However, clear 
evidence of their migration was found [12]. This is a puzzling observation, since 
Durasphere® beads have a large diameter (ranging from 251 to 300 µm); this diameter is 
at least three times larger than the reported threshold for particle size migration (80 µm) 
[5]. A factor that may be responsible in part for the apparent migratory aptitude of 
Durasphere in vivo is the density of the bulk material (zirconium dioxide, 5.89 g/cm3 
density), which is much higher than the density of the surrounding soft tissue 
(approximately 1 g/cm3) [13]. It must be noted that migration of Durasphere® particles 
could be monitored in a straightforward manner, due to their excellent X-ray visibility 
[3b]. Migration of the other polymeric beads (PTFE, silicone) is much more difficult to 
assess, since these polymers are radiolucent. Our new polymeric microspheres share the 
advantage of having clear X-ray visibility with Durasphere®. We envisage two 
additional advantages of the new radiopaque microbeads: (i) a better match of the 
density of the microbeads (approximately 1.35 g/cm3) with the surrounding soft tissue 
and (ii) the possibility for further modification of the surface, e.g., to promote anchoring 
in the surrounding tissue in order to minimize the risk of migration. We have started to 
work on this type of surface engineering of radiopaque polymeric microspheres, 
combined with testing of biocompatibility, functionality, and migratory aptitude in vivo. 
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Conclusion 
The microbeads described in this work are potentially useful as injectable and afterward 
traceable bulking agents. This expectation is based on (i) the combined physical 
properties of the copolymer and the beads, (ii) their non-cytotoxicity, and (iii) their cell 
friendliness, at least with respect to fibroblasts in vitro. With respect to clinical utility, it 
is mandatory that migration of the microbeads, after injection, is prevented. In vivo 
animal experiments to test this point are ongoing. It is of interest that surface 
modification of the microbeads may be required in order to achieve sufficient anchoring 
in the soft tissues of the implantation site.  
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Abstract 
Radiopaque polymeric microspheres have a potential as new bulking agents for 
treatment of stress urinary incontinence (SUI). The advantage over existing bulking 
agents lies in their X-ray visibility in situ; other polymeric bulking agents (e.g., PTFE or 
silicone rubbers) are practically radiolucent (i.e., incapable of absorbing X-radiation). 
Radiopacity is useful in practice because of the high spatial accuracy of X-ray imaging. 
For instance, X-ray fluoroscopy can be used to assess possible migration of the bulking 
agent over time or to provide guidance in cases in which a second injection of a bulking 
agent is necessary (repeated treatment of SUI). Biocompatibility of injected radiopaque 
microspheres was investigated in vivo by using the mouse as a model. Microspheres 
were injected subcutaneously (9 animals) or intramuscularly (9 animals), and follow-up 
was 8 days or 3 months. X-ray fluoroscopy gave clear images of the microspheres as an 
ensemble, and it was found that no migration occurred during 3 months. Histopathology 
confirmed that all microspheres stayed close to the site of the injection. The 
microspheres appeared to be well tolerated; only a few giant cells, manifesting a mild 
inflammatory reaction, were encountered. At 3 months, capillary blood vessels were 
observed throughout the microsphere beds, and macrophages and fibroblast cells were 
seen in between the microspheres. This is encouraging with respect to the intended 
application, although it must be acknowledged that the data refer merely to a mouse 
model. Further experiments with larger, more representative models (rabbit and goat) 
are in progress.  
 
Introduction 
Polymeric spheres with a diameter in the micrometer range find use in several 
therapeutic strategies. Degradable polymer microspheres can be applied as vehicles for 
controlled local administration of drugs. This principle is used in numerous drug 
delivery strategies: 
1. oral administration of low-molecular-weight heparin [1,2],  
2. development of better delivery systems in antisense therapy[3],  
3. controlled local release of cytostatic agents [4,5],  
4. treatment of Heliobacter pylori through mucoadhesive gastric retention [6,7],  
5. oral delivery of insulin [8],  
6. production of systemic and mucosal antibodies in mice [9], and  
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7. sustained release of drugs (gancyclovir) to the vitreous body of the eye [10]. 
 
Nondegradable polymeric microspheres find use in totally different applications; two 
examples may serve to illustrate this. First, microspheres of poly(methylmethacrylate) 
(PMMA) suspended in collagen or dextran microbeads suspended in hyaluronic acid 
gels are used by plastic surgeons and ophthalmologists as soft tissue fillers for facial 
rejuvenation [11]. These materials provide reduction of wrinkles, volume augmentation, 
and contour improvement when injected into lines and furrows. Second, stable 
polymeric microspheres play a role in an emerging technique to treat recurrent stress 
urinary incontinence (SUI) in women [12–14]. We focus in this article on new 
polymeric microspheres that are potentially useful for SUI treatment. SUI is a 
complicated phenomenon that is associated with weakening of the soft tissue around the 
bladder neck. This may result from local denervation after childbearing, estrogen 
deficiency, and/or congenital factors. Periurethral injection of microspheres is a 
promising therapeutic option [12]; the microparticles are believed to provide more 
stiffness to the soft tissue, thus compensating deficiency of the sphincter muscle. 
Periurethral injection therapy for SUI was first described in 1938 by Murless, who used 
sodium morrhuate [15]. The first use of polymer microspheres in SUI treatment dates 
back to 1973 when Berg used poly(tetrafluoroethylene) (PTFE) [16]. Clinical 
experience showed, however, that PTFE is by no means the ideal biomaterial for SUI 
treatment. It is stable, biocompatible, and nonantigenic, but it induces granuloma 
formation [17]. Moreover, PTFE microparticles tend to migrate away from the injection 
site [18], even to distant sites (e.g., lungs, brain, kidneys, and choroids plexus). Other 
biomaterials did not provide an adequate solution, so far. Poly(dimethylsiloxane) 
microspheres were also found to migrate, and collagen-based agents rapidly lost their 
augmenting effect due to degradation in situ [20]. Durasphere®, a new agent consisting 
of microspheres of zirconium dioxide with a coating of pyrolytic carbon, was also found 
to migrate, despite the relatively large diameter of the microbeads (251–300 µm) [21]. 
We recently described the preparation, properties, and biocompatibility in vitro of new 
polymeric microspheres, consisting of a copolymer of methyl methacrylate (MMA) and 
a methacrylate monomer that contains covalently bound iodine [22]. We advocated that 
these microspheres are potentially useful for SUI treatment; they offer an important 
advantage over the existing polymeric agents. Our microspheres can be detected and 
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visualized directly through X-ray fluoroscopy, not only shortly after the injection but 
also on the long term. In this way, the clinician can assess possible migration in a direct 
manner. This information may be very useful in cases in which a second injection of 
bulking agent is necessary (repeated treatment). Here, we report a study on the in vivo 
biocompatibility of the new radiopaque microspheres by using a mouse model. Sterile 
suspensions of the new microspheres in collagen were injected subcutaneously or 
intramuscularly. The animals were sacrificed after 8 days or 3 months. 
 
Materials and Methods 
Materials 
All chemicals were purchased from Sigma/Aldrich/Fluka or Acros Organics. MMA was 
distilled at atmospheric pressure and stored for a maximum of 24 h at -20° C. The 
iodine-containing monomer, 2-[2’,3’,5’-triiodobenzoyl]oxoethyl methacrylate (1) was 
synthesized as described previously [22]. 
 
O
O
O
O
I I
I
 
1 
Analytical methods 
1H and 13C NMR spectra were recorded at 400 and 100.6 MHz, respectively, on a 
Varian Unity-Plus spectrometer using deuterated chloroform as the solvent. Tetramethyl 
silane (TMS) was used as the internal chemical shift reference (δ = 0.00 ppm). 
Morphology and size of the microspheres were characterized by scanning electron 
microscopy (SEM) with use of an RJ Lee Personal SEM75 system (Goffin Meyvis, 
Etten-Leur, The Netherlands).  
Differential scanning calorimetry (DSC) was performed with a PerkinElmer DSC-7 
instrument. Samples (~14 mg) were placed in aluminum pans. The heating rate was 10 
degrees/min. Each sample was heated beyond the glass transition, cooled rapidly, and 
heated again. The glass transition temperature was measured during the second heating 
scan and taken as the midpoint of the heat capacity change. Indium and gallium were 
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used as the standards for temperature calibration. Gel permeation chromatography 
(GPC) was performed on a Waters Wisp autoinjection apparatus (Millipore Corp., 
Milford, MA), equipped with 105, 104, and 103 µ-Styragel columns (Alltech, Deerfield, 
IL). Tetrahydrofuran was used as the mobile phase (flow rate 1.0 mL/min). Detection 
was based on Ultraviolet absorption at 260 nm and refractive index. Calibration was 
against polystyrene standards (580 - 6 × 106 Da) X-ray images were recorded with a 
Philips Diagnost 88 system (40 kV) or with a Bennet-Trex Medical system (24 kV) 
using a protocol for mammography. Both systems are in use in the Department of 
Radiology of the Academic Hospital, Maastricht.  
 
Polymerization 
A 500-mL round bottom flask was charged with 1 (10.00 g, 16.34 mmol) and MMA 
(30.00 g, 299.64 mmol), dibenzoyl peroxide (BPO; 1.2 mol%, 0.92 g, 3.8 mmol) as the 
source of free radicals, and N,N-dimethyl-p-toluidine (0.13 mL, 0.91 mmol) as the 
accelerator.  
 
Table 1. Time-Temperature Profile for the Polymerization 
Step No. Temperature Time (h) Step No. Temperature Time (h) 
1 heat to 60ºC 0.5 5 heat to 100ºC 1.0 
2 maintain at 60ºC 8.0 6 maintain at 100ºC 4.0 
3 heat to 80ºC 1.0 7 cool down to 40ºC 2.0 
4 maintain at 80ºC 4.0    
 
The flask was shaken until homogenization of the contents was achieved and placed in 
an oil bath, which was interfaced with a time-temperature control system (PM Lauda, 
Köningshofen, Germany). The time-temperature profile as outlined in Table 1 was then 
run. This procedure resulted in the desired copolymer as an amber like solid. A 
conversion of approximately 95% was achieved, as judged by 1H NMR of the crude 
material. The NMR spectra showed the presence of traces of unreacted 1 and MMA, 
vide infra. 
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Preparation of microspheres 
The copolymer was dissolved in chloroform by overnight mechanical stirring 
(concentration 150 mg/mL). This solution was added dropwise (in the fume hood) to a 
bowl containing 2 L of distilled water and 12 g of detergent. The contents of the bowl 
were mechanically stirred at 500 rpm. Stirring was continued overnight, which allowed 
the chloroform to evaporate. Stirring was stopped in the morning, and the microspheres 
were seen to precipitate readily. They were thoroughly washed with water (2 times), 
ethanol (3 times), and water (3 times) and transferred into a 100-mL round bottom flask 
and dried by lyophilization. Yield was 84%. 1H NMR (CDCl3): δ 0.71–2.10 (aliphatic 
H), 3.59 (OMe), 4.30 and 4.52 (methylene H), and 7.81 and 8.36 (aromatic H). No 
signals corresponding to unreacted residual monomers (MMA, 1) could be found in 
these NMR spectra; indicating that these were effectively removed during the solvent 
evaporation and the subsequent wash steps. Radiopaque microspheres (3.00 g) were 
mixed with a solution of bovine collagen (10.0 mL, 20%), and this suspension was 
transferred into 10 1-mL syringes. Samples were sterilized with gas (ethylene oxide). 
The formulation stayed homogeneous for > 12 months and proved to be easily 
injectable (23-gauge needle, blue). 
 
Scanning Electron Microscopy 
Microspheres were stuck on an aluminum stub with use of double-faced carbon tape. 
The samples were sputter-coated with gold and examined at an accelerating voltage of 
20 kV. Three different windows of view were chosen, and ~300 spheres were included 
in each determination of average size and size distribution. 
 
Biocompatibility in vitro  
The microspheres passed tests for cytotoxicity and cell friendliness in vitro. These 
experiments (MTT assay, culturing of mouse 3T3 fibroblast cells in direct contact with 
the microspheres) were described previously [22]. 
 
Animal experiments 
This study comprised 18 Adult Swiss mice. All experiments were approved by the 
Maastricht University Animal Experimental Committee. European and Dutch laws on 
animal experimentation were followed strictly. The animals were anesthetized through 
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an intraperitoneal injection with pentabarbital (Nebutal; Ceva, Maassluis, The 
Netherlands). Dose was 100 µg/g body weight.  
Injections were performed as follows: 1) 100 µL of the microsphere/collagen 
suspension were injected underneath the subcutus (9 animals); 2) 50 µL of the 
microsphere/collagen suspension was injected intramuscularly (in the hamstrings, 9 
animals); 3) as controls, only the collagen suspension was injected on the contra-lateral 
side. Sterile 23-gauge needles were used. All animals were subjected to X-ray 
fluoroscopy at two time points: immediately after the injection and just prior to 
sacrificing. Comparing the X-ray images per animal provided information about 
possible migration of the microspheres. None of the animals showed unusual behavior, 
and no premature deaths occurred. Nine animals were sacrificed after 8 days (4 with 
microspheres in the subcutaneous tissue and 5 with microspheres injected 
intramuscularly). The other animals were sacrificed after 3 months. The X-ray images 
provided a convenient guidance during harvesting of tissue parts that contained the 
microspheres. Animals were anesthetized by inhalation of CO2, followed by cervical 
dislocation. Microspheres with surrounding tissue were excised, and the explants were 
immediately immersed in 10% neutral buffered formalin for fixation and left for 24 h at 
least. After rinsing in distilled water and dehydration in an alcohol series (50, 70, 96, 
and 100%), explants were embedded in glycidyl methacrylate (Technovit 7100; Heraeus 
Kulzer, Darmstadt, Germany). Sections (5 µm) were cut and stained with hematoxylin 
and eosin to be used in histopathological evaluations using light microscopy. 
 
Results and Discussion 
Figure 1 represents an SEM micrograph of the microspheres; their average size was 63 
± 18 µm. High resolution 1H NMR spectroscopy of these microspheres, redissolved in 
deuterated chloroform, revealed the absence of unreacted 1 and MMA. 
Apparently, these impurities were removed effectively during microsphere workup. 
This is essential because remnants of unreacted monomer would render the 
microspheres cytotoxic. In the literature, it is generally assumed that the migratory 
aptitude of microspheres is related to their diameter. 
Migration is generally believed to be unlikely when the diameter is larger than 80 µm 
[23,24]. Recent studies have shown, however, that particle migration can also occur for 
much larger diameters (251–300 µm) [21]. This may be explained by the fact that these 
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particles (which are composed of carbon-coated zirconium dioxide) have a significantly 
higher density than the surrounding soft tissue. 
 
 
Figure 1. Scanning electron micrograph showing the microspheres used in this study. Scale bar 
= 100 µm. 
 
We made numerous attempts to enlarge our microspheres further, but this proved to be 
very difficult, whereas increasing the concentration of the copolymer-in-chloroform 
solution leads to high viscosity, which precludes the formation of droplets before 
immersion in the aqueous detergent solution. Mixing of the microspheres with the 
solution of bovine collagen, subsequent transfer to 1-mL syringes, and gas sterilization 
proceeded without difficulties. Several mice were injected from the same syringe; each 
injection was only 50 µL (intramuscular) or 100 µL (subcutaneous). Each injection was 
done with a new sterile needle. 
Figure 2 shows representative X-ray images of mice after subcutaneous (A) or 
intramuscular (B) injection. Note the clear visibility of the microspheres in all cases. 
The X-ray images indicated that all microspheres resided closely packed at the site of 
the injection; no evidence of any particle migration could be inferred from the X-ray 
images.The same conclusion could be drawn from histology. Macroscopically, there 
were no differences between the two time points (8 days and 3 months) and no 
difference between the two sites of injection (subcutaneous and intramuscular). 
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Figure 2. X-ray images of two mice before sacrificing at 3 months. Microspheres are indicated by 
a small white arrow. (A) Subcutaneous microspheres. (B) Microspheres located in the hamstrings 
(intramuscular). 
 
Microspheres were retrieved as closely packed ensembles in all cases. Microscopically, 
we also noted similarity between 8 days and 3 months follow-up. The microspheres 
were well tolerated, irrespective of the site of injection. After 8 days, some 
inflammatory cells invaded the microsphere beds; these were mostly macrophages and 
granulocytes. Most of the macrophages were isolated; in some cases, they fused to form 
a giant cell. 
Figure 3 shows two representative light micrographs of microspheres that resided in the 
subcutaneous tissue for 3 months. Figure 3(A) (low magnification) is an overview of the 
skin with some subcutaneous fat, a thin muscle layer, and the bed of microspheres 
underneath. The microspheres are closely packed, and there is no evidence of any 
particle migration. Figure 3(B) shows a part of the microsphere bed at a larger 
magnification. 
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Figure 3. Light micrographs of subcutaneous microspheres after 3 months of follow-up. (A) d = 
dermis; sf = subcutaneous fat cells; and sm = subcutaneous muscle layer. The microspheres are 
seen in the lower half of this micrograph; scale bar = 1 mm. (B) Part of the microspheres in (A) 
shown at larger magnification; cbv = capillary blood vessel; the arrow points to an endothelial 
cell in the capillary’s wall. The asterisk indicates a microsphere surrounded by a giant cell. Scale 
bar = 100 µm 
 
Invaded macrophages are seen throughout the entire implant site. Most macrophages are 
apart, although in some cases they fused to form a giant cell. The asterisks in Figure 
3(B) mark such giant cells; they consist of several nuclei and surround an entire 
microsphere in an apparent attempt to engulf it. This is an example of frustrated 
phagocytosis. Some invaded fibroblast cells were spotted as well. 
Histology after 8 days and 3 months was different in two subtle respects: 1) 
granulocytes were found only after 8 days and 2) capillary blood vessels were found 
only after 3 months (Figure 3). Red blood cells are seen in the lumen, the small arrow 
points at an endothelial cell. Angiogenesis is not manifest during the 1st week of 
implantation. 
Figure 4 shows a light micrograph of microspheres after intramuscular injection 
(follow-up of 3 months). The microspheres are closely packed, and no polymer 
degradation is seen. All microspheres were found close to the injection site (low 
magnification) (i.e., there is no evidence of particle migration). This is noteworthy 
because these microspheres resided in musculature tissue, which is highly dynamic. 
Macrophages invaded the space in between the microspheres. 
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Figure 4. Light micrograph of intramuscular microspheres after 3 months of follow-up; m = 
muscular tissue; cbv = capillary blood vessel. The arrow points to an endothelial cell in the 
capillary’s wall. Scale bar = 100 µm. 
 
Several giant cells were found; these always surrounded an entire microsphere, in an 
apparent attempt to engulf and degrade that microsphere. Capillary blood vessels were 
present throughout the entire bed of microspheres, which reveals that angiogenesis can 
proceed close to and in between the microspheres. 
We attempted to quantify the migratory aptitude of the injected microspheres on the 
basis of the X-ray images. For each image, we determined the ratio area occupied by 
microspheres: area occupied by the entire animal, as an estimate of the volume fraction 
of the particle-rich tissue. Immediately after injection, the ratio was found to be 0.021 ± 
0.004 (n = 18). After 8 days, the ratio was 0.020 ± 0.005 (subcutaneous, n = 4) and 
0.019 ± 0.006 (intramuscular, n = 5). After 3 months, the ratio was 0.022 ± 0.007 
(subcutaneous, n = 5) and 0.023 ± 0.009 (intramuscular, n = 4). These data do not show 
a statistically significant increase of the area that is occupied with microspheres. By no 
means, however, can this be taken as proof for nonmigration of the particles: the X-ray 
images provide merely vague contours of the injected ensembles of particles, and our 
data sets are far too small for a proper statistical analysis. It is clear, however, that the 
volume of particle-rich tissue never expanded by >10%. 
Finally, it should be noted that we are uncertain about the fate of the collagen that was 
injected with the microspheres. Most likely, it was resorbed quickly, without causing 
any adverse effects. This would explain why the microspheres were found to be closely 
packed already after 8 days. Moreover, we consistently failed at retrieving collagen 
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samples that were injected as contra-lateral controls (both subcutaneously and 
intramuscularly). This could also be explained by rapid degradation and removal of the 
collagen from site of the injection. 
 
Concluding Remarks 
The radiopaque microspheres described here have the potential to become an attractive 
alternative to silicone and PTFE microspheres, which are used clinically as bulking 
agents in, for instance, SUI treatment. Our microspheres bring the benefit of clear X-ray 
fluoroscopic visibility in situ. The data generated in this study provide further support 
for this idea. Microspheres injected into mice showed clear X-ray contrast, and they 
were well tolerated in the subcutaneous tissue as well as in the hamstrings. After 3 
months, capillary blood vessels penetrated the implants, macrophages and fibroblasts 
invaded the space in between microspheres, and giant cells were found only 
occasionally. The presence of the giant cells points at a mild inflammatory response. 
This is considered to be normal (i.e., the microspheres typically behave as a passive 
implant that is not engaged in any interaction with the surrounding tissue). No 
granuloma was observed, and there was no evidence of significant particle migration. 
The histopathological data are reminiscent of our previous study on long-term 
biocompatibility and stability of related iodine-containing radiopaque biomaterials, 
albeit that these were studied as bigger, more massive samples (cylinders with 3-mm 
diameter and 10-mm length) [25]. Taken together, the data reinforce the idea that 
radiopaque polymeric microspheres have potential use as new bulking agents. We 
realize that the mouse model has only little predictive value with respect to the actual 
application, which involves periurethral injection around the bladder neck in humans. 
Current experiments are aimed at further increasing the size of these microspheres. 
Finally in vivo experiments with larger animals, which may provide more realistic 
models, are required to evaluate these radiopaque microspheres as bulking agent. 
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Abstract  
Injectable polymer particles with a diameter in the range 30 – 300 µm find applications 
as a biomaterial in different clinical fields, such as cosmetic surgery, reconstructive 
surgery and urology. However, clinical effects tend to disappear after several months, 
either due to migration of the particles away from the injection site (caused by weak 
adherence with the surrounding soft tissues), or due to fibrosis (caused by excessive 
encapsulation of the particles by fibrous tissue). Little is known about the fate of 
injected microparticles, due to the fact that they are extremely difficult to trace in a non-
invasive manner. Design, synthesis and characterization of new polymeric microspheres 
with two additional features that can enhance safety and can help to overcome 
drawbacks of existing products are reported. First, the new microparticles feature clear 
radio-opacity (X-ray visibility) as they are prepared on the basis of a reactive 
methacrylic monomer that contains covalently bound iodine. Model experiments reveal 
that the level of X-ray contrast is sufficient for clinical monitoring; they can be 
visualized both during the injection and afterwards. The particles feature excellent 
cytocompatibility in vitro and in vivo. Secondly, a method is explored to functionalize 
the surface of the particles, e.g., through immobilization of collagen. Other extracellular 
matrix proteins can also be immobilized, and this provides mechanism to control 
anchoring of the particles in soft tissue. The results are briefly discussed in the context 
of improved biomaterials, contemporary X-ray imaging, and control over biomaterial – 
soft tissue interactions in vivo. 
 
Introduction 
Several medical treatments are based on local injection of polymeric particles with a 
diameter in the 30 - 300 µm range. Augmentation of soft tissues (e.g., correction of lips 
[1], reduction of wrinkles [2],) can be achieved through local injection of a “filler 
agent”, which is a suspension of non-degradable synthetic microparticles in a 
biodegradable solution or dispersion [3]. Another example is found in urology: stress 
urinary incontinence in women (SUI) -defined as the complaints of involuntary leakage 
of urine on effort or exercise, sneezing or coughing- can be treated through precise peri-
urethral injection of polymeric particles [4]. 
There are concerns, however, about possible complications and long-term effects of 
injected polymeric microspheres [5]. Cosmetic fillers can induce the formation of 
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granulomatous tissue, or they may migrate away from the site of injection [6]. Zullo et 
al. have reported that peri-urethral injection of poly(dimethylsiloxane) (PDMS) particles 
to treat SUI had a high initial success rate (90% after 1 month), which decreased to 75% 
after 3 months and 57% after 60 months [7]. This pattern was confirmed in a series of 
other publications [8]. These disappointing long-term effects have been attributed, quite 
generally, to the migratory aptitude of injected microparticles. Indeed, 
poly(tetrafluoroethylene) (PTFE) particles can migrate from the injection site into lungs 
and brain [9]. Analogously, carbon-coated ZrO2 microbeads (Durasphere®) [10], 
injected to treat SUI in patients, were found to migrate into local and distant lymph 
nodes, and into urethral mucosa [11]. The marginal long-term results have prompted the 
industry to introduce a variety of new bulking agents, especially with respect to SUI 
treatment. Most of these agents actually consist of a classic inert biomaterial with a 
well-established record of safety and durability, albeit in totally different applications. 
The most important examples, after PTFE, PDMS and Durasphere® are: glutaraldehyde 
crosslinked bovine collagen (GAX collagen) [12], calcium hydroxylapatite [13], 
dextranomer/hyaluronic acid copolymer (Dx/HA) [14] and autologous fat [15]. Claims 
of improved performance in SUI treatment were usually unsubstantiated. Some new 
agents even led to complications, such as pulmonary embolism (autologous fat) [16], or 
a severe local inflammatory response (GAX collagen) [17].  
Migration of injected or implanted microparticles has been studied in animal models, 
but –to the best of our knowledge- only scarcely in humans [6a].  This may be 
explained, in part, by the fact that commercial particles are extremely difficult to trace 
in vivo. The only exception is Durasphere®, for which the particles have a core of ZrO2, 
a notoriously radio-opaque material [10,11]. However, Durasphere® particles are not 
particularly suitable for long-term model studies in animals; the high density of ZrO2 
(5.89 x 103 kg/m3) may lead to movement of the particles due to gravitation. Here, we 
report on new polymeric microspheres that combine soft-tissue-like density with 
intrinsic radio-opacity; one of the building blocks is 1, a methacrylate monomer that 
contains three covalently bound iodine atoms [18]. The iodine-containing microparticles 
are stable in vivo, and they feature a high level of biocompatibility, both in vitro and in 
vivo. Their radio-opacity allows for accurate non-invasive monitoring through X-ray 
fluoroscopy and micro-CT techniques. 
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Furthermore, our microspheres have a reactive surface, which can be used to 
immobilize a plethora of compounds, such as collagen and other proteins. First, the new 
particles are useful vehicles to study the problem of injected-particle migration in 
animal models. Secondly, the pertaining question whether the anchoring of injected 
particles in soft-tissues can be improved through surface-tethering of molecules that are 
recognised biologically, can be addressed. Ultimately, the use of radio-opaque and 
surface-modified polymeric microparticles as described here, may open the way to safer 
and improved methods to treat SUI or to achieve safer and more long-lasting therapies 
in cosmetic surgery. 
 
Materials and Methods 
Materials 
Chemicals were purchased from Sigma/Aldrich/Fluka, Acros, or Invitrogen. 
Methylmethacrylate (MMA) was distilled at atmospheric pressure and stored at -20 oC. 
2-Hydroxyethyl methacrylate (HEMA) was distilled in vacuo and stored at -20 oC. The 
monomer 2-[2’,3’,5’-triiodobenzoyl]-oxo-ethyl methacrylate (1) was prepared as 
described previously [18d,f]. All other commercially available chemicals were used as 
received. Porcine alkaline phosphatase and FITC-labelled collagen (type I, bovine) were 
from Sigma. Buffer solutions were prepared as follows: MES buffer: 2-(N-
Morpholino)ethanesulfonic acid (MES, 9.76 g, 50 mmol) was dissolved in 1 L of water 
and the pH was set to 5.5 with NaOH. Tris buffer: Tris(hydroxyl-methyl)aminomethane 
(Tris, 6.06 g , 50 mmol) was dissolved in 1 L of water and the pH was set to 9.0 with 
HCl. Carbonate buffer: two solutions were made: NaHCO3 (4.20 g, 50 mmol) in 500 
mL water, and Na2CO3 (5.27 g, 50 mmol) in 500 mL water. These were mixed in the 
ratio 100 mL : 285 mL (Na2CO3 : NaHCO3), which gave pH = 9.6. 
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Microscopy 
Scanning electron micrographs were recorded with a RJ Lee Personal SEM system 
(Goffin-Meyvis, Etten-Leur, The Netherlands). Microspheres were sprinkled onto an 
aluminium stub with double-faced carbon tape. Samples were sputter-coated with gold 
(2 min.) and examined at an accelerating voltage of 20 kV. Approximately 500 
microspheres were included in the analysis of size and size distribution of each batch. 
Light microscopy was performed on a Leica DM-IL inverted microscope, equipped with 
a Sony DSC-70 digital camera. Fluorescence microscopy was performed with Nikon 
Eclipse E800, equipped with an RS Photometrics CoolSNAP camera. 
 
Preparation of microspheres 
A solution of poly(vinylalcohol) (PVA, Mw 86,000; 99-100% hydrolyzed; 1.25 g), 
poly(ethylene glycol) (PEG, Mw 1,000; 1.50 g), and poly(N-vinyl-pyrrolidinone) (PVP, 
Mw 58,000; 250 mg) in 100 mL distilled water was mechanically stirred and heated to 
75 oC. MMA (5.00 g, 49.93 mmol), monomer 1 (1.00 g, 1.63 mmol), benzoyl peroxide 
(125 mg, 0.52 mmol) and tetra-ethylene glycol dimethacrylate (TEGDMA, 340 mg, 
1.03 mmol) were mixed, and this mixture was added dropwise to the stirred aqueous 
PVA-PEG-PVP solution [19]. After the addition, stirring at 75 oC was continued for 3 h. 
The microspheres precipitated immediately as stirring was stopped, and the supernatant 
was decanted carefully. The microspheres were allowed to cool to room temperature, 
and washed (water (3x), ethanol (3x), water (3x)). The microspheres were then taken up 
in boiling water (1 h), decanted, frozen (-180 oC, liquid nitrogen), and lyophilized. 
Yield: 5.04 g (84%). 
 
Surface hydrolysis 
Microspheres (1.00 g), ethylene glycol (50 mL), and KOH (2.80 g) were transferred into 
a 100-mL round bottom flask [20]. The flask was immersed in an oil bath (180 oC), and 
the reaction was allowed to proceed for 5 min. Two identical batches were prepared, 
and these were reacted for 15 and 30 min, respectively. The flask was removed from the 
oil bath, and allowed to cool to room temperature. Microspheres were decanted, washed 
(water, ethanol, water, vide supra), frozen, and lyophilized.  
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Titration of carboxylic groups on microspheres  
Microspheres (100 mg) were resuspended in 100 µL 0.100 M NaOH and 10 µL of 
phenophtalein (400mg in 40 mL 96% ethanol). Carefully small amounts of 0.010M HCl 
were added until the colour changed from bright purple to colourless [21]. Untreated 
spheres that do not contain carboxylic groups needed the same amount of HCl to 
neutralize the solution without spheres. The hydrolyzed spheres were neutralized with 
less HCl. The difference in added volume of HCl is a direct measure for the amount of 
carboxylic groups generated on the spheres by surface hydrolysis. 
 
Cytocompatibility of microspheres 
Mouse fibroblasts (3T3 cells) were grown in DMEM/F12 medium containing Glutamax 
and supplemented with 10% fetal bovine serum and antibiotics (10 U/mL penicillin, 10 
µg/mL streptomycin, 0.25 µg/mL amphotericin B). Cells were harvested with 0.05% 
Trypsin/0.53 mM EDTA and seeded in a 24 well plate at a density of 25,000 cells per 
well. The cells were allowed to attach for 16 hours at 37ºC/5%CO2. Microspheres were 
added in such amount that approximately 20% of the surface was covered by 
microspheres. The cells were allowed to grow for a further 48 hours and subsequently 
photographs were taken with a Leica DM-IL inverted microscope equipped with a Sony 
DSC-70 digital camera. In order to quantify cell viability, after the 48 hour incubation, 
medium was exchanged for medium containing 0.5 mg/mL MTT. The cells were 
incubated for a further 1.5 hours at 37 ºC. MTT is converted into an insoluble 
blue/purple formazan by intact mitochondria, meaning incubation with non-viable cells 
will not result in staining. The medium was aspirated, the formazan was dissolved in 
isopropanol and absorbance at 550 nm was determined as a direct measure for viability. 
 
Surface coupling of coumarin 
Surface-hydrolyzed microspheres (100 mg) were transferred to a 1-mL Eppendorf tube, 
and washed with MES buffer for 30 min [22]. Then, the supernatant was removed. A 
stock solution of reactants was prepared as follows: 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) (191.5 mg, 0.999 mmol), N-hydroxysuccinimide (NHS) (46.5 mg, 
0.404 mmol), and 7-amino-4-methylcoumarin (5.0 mg, 0.029 mmol) were dissolved in 5 
mL of MES buffer. Then, 1 mL of the stock solution was mixed with the washed 
microspheres, and the reaction was allowed to proceed for 2 h.  The tube was mounted 
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on a carousel that rotated at a slow speed. After 2 h, the supernatant was removed, the 
microspheres were washed with MES buffer, and examined by fluorescence 
microscopy. The reaction was run for different batches of KOH-treated microspheres (5, 
15 or 30 minutes treated), and for microspheres that did not receive KOH treatment 
(control). 
 
Protein immobilization 
KOH-treated microspheres (100 mg) were transferred to a 1-mL Eppendorf tube, and 
washed with MES buffer for 30 minutes [23]. The supernatant was removed.  A new 
stock solution was made, as follows: EDC (191.5 mg, 0.999 mmol), and NHS (46.5 mg, 
0.404 mmol) were dissolved in 5.0 mL of MES buffer. Then, 0.5 mL of the stock 
solution and 0.5 mL of MES buffer were added to the washed microspheres. The 
Eppendorf tube was mounted on the carousel and rotated for 30 minutes. The 
supernatant was discarded, and the microspheres were briefly washed with MES buffer. 
As proteins we used: (i), porcine alkaline phosphatase (2 mg/mL in MES buffer); (ii), 
heat-denatured FITC-labeled bovine collagen I (0.8 mg/mL) in carbonate buffer. In each 
case, microspheres pre-treated with EDC and NHS, were incubated with 1 mL of the 
protein solution for 2 h, while the vial was rotated on the carousel. Subsequently, 
microspheres were washed repeatedly with MES buffer.  
Microspheres, to which alkaline phosphatase was coupled, were incubated with p-nitro-
phenylphosphate (PNPP). A solution of PNPP (26.3 mg, 0.1 mmol) and MgCl2 (9.5 mg, 
100 µmol) in 10 mL Tris buffer was made. 1 mL of this solution was added to the 
microspheres. For all different microspheres, control measurements (microspheres 
incubated with alkaline phosphatase but without EDC and NHS) were performed, to 
subtract the contribution of non-specific adsorbed alkaline phosphatase. Aliquots were 
taken regularly, and extinction at 405 nm was determined. Increase in extinction at 405 
nm in time is a direct measure for the amount of converted PNPP and thus of the 
amount of alkaline phosphatase. By comparing conversion rates of the microspheres 
with the rates of known amounts of alkaline phosphatase, the amount of covalently 
bound alkaline phosphatase could be estimated. Collagen-FITC-labeled microspheres 
were examined directly by fluorescence microscopy. Part of the microspheres was 
treated with collagenase (0.5 mg/mL) in 10 mM phosphate buffered saline. 
Fluorescence (ex 485 nm/em 520 nm) was determined with a Gemini XS fluorometer. 
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X-ray visibility  
X-ray contrast of the microspheres was assessed under routine hospital conditions, using 
a digital mammography imaging system (ThermoTrex Corporation, San Diego, CA).  
 
Results and Discussion 
Microspheres  
Iodine-containing radio-opaque cross-linked polymer microspheres readily formed 
within 3 h during suspension polymerization of the mixture MMA + 1 + TEGDMA.  
 
 
Figure 1. Scanning electron micrographs showing the radio-opaque microspheres at two 
different magnifications (see bars). 
 
The yield was 84% after work-up and lyophilization. Monomer 1 was prepared from 
2,3,5-triiodobenzoic acid and HEMA as described previously [18d,f]. The beads were 
washed thoroughly, in order to remove traces of unreacted monomers, which would 
otherwise exert a cytotoxic effect on contacting cells.SEM analysis revealed that the 
beads are smooth, perfectly spherical, and non-porous (Figure 1). Of a typical batch, the 
average diameter was 333 µm, with a standard deviation of 112 µm. Size and size 
distribution were reproducible, although the exact stirring parameters (speed, depth of 
the rotating paddle, flask geometry) influenced the outcome substantially. 
The reaction conditions represent a delicate balance: saponification proceeds very 
slowly at lower temperatures, and higher temperatures or longer reaction times were 
found to result in structural deterioration of the particles. The reaction was run in three 
different batches, one for 5 min, one for 15 min, and one for or 30 min. We anticipated 
Radiopaque and surface-functionalized polymeric microspheres   
 69
that a longer reaction time would result in an increased surface density of -COOH 
groups. After treatment, the microspheres were washed thoroughly, in order to remove 
the last traces of ethylene glycol. Inadequate washing resulted in coalescence of the 
particles during lyophilization, and loss of the spherical shape. Figure 2 shows SEM 
micrographs of microspheres after KOH treatment and work-up. The smooth surface 
was preserved in the 5-min treatment (A), while the 15-min treatment led to some 
surface spots (B). After 30 min of KOH treatment (C), the surface became rough with 
incrustations and some flakes. 
 
 
Figure 2. Scanning electron micrograph showing the effect of the incubation with KOH (180 °C) 
on the surface of the microspheres. A: 5 min; B: 15 min; C: 30 min. 
 
The amount of -COOH groups on the surface was determined by titration. The results 
given in Table 1 demonstrate that with increasing time of KOH treatment an increasing 
amount of carboxylic groups were generated on the surface of the microspheres.  
 
Table 1. Results of titration of hydrolysed microspheres. 
 
Time of KOH treatment 
(min) 
-COOH groups 
(µmol/gr spheres) 
0 0 
5 0.96 ± 0.27 
15 1.61 ± 0.41 
30 10.26 ± 1.80 
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The large increase of carboxylic groups between 15 and 30 minutes may indicate that 
the surface of the microspheres starts disintegrating, as can also be seen in Figure 2C. 
The presence of -COOH groups was also confirmed using a fluorescent chromophore. 
The dye 7-amino-4-methylcoumarin was coupled to the -COOH through an activated 
ester (NHS) + EDC protocol.  
 
 
Figure 3. Fluorescence micrographs revealing the presence of immobilized coumarin. B: typical 
microsphere incubated with KOH for 5 min (180 °C), prior to reaction with coumarin; C: idem, 
but incubated with KOH for 15 min; D: idem, but incubated with KOH for 30 min. A: control, i.e., 
this particle was not treated with KOH, but treated with NHS, EDC and coumarin in an identical 
manner, as for B – D. 
 
This one-step procedure was straightforward; 2 h reaction time was sufficient for clear 
labelling. Figure 3 shows fluorescence micrographs for the untreated control (A), and 
KOH-reaction times of 5, 15 and 30 min, respectively (B-D). Differences in 
fluorescence intensity due to the labelling (A vs. B–D), and due to the density of -
COOH groups at the surface (within the series B–D), are clearly visible. 
 
X-ray visibility 
A model set-up was used to test whether our particles feature an adequate level of X-ray 
visibility. First, we dispersed microspheres from 4 different batches (untreated, treated 
with KOH for 5, 15 or 30 min) in molten gelatine, which served to mimic the filler 
agent. After cooling, the samples were implanted in the soft tissue part of a chicken leg; 
the bones served as a qualitative internal standard for the X-ray contrast of the particles 
[18d]. Figure 4 shows the X-ray image. The particles are clearly visible, especially in 
the expansion (B). Noteworthy, not only conglomerated particles are seen; some of the 
larger particles can also be discerned individually. The images do not reveal any effect 
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of the KOH treatment on the X-ray contrast. This is expected, since the saponification 
only affects the surface of the particles. We believe, based on Figure 4, and based on 
comments of an experienced radiologist, that the particles exhibit sufficient X-ray 
visibility for clinical use, e.g., most likely they would be traceable if injected in peri-
urethral tissue to treat SUI in human patients. 
 
 
Figure 4. A: X-ray of the chicken leg with 4 different samples of the radio-opaque microparticles, 
embedded in gelatin as a mimic for the filler agent used clinically, implanted in the soft tissue 
part (see text). B: Expansion of the soft-tissue containing the four samples. 
 
Cytocompatibility in vitro 
Growth of cells (mouse 3T3 fibroblasts) in direct contact with our particles was 
examined in vitro. Figure 5 shows light micrographs, taken after 4 days of incubation.  
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Figure 5. Light microscopic images, taken during the direct-contact cytocompatibility assay. The 
images were recorded after 4 days of incubation with mouse 3T3 fibroblast cells. A: fibroblasts in 
contact with microspheres that were not incubated with KOH (control); B: fibroblasts in contact 
with microspheres that were incubated with KOH for 5 min; C: idem, but KOH treatment lasted 
15 min; D: idem, but KOH treatment lasted 30 min; E: fibroblasts proliferating in the absence of 
any biomaterial (control); F: 3T3 cells in the presence of Latex, which is a toxic control 
biomaterial (control); G: Quantification of cytocompatibility with the MTT conversion assay. 
 
Figures 5A – D reveal that the fibroblasts cells grow readily in the presence of the 
untreated microspheres (5A), and in the presence of KOH-treated microspheres (B – D). 
Note that cells lie adjacent to the biomaterial’s surface in all 4 cases, which indicates 
that their affinities for the iodine-containing biomaterial and for the tissue-culture 
poly(styrene) (TCPS) of the culture plate are comparable. Apparently, the presence of -
COOH groups does not affect cytocompatibility of the surfaces. Figures 5E and F 
represent controls: 5E shows the fibroblasts cultured on TCPS in the absence of any 
biomaterial, and 5F shows the effect of a toxic biomaterial (latex): much less cells are 
found in near the material’s surface, and the morphology of the cells is clearly distorted. 
Cell viability of the cells was determined using a MTT assay in order to quantitatively 
confirm these results. Figure 5G clearly demonstrates that the microspheres are 
completely non-toxic. 
 
Immobilization of proteins  
Our first attempt to couple a protein to the surface -COOH groups on the microspheres 
was performed with the enzyme alkaline phosphatase (porcine). An activated ester 
(NHS) / carbodiimide (EDC) protocol was used, exactly in the same manner as for the 
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coupling of 7-amino-4-methylcoumarin. Spheres were thoroughly washed after the 
reaction, in order to remove adsorbed, uncoupled enzyme as much as possible. 
Incubation of the modified spheres with p-nitrophenylphosphate led to conversion; 
formation of p-nitrophenol could be monitored spectrophotometrically. The occurrence 
of the reaction implies that the spheres have active enzyme molecules on their surface. 
Figure 6 shows the increase of the optical density as a function of time, for the 
microspheres that received 5, 15 or 30 min KOH treatment prior to the reaction with 
alkaline phosphatase. 
The data indicate that prolonged KOH treatment first resulted in higher -COOH surface 
density, and later in higher surface density of active enzyme (Figure 6B). Microspheres 
that were not treated with KOH served as a control. Furthermore, all spheres were also 
treated with alkaline phosphatase but without the cross-linking agents EDC and NHS to 
correct for non-specific adsorption of alkaline phosphatase (adsorption controls). 
 
 
Figure 6. A) Para-nitrophenol formation over time followed by absorbance at 405 nm, in the 
presence of the different spheres with surface coupled alkaline phosphatase. Note that the rate of 
the reaction, i.e., the surface density of the enzyme molecules, correlates with the duration of 
KOH treatment. B) Amount of covalently coupled alkaline phosphatase to the different spheres, 
determined by comparing rates of para-nitrophenol formation with those of a standard curve of 
alkaline phosphatase. These data are representative for three independent experiments using 
different batches of spheres. 
 
Upon incubation with PNPP all control spheres, both the non-KOH treated spheres as 
well as the adsorption control, demonstrated virtually the same slight p-
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nitrophenylphosphate conversion. The total amount of covalently surface-linked 
alkaline phosphatase increases with longer KOH treatment (Figure 6B).  
The carbodiimide protocol was also used to bind fluorescently labelled collagen to our 
particles, as was verified through fluorescence microscopy (Figure 7A-D). Note that the 
fluorescence intensity again correlates with the time of KOH treatment. To quantify 
collagen coupling, the microspheres were incubated with collagenase. This rendered the 
supernatant fluorescent and this fluorescence could be compared to known 
concentrations of fluorescent collagen (Figure 7E). Up to approximately 190 µg per 
gram spheres could be covalently coupled. The apparent possibility to bind collagen to 
the surface of the microspheres is of great interest with respect to the aim of this study: 
to explore new methods to prevent migration of injected microparticles in vivo. 
 
 
Figure 7.  Fluorescence micrographs, showing immobilized fluorescent collagen at the surface of 
the microspheres (B–D). B: microspheres that were incubated with KOH for 5 min prior to 
reaction with NHS, EDC and labeled collagen. C: idem, but incubation with KOH lasted 15 min; 
D: idem, but incubation with KOH lasted 30 min. A: control, i.e., this particle was not treated 
with KOH, but treated with NHS, EDC and labeled collagen in an identical manner as for B–D.  
 
There are numerous studies that describe strongly increased cell adhesion on surfaces 
coated with collagen type I leading to the frequent use of collagen matrices for tissue 
engineering purposes [24]. Our ongoing research is directed toward the question 
whether immobilized collagen molecules will bind to extracellular matrix proteins (e.g., 
collagen) that are present in soft tissues. If such molecular recognition and binding 
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occurs, then it must be expected that the microparticles have a decreased tendency to 
migrate. We will address this question in a series of in vitro and in vivo model studies. 
 
Concluding remarks 
Injectable synthetic polymer microparticles that are currently used in the clinic, e.g., in 
cosmetic/reconstructive surgery, or to treat SUI, all consist of passive biomaterials. 
Their primary function inside the body is to fill space. Usually, they are surrounded by a 
fibrous capsule and there is no interaction whatsoever with surrounding tissues. This 
study makes clear that polymeric microspheres with several different and potentially 
useful functionalities can be manufactured. Firstly, radio-opacity can be introduced 
through incorporation of covalently bound iodine in the polymer’s structure, without 
affecting the density of the biomaterial and without compromising the cytocompatbility 
of the biomaterial. Clinically, it is important that injected biomaterials can be visualised 
through X-ray fluoroscopy. Moreover, a method to engineer the surface of the particles 
is described. Attachment of proteins, especially those that are recognized and bound by 
the extracellular matrix proteins in soft tissues, may turn out to be an effective strategy 
to prevent migration of injected microparticles away from the site of injection.  
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Abstract 
Particles currently used in arterial embolization therapy have several disadvantages, 
most importantly their radiolucency. This means the radiologist can not precisely asses 
the fate of embolization particles. Microspheres that combine two additional features 
have been designed. By incorporating an iodine-containing monomer, radiopaque 
microspheres were obtained that display good visibility under standard X-ray 
conditions. Incorporation of methacrylic acid makes the surface of the spheres suitable 
for surface functionalization. Here, thrombin was covalently attached to the surface of 
the radiopaque microspheres. By induction of a thrombus, improved anchoring of the 
embolization spheres in the blood vessel can be obtained. The immobilized thrombin 
induced a biphasic response of the blood namely: (1) fast deposition of fibrin on the 
surface resulting in sphere aggregation and (2) additional thrombin generation in the 
surrounding blood and a subsequent local thrombus formation. These microspheres with 
both intrinsic X-ray visibility and a biofunctionalized surface can potentially improve 
embolization therapies. 
 
Introduction 
Polymeric microspheres are employed in a wide variety of medical applications. They 
are used as bulking agents in plastic surgery to fill up subcutaneous defects [1,2] and to 
treat stress urinary incontinence [3,4]. Microspheres are also used in interventional 
radiology, especially for embolization therapy [5-7]; by injecting particles in a feeding 
blood vessel occlusion occurs and as a result shrinkage of a lesion, e.g., a tumor, is 
obtained [8]. Embolization has emerged as a highly effective technique in a wide variety 
of diseases. Since 1995, more than 50,000 cases of uterine fibroid embolizations 
(UFEs), which are the most common tumors in the female genital tract, were performed 
worldwide [9-11]. Embolization is also used for treatment of inoperable tumors [12], 
arterio-venous malformations (AVMs) [8] and haemoptysis (excessive bleeding) 
[13,14].  
While polyvinyl alcohol particles are probably the most widely used particulate embolic 
agents, microspheres, e.g., trisacryl gelatin microspheres, are also emerging as valuable 
tool in therapeutic embolization [15]. The advantage of microspheres over irregularly 
shaped particles is that the former have a uniform geometrical shape, which allows 
precise location of the embolic material. 
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A shortcoming of commercially available embolic agents is that they are radiolucent, 
which means that they cannot be visualized radiographically. Consequently, 
complications such as ‘reflux with non-target embolization’ and ‘through embolization’ 
are essentially undetectable. Currently, prior to the injection particles are dispersed in 
saline that has been enriched with contrast medium [12,15]. This indirect method of 
introducing radiopacity has the disadvantage that in case of improper dispersion of the 
particles in the medium, the liquid can pass more distal into the tumor than the particles 
and as a result fluoroscopic exploration provides incorrect information about the 
position of the particles. The challenge is therefore to render the embolic agents, 
preferably microspheres, themselves radiopaque.  
This unique feature of intrinsic radiopacity has been introduced about one decade ago 
for polymeric biomaterials [16-20]. Since then, several applications have emerged [20-
24]. Recently, we started the development of intrinsically radiopaque microspheres, in 
first instance for use in stress urine incontinence [22]. Also, in embolization therapies 
these types of spheres can be of great importance. It will enable the interventional 
radiologist to determine precisely the amount and location of the injected microspheres.   
Further improvement of the microspheres can be obtained by biofunctionalization of the 
surface. By immobilization of a coagulation factor, like thrombin, on the surface, blood 
coagulation can be triggered. The advantage for embolization therapies can be that in 
this way the spheres get anchored. We therefore have developed a range of 
microspheres that combine the unique traits of intrinsic radiopacity, i.e., X-ray 
visibility, with controllable modification of the surface. The microspheres were 
synthesized from methyl methacrylate (MMA), methacrylic acid (MAA) and a 
radiopaque building block, i.e., 2-[4-iodobenzoyloxy]-ethyl methacrylate (4IEMA, 1) 
by a suspension polymerization technique. The covalently bound iodine is responsible 
for X-ray visibility. The methacrylic acid provides carboxylic groups at the particles, 
surface. These can be used to couple proteins and peptides to the surface. In this study, 
thrombin was coupled to the spheres. 
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It was hypothesized that the thrombin modified spheres will induce local thrombus 
formation and thereby anchor the spheres. By varying the ratio of the different 
monomers, the radiopacity and the surface modification of the spheres can be tuned to 
the needs of the interventional radiologist. 
In this article, the synthesis of microspheres with dual functionality will be described. 
The spheres have been characterized for their X-ray visibility, cytocompatibility and 
thrombus-inducing capacities.  
 
Materials and Methods 
Materials 
Chemicals were purchased from Sigma/Aldrich/Fluka (Zwijndrecht, The Netherlands) 
and Acros (Landsmeer, The Netherlands). Methylmethacrylate (MMA) was distilled at 
atmospheric pressure and stored at -20 °C. The monomer 4IEMA (1) was synthesized 
from 4-iodobenzoyl chloride as described previously [16]. Methacrylic acid (MAA), 
benzoyl peroxide (BPO), tetraethylene glycol dimethacrylate (TEGDMA), poly(vinyl 
alcohol) (PVA; M.W. 86,000; 99-100% hydrolyzed), poly(ethylene glycol (PEG; M.W. 
1,000) and poly(vinyl pyrrolidone) (PVP; K-23-32; M.W. 58,000) were used as 
purchased. Cell culture medium (DMEM/F12), fetal bovine serum, and antibiotics were 
from Invitrogen (Breda, The Netherlands). The fluorescent thrombin-specific substrate 
Z-Gly-Gly-Arg-AMC was from Bachem (Weil am Rhein, Germany). Thrombin with 
high specificity (>2,000 U/mg solid) was purchased from Synapse (Maastricht, The 
Netherlands) and thrombin with low specificity (43 U/mg solid) was from Sigma.  
 
Preparation of microspheres  
A solution of PVA (1.25 g), PEG (1.50 g) and PVP (0.25 g) in 100 mL distilled water 
was magnetically stirred and heated to 85 °C. MMA, 4IEMA, MAA, BPO and 
TEGDMA were mixed, and this mixture was added drop wise to the stirred aqueous 
PVA-PEG-PVP solution [25]. After the addition, stirring at 85 °C was continued for 6 
h. The microspheres precipitated immediately as stirring was stopped, and the 
supernatant was decanted carefully. The microspheres were allowed to cool to room 
temperature, and washed several times in water. In the end, microspheres were frozen (-
196 °C, liquid nitrogen), and lyophilized. Two types of spheres were prepared: (i) 10%I, 
containing 10%w/w iodine, consisting of MMA (2.312 g, 23.09 mmol), 4IEMA (1.700 
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g, 4.72 mmol), MAA (1.988 g, 23.09 mmol), 1 mol% BPO and 2 mol% TEGDMA; and 
(ii) 20%I, containing 20%w/w iodine, consisting of MMA (1,26 g, 12,55 mmol), 
4IEMA (3.402 g, 9.45 mmol), MAA (1.54 g, 17.95 mmol), 1 mol% BPO and 2 mol% 
TEGDMA. Microspheres were examined by scanning electron microscopy using a 
Philips XL30 SEM system. 
 
Cytocompatibility  
Mouse 3T3 fibroblasts were grown in Dulbecco’s modification of Eagle medium/F-12 
nutrient mix containing Glutamax-I and supplemented with 10% fetal bovine serum and 
antibiotic/antimycotic solution (100 U/mL penicillin, 100 µg/mL streptomycin, 0.25 
µg/mL amphotericin B). Cells were harvested and 25,000 cells were inoculated in each 
well of a 24-well plate. The cells were cultured at 37 °C/5% CO2 for 20 h before 
microspheres were added. Microspheres were sterilized with UV light for 15 min and 
subsequently were added to the cells in such a way that estimated 20% coverage of the 
total area by the spheres was achieved. Latex was used as a positive, toxic, control. 
After 5 days of incubation, photographs of the cells were taken using a Leica DM-IL 
inverted microscope. From a separate plate, the medium was removed and replaced with 
culture medium containing 0.5 mg/mL MTT to measure cell viability [26]. The cells 
were incubated for 1 h at 37 °C, the medium was removed, and the precipitated 
formazan was dissolved in isopropanol. The absorbance at 550 nm of the samples was 
determined using a micro-plate reader.  
 
X-ray visibility  
For demonstration of radiopacity of the microspheres, a realistic model under routine 
hospital conditions was used. Microspheres were inserted into a rabbit cadaver in two 
ways: 1) 25 mg loose spheres were inserted into the back muscle and 2) 75 mg spheres 
were resuspended in 3% gelatin and inserted into the back leg. X-ray pictures were 
taken using a digital mammography imaging system (Bennet Trex Medical).  
 
Immobilization of thrombin  
The microspheres were washed in 50 mM MES buffer, pH 5.5 for 30 min, resuspended 
in 20 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 50 mM N-
hydroxysuccinimide (NHS) in 50 mM MES, and incubated at room temperature for 30 
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min under continuous mixing [27]. Then microspheres were washed once with 50 mM 
MES and 700 µL thrombin solution was added. For determining the optimal 
composition of the microspheres, 2.5 mg/mL thrombin with low specific activity was 
used because of economical reasons. For the following experiments, thrombin of a high 
quality, >2,000 U/mg, was used at a concentration of 0.4 mg/mL. The thrombin was 
dissolved in thrombin-coupling buffer (50 mM Hepes, 150 mM NaCl pH 8.2). After 2 
hours incubation at room temperature, spheres were washed at least 6 times in 
thrombin-coupling buffer. 10 mg microspheres (in triplo) were put into a 96-well plate. 
120 µL thrombin-assay buffer (20 mM Hepes, 150 mM NaCl, 5 mM CaCl2 pH 7.4) was 
added to each well with spheres. The plate was warmed to 37 °C and 80 µL 1 mM 
fluorescent thrombin-substrate, in thrombin-assay buffer, was added to start the 
quantification of thrombin. Fluorescence increase (ex 485 nm/em 520 nm) was 
determined with a Gemini XS fluorometer. The increase in fluorescence is directly 
related to thrombin activity. The amount of coupled thrombin could be estimated by 
comparison to a standard curve with known amounts of thrombin.  
 
Microsphere induced fibrin formation  
Blood was obtained from a healthy donor by venipuncture and mixed with 0.13 M Na-
citrate (9 parts blood: 1 part Na-citrate). Platelet rich plasma (PRP) was prepared by 
centrifugation of blood at 180 g for 15 min. PRP was recalcified by addition of 40 
µL/mL 0.5 M CaCl2. Microspheres were incubated at room temperature with recalcified 
platelet rich plasma (PRP) in a 35 mm Petri-dish. The dishes were gently shaken and 
photographs were taken at regular intervals on a Nikon Eclipse 800 microscope 
equipped with a RS Photometric CoolSnap digital camera. Aggregates of microspheres 
that were formed after 2-3 min of incubation in PRP were fixed in 2.5% glutaraldehyde 
in phosphate buffered saline (pH 7.4) at 4 ºC. The samples were extensively washed and 
dried, attached on a stub with double-sided carbon tape, sputter-coated with gold and 
examined by SEM.  
 
Microsphere induced thrombin generation  
To test the ability of the covalently coupled thrombin to induce blood coagulation, 
microspheres were mixed with recalcified whole blood, PRP, or platelet poor plasma 
(PPP) that was prepared by centrifugation of blood at 1,800 g for 10 min. Recalcified 
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blood, PRP, or PPP was added to 10 mg microspheres to start the reaction, which was 
allowed to proceed at 37 ºC. Samples (17.5 µL) were taken every minute and added to 
282.5 µL thrombin-stop buffer (20 mM Hepes pH 7.4, 140 mM NaCl, 20 mM EDTA, 1 
mg/mL BSA, 200 µM S2238). EDTA was used to directly abolish any further thrombin 
formation by binding all available calcium, S2238 is a chromogenic thrombin-specific 
substrate. Sampling was stopped upon complete clotting of the blood, PRP or PPP. In 
the case of incubation with whole blood, erythrocytes were removed by short 
centrifugation (5 sec) and the supernatant was pipetted into a 96-well microplate. The 
plate was heated to 37 ºC and increase in extinction at 405 nm could be directly 
converted to thrombin concentration. For PRP and PPP samples, no centrifugation was 
needed, and so the samples could be measured directly in a 96-well microplate. Also 
spheres without coupled thrombin (control spheres) were used as well as the empty 
tube. The concentration of thrombin was plotted against time. 
 
Results and discussion 
We set out to design microspheres for embolization purposes that combine multiple 
characteristics: (i) uniform shape, (ii) radiopacity, and (iii) biofunctionalized surface. 
SEM was used to confirm the shape and size of the 10%I and 20%I microspheres. From 
Figure 1 it is clear that the spheres are solid and perfectly spherical. The size of at least 
500 microspheres was determined and average sizes of 150 ± 42 µm and 113 ± 54 µm 
for 10%I and 20%I respectively were obtained. 
 
 
Figure 1. Scanning electron micrographs of 10%I (A) and 20%I (B) microspheres. The scale bar 
represents 200 µm. 
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When these microspheres are to be used in animals or human patients, the spheres must 
be safe and non-toxic. Therefore, cytocompatibility of the microspheres was determined 
in vitro in two ways: (1) by a direct contact assay and (2) by a MTT cell viability assay.  
 
 
Figure 2. Cytocompatibility of microspheres. (A) Photographs of direct contact between 
microspheres and mouse fibroblasts. Latex was taken as a toxic control. (B) Viability assay 
(MTT) of the cells in contact with microspheres for 5 days. Note that the microspheres have no 
adverse effect on the cells. 
 
Mouse fibroblasts were incubated with microspheres and photographs were taken after 
2 days of incubation (Figure 2A). No adverse effect of the spheres on the morphology of 
the cells could be observed. To quantify cytocompatibility, viability of cells in contact 
with spheres was determined using MTT (Figure 2B). No toxic effect of the spheres 
could be measured, which is in line with an earlier work on the biosafety of iodine-
containing microspheres [22,28]. The cytocompatibility of our current spheres is 
supported by the biosafety of iodine-containing polymers in general [29,30]. Therefore 
one can assume that our microspheres will be safe for in vivo use, although animal 
experiments should still be performed.  
In order to confirm radiopacity, 10%I and 20%I microspheres were implanted in two 
different ways in a rabbit cadaver (Figure 3). First, loose spheres were inserted into the 
back (Figure 3 right bottom panel). 
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Figure 3. X-ray radiography of the microspheres inserted into a rabbit cadaver. The left panel 
shows the X-ray image. A and a represent radiolucent microspheres (without iodine), B and b 
indicate 10%I spheres, C and c 20%I microspheres. The upper right panel photograph shows 
how spheres were inserted in the back leg. The lower right panel is an enlargement of the spheres 
inserted in the back muscle of the rabbit. 
 
The spheres are nicely visible under standard X-ray conditions and it is also clear that 
the 20%I spheres are better visible, i.e., more radiopaque, than the 10%I spheres. 
Radiolucent spheres, that do not contain iodine, were not visible under these X-ray 
conditions. Alternatively, approximately 75 mg spheres were suspended in 3% gelatin 
and inserted into the back leg of the rabbit (Figure 3 right upper panel). Again, the 
spheres are clearly visible under X-ray and again the 20%I is more radiopaque than the 
10%I spheres. The difference seems to be somewhat less than for the microspheres 
implanted in the back, but this is caused by saturation of the X-ray signal by the larger 
amount of spheres.  
The surface of the microspheres was biofunctionalized by covalently coupling a 
coagulation inducing agent, in this case thrombin, but in fact any desired protein can be 
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coupled to the surface of these spheres. Thrombin is the key enzyme in thrombus 
formation [31]. Fibrinogen is cleaved by thrombin and multimerizes subsequently to 
form a fibrin network which will capture erythrocytes and platelets, forming the final 
thrombus [32]. To immobilize protein onto the microspheres, we attempted to induce 
carboxylic groups on copolymer spheres derived from 4IEMA and MMA, by treatment 
with strong base [33,34]. Although successful, this method was difficult to control, 
resulting in batch to batch variation, as well as disintegration of spheres after prolonged 
treatment [34]. Therefore we chose to produce terpolymer microspheres containing 
MAA. Proteins can readily be coupled to the carboxylic groups on the surface of these 
spheres by cross-linking chemistry based on the use of EDC and NHS [27]. In this way 
X-ray visible microspheres are obtained that not only mechanically block blood vessels, 
but also improve blocking and anchoring by inducing blood coagulation. The protein 
linked to the surface, in this case thrombin, will anchor the spheres in a blood clot.  
In order to determine the optimal composition of the microspheres for coupling of 
thrombin, a range of 10%I spheres, that differ in the content of MAA, was prepared. 
The data presented in Figure 4A demonstrate that spheres with 45 mol% MAA have the 
highest thrombin activity on their surface. 
 
 
Figure 4. (A) Thrombin activity of 10%I spheres with varying methacrylic acid content. Thrombin 
was coupled to these spheres and activity was determined using a fluorescent peptide substrate. 
(B) Thrombin activity of 10%I and 20%I spheres with 45% methacrylic acid. 
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The spheres with less MAA show much lower thrombin activity, which can be 
explained by lower number of carboxylic groups on their surface, and thus less chance 
of forming a bond with thrombin in solution. The fact that a peak of thrombin activity 
was found may be explained by the possibility that on the surface of spheres with higher 
MAA content, multiple cross-links per thrombin molecule may occur, rendering 
thrombin inflexible and subsequently inactive. To improve radiopacity (Figure 3), 20%I 
spheres with 45% MAA were prepared, and compared to 10%I spheres (Figure 4B). For 
this experiment thrombin with a very high specific activity (> 2,000 U/mg) was used. 
Therefore a higher thrombin activity, 213 and 174 U/g spheres for the 10%I and 20%I 
spheres respectively, was achieved, when compared to the 10%I spheres (28 U/g 
spheres) in Figure 4A. Thus, increasing the iodine content had little effect on the 
coupling efficiency of thrombin to the sphere surface. 
The microspheres with immobilized thrombin were tested for their ability to induce 
thrombus formation in blood. Upon contact of blood with our thrombin-carrying 
spheres, a sequence of events will be initiated. First, a fast deposition of fibrin on the 
surface will occur. The immobilized thrombin will cleave fibrinogen, resulting in fibrin 
network formation. This fibrin can act as a procoagulant surface, especially when 
activated platelets are enclosed in the fibrin clot [35,36]. In a second phase, free 
thrombin will be generated in the surrounding blood.  
 
 
Figure 5. Thrombin-induced microsphere aggregation. 20%I spheres with (upper) or without 
(bottom) coupled thrombin were mixed with recalcified platelet rich plasma. The samples were 
gently shaken at room temperature and pictures were taken. Microspheres with thrombin form 
stable aggregates within 1 min while the control spheres do not. 
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Feed-back activation of factor XI or factor VIII by the immobilized thrombin will result 
in generation of free thrombin in the surrounding blood and subsequent thrombus 
formation [31]. Additionally, the procoagulant surface on the spheres (fibrin with 
activated platelets) will accelerate the conversion of prothrombin to thrombin and thus 
result in faster thrombus formation [35,36]. Result will be a biphasic formation of 
thrombus on and near the thrombin-modified-spheres.  
First, we investigated the fibrin formation on the surface of the 10%I and 20%I spheres 
with immobilized thrombin. When these spheres were mixed with whole blood or PRP, 
an aggregate/clot formed directly around the spheres within a minute at room 
temperature (Figure 5). Only thrombin carrying microspheres aggregated, suggesting 
the formation of a fibrin network entrapping the spheres in a clot.  
 
 
Figure 6. Scanning electron micrographs of microspheres treated with platelet rich plasma for 3 
minutes. The control spheres show no fibrin network on their surface, while the 10%I and 20%I 
microspheres carrying thrombin do induce fibrin network on their surface. Scale bars represent 
200 µm (upper), 100 µm (middle), and 5 µm (bottom). 
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To visualize the fibrin network on the surface of the spheres, we fixed spheres that had 
been shortly incubated in PRP and observed the aggregates/clots by scanning electron 
microscopy (Figure 6). Surface-linked thrombin will not only directly induce fibrin 
formation but can also induce additional thrombin generation in the surrounding blood 
via a feed back loop involving platelets [31,35]. 
 
 
Figure 7. Microsphere-induced thrombin generation in whole blood (A), platelet rich plasma (B), 
and platelet poor plasma (C). Microspheres were mixed with recalcified blood, PRP, or PPP and 
samples were taken every minute. Thrombin concentration was determined by the conversion of 
the chromogenic thrombin substrate S2238. Sampling was stopped upon complete clotting of the 
blood, PRP, or PPP. Control spheres were 20%I spheres without coupled thrombin. The control 
was the empty tube used for this experiment. 
 
In addition, the fast formation of a pro-coagulant surface on the spheres can accelerate 
thrombin generation. To determine the thrombin generation by modified microspheres, 
they were incubated with whole blood (Figure 7A), platelet rich plasma (PRP, Figure 
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7B) and platelet poor plasma (PPP, Figure 7C). Both 10%I and 20%I spheres with 
thrombin induced an accelerated burst in free thrombin, and subsequent full clotting of 
the blood and PRP by 6-8 minutes while the control needed 12-14 minutes. In PPP 
slower thrombin generation was observed, confirming the hypothesis that platelets play 
an important role in thrombin generation and subsequent thrombus formation. The 
microspheres with immobilized thrombin can thus induce anchoring by formation of a 
fibrin network as well as by inducing a local thrombus. This process of thrombin 
formation can also be initiated by coupling of other coagulation factors that are 
upstream in the coagulation cascade like factor Xa or XIIa, but these sorts of spheres 
have not been investigated yet. 
In this study, a maximum loading with thrombin was pursued. The optimal extent of 
surface modification for in vivo use can only be determined with animal experiments. 
Too much thrombin will induce too rapid thrombus formation and cause the spheres to 
clot prematurely, in the worst case even blocking the tip of the catheter. The level of 
surface modification can be tuned either by using spheres with less MAA or by diluting 
the protein solution with an inactive protein like albumin. Additionally, virtually any 
protein, or combination of proteins, can be linked to the surface of the microspheres, 
making these microspheres a flexible system with numerous possible applications. 
 
Conclusion 
Microspheres that combine uniform shape, radiopacity and biofunctionality were 
successfully made. These spheres may be used in different interventions as for instance 
embolization therapy or management of excessive bleeding. The intrinsic radiopacity of 
our microspheres can be of great help to the interventional radiologist. Using standard 
X-ray fluoroscopy, the fate of the spheres can be observed. This means the radiologist 
can easily observe if enough spheres have been injected and if these remain at the 
intended site. The surface modification with active proteins is also of great importance 
for use of the spheres. Biofunctionalization of X-ray visible microspheres with proteins 
of choice opens a wide variety of possible applications. 
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Abstract 
Polymeric microspheres find use in minimally invasive treatments as fillers and bulking 
agents. A frequently encountered problem of currently used microspheres is migration 
away from the injection site. Also many polymeric microspheres are invisible for X-
radiation and are difficult to detect with MRI. Here we present the synthesis of 
polymeric microspheres that are composed of methylmethacrylate (MMA), acrolein (2-
propenal), and the iodine-containing monomer 4IEMA. The aldehyde groups that are 
introduced by the addition of acrolein were used to covalently couple protein to the 
spheres. The microspheres were demonstrated to be non-toxic in vitro. The optimal 
composition of the microspheres for coupling of albumin and collagen type I was 
determined to be 10-20 weight% acrolein. Microspheres decorated with collagen I were 
shown to support the migration and growth of cells on their surface, which leads to 
anchoring of the spheres to a cell layer. These collagen modified spheres may improve 
anchoring in the surrounding tissue and thereby prevent migration of the microspheres 
from the injection site. The here presented microspheres combine intrinsic radiopacity 
with the possibility of surface bio-functionalization, and present an improvement for use 
of microspheres as filler or bulking agent. 
 
Introduction 
Polymeric microspheres have attracted attention in a wide array of medical and 
pharmacological applications. A widespread utilization of polymeric microspheres is 
their use as fillers, for soft tissue augmentation, or as bulking agent. Soft tissue 
augmentation is the most effective and least invasive treatment of acne scars [1,2], 
wrinkles [3], facial lypoathropy, which is associated with human immunodeficiency 
virus(HIV)-infected individuals [4,5], and aesthetical lip augmentation [6]. 
Additionally, polymeric microspheres can be employed as injectable bulking agent 
everywhere in the body to improve open-closing systems. In 1911 the first injection 
laryngoplasty was performed [7], a procedure that aims to support to a vocal fold during 
unilateral vocal fold paralysis (UVFP). UVFP is a disorder that occurs when one or both 
of vocal cords do not open or close properly because nerve impulses to the muscles of 
the voice box are interrupted. Another example is vesico-ureteral reflux [8], the back-
flow of urine from the bladder into the ureters and often even into the kidneys, which is 
increasingly managed by periurethral injection of different bulking agents [8]. The use 
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of injectable bulking agents to improve intrinsic sphincter deficiency, which is the 
major cause of stress urinary incontinence, has become more prevalent in recent years 
as a minimally invasive alternative for surgical procedures [9,10]. Since 1911, various 
synthetic or biologic materials were used for unilateral vocal fold paralysis 
augmentation and other minimally invasive procedures [11]. It is remarkable, that the 
same injectables found use in urology and plastic surgery. All these injectables can be 
separated in two groups: (i) injectable agents with temporary effect, such as xenograft 
(bovine collagen, hyaluronic acid), autograft (autologous fat, fascia, autologous 
collagen) and homograft; and (ii) permanent synthetic injectable agents, such as carbon-
coated zirconium oxide beads, PDMS (polydimethylsiloxane paste), calcium 
hydroxylapatite, PTFE (polytetrafluoroethylene paste), silicone, PMMA 
(polymethylmethacrylate microspheres). The shortcoming of the first group materials is 
that, the initial volume is not conserved, resulting in repetitive injections, which causes 
high expenses. Also allergic reactions of these materials are frequently observed. One 
study demonstrated that 13% of patients developed calcification, surrounded by chronic 
inflammation, after of glutaraldehyde cross-linked collagen injections for incontinence 
treatment in children [12]. Ophthalmic artery occlusion, after a paranasal injection of 
autologous fat, can result in visual loss [13]. In a significant number of cases a 
suburethral mass develops and urinary retention occurs after dextranomer/hyaluronic 
acid copolymer urethral injection [14]. The second group of materials showed better 
results in durability, but, concerns regarding the side effects of these materials have 
limited general acceptance of their use. PTFE paste [15-17], pyrolitic carbon-coated 
zirconium oxide beads [18,19] and calcium hydroxylapatite microspheres [20] all have 
been shown to migrate away from the site of implantation to distant organs and tissues. 
Micropsheres have been demonstrated to migrate far away from the site of application, 
e.g., as the antecubital fossa, to the upper arm, chest and shoulder, along the chest and 
abdominal walls, as far away as the groin [21]. Finally, the development of granulomas 
or cutaneous sarcoids were frequently described for certain microspheres [22,23]. 
The “ideal” bulking agent has to be non-immunogenic, hypoallergenic, biocompatible, 
non-carcinogenic, non-migratory, and somehow traceable for surgeons after injection 
into the patient. In earlier reports synthesis of microspheres with intrinsic X-ray 
visibility was described [24-26]. These microspheres contained an iodine-containing 
building block, e.g., 2-[4-iodobenzoyloxy]-ethyl methacrylate (4IEMA, 1) that is 
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responsible for intrinsic radiopacity. Furthermore, the microspheres were designed with 
reactive groups on their surface, e.g., carboxylic groups, to facilitate attachment of 
protein. Coupling of thrombin to the surface of microspheres that were designed for 
embolotherapy, resulted in a dramatically increased fibrin deposition on the spheres as 
well as accelerated blood coagulation [26]. In this manuscript microspheres are 
described that combine intrinsic radiopacity with surface aldehyde groups for protein 
attachment under mild conditions. 
O
O
O
O
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For this, acrolein (2-propenal) was combined with methylmethacrylate (MMA) and 1 
(4-IEMA) to produce microspheres by suspension polymerization. The covalent 
attachment of especially collagen was studied in relation to improved cell adhesion, to 
enhance anchoring of the spheres into the surrounding tissue upon implantation into 
patients. In this way the chance of migration of microspheres after injection into the 
patient can be reduced. 
 
Materials and Methods 
Materials 
Chemicals were purchased from Sigma/Aldrich/Fluka (Zwijndrecht, The Netherlands), 
Acros (Landsmeer, The Netherlands), or Invitrogen (Breda, The Netherlands). 
Methylmethacrylate (MMA) was distilled at atmospheric pressure and stored at -20 oC. 
The monomer 4IEMA was synthesized from 4-iodobenzoyl chloride as described 
previously [27]. Acrolein (2-propenal), benzoyl peroxide (BPO), tetraethylene glycol 
dimethacrylate (TEGDMA), poly(vinyl alcohol) (PVA; M.W. 86,000; 99-100% 
hydrolyzed), poly(ethylene glycol (PEG; M.W. 1,000), poly(vinyl pyrrolidone) (PVP; 
K-23-32; M.W. 58,000) were used as purchased. Cell culture medium (DMEM-F12), 
foetal bovine serum (FBS), and antibiotics were purchased Invitrogen (Breda, The 
Netherlands). MTT and dinitrophenyl-hydrazine were from Acros, Cyquant reagent 
from Invitrogen. The FITC labelled forms of collagen and albumin were from Sigma. 
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Buffers composition are: 0.2 M carbonate buffer was prepared from 0.2 M Na-
bicarbonate and 0.2 M Na-Hydrogencarbonate, mixed to pH 9.6. Phosphate buffered 
saline (PBS) is 8.0 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 in 1 l distilled 
water and set to pH 7.4. 
 
Production of microspheres  
The method of preparation of spheres was described previously [26]. Briefly, solution of 
PVA (1.25 g), PEG (1.50 g) and PVP (0.25 g) in 100 mL distilled water was 
magnetically stirred and heated to 85 oC. Microspheres were synthesized in batches of 6 
grams. The amount of monomer 1 used (here 1.7 g, 4.72 mmol) was such that the final 
iodine content is 10 weight%. The rest of the monomers, MMA and acrolein were 
divided so that different weight percentages of acrolein were obtained (Table 1). The 
cross-linking agent TEGDMA was used at a 2 mol%, BPO was used at 1 mol%. For 
microspheres with high acrolein content more BPO was needed to get successful 
suspension polymerization. In this way 8 different acrolein containing microspheres 
were obtained (Table 1).  
 
Table 1. Composition of the range of acrolein containing microspheres. 
 
 MMA Acrolein Monomer 1 BPO TEGDMA 
0% acrolein 
4.3 g 
42.95 mmol ------- 
1.7 g 
4.72 mmol 
0.11 g 
0.45 mmol 
0.32 g 
0.97 mmol 
2% acrolein 
4.21 g 
42.04 mmol 
0.086 g 
1.534 mmol 
1.7 g 
4.72 mmol 
0.11 g 
0.45 mmol 
0.32 g 
0.97 mmol 
5% acrolein 
4.09 g 
40.85 mmol 
0.22 g 
3.92 mmol 
1.7 g 
4.72 mmol 
0.11 g 
0.45 mmol 
0.33 g 
0.99 mmol 
10% acrolein 
3.87 g 
38.65 mmol 
0.43 g 
7.67 mmol 
1.7 g 
4.72 mmol 
0.12 g 
0.49 mmol 
0.34 g 
1.03 mmol 
20% acrolein 
3.44 g 
34.36 mmol 
0.86 g 
15.34 mmol 
1.7 g 
4.72 mmol 
0.13 g 
0.54 mmol 
0.36 g 
1.09 mmol 
30% acrolein 
3.01 g 
30.06 mmol 
1.29 g 
23.01 mmol 
1.7 g 
4.72 mmol 
0.14 g 
0.58 mmol 
0.38 g 
1.16 mmol 
50% acrolein 
2.15 g 
21.47 mmol 
2.15 g 
38.35 mmol 
1.7 g 
4.72 mmol 
0.16 g 
0.66 mmol 
0.43 g 
1.29 mmol 
70% acrolein 
1.29 g 
12.88 mmol 
3.01 g 
53.69 mmol 
1.7 g 
4.72 mmol 
0.52 g 
2.15 mmol 
0.47 g 
1.43 mmol 
100%acrolein ------- 
4.3 g 
76.70 mmol 
1.7 g 
4.72 mmol 
0.59 g 
2.44 mmol 
0.54 g 
1.62 mmol 
Chapter 6 
 98
The mix of monomers and BPO was added drop-wise to the aqueous PVA-PEG-PVP 
solution. After the addition, stirring at 85 oC was continued for 6 h. The microspheres 
precipitated immediately after stirring was stopped, and the supernatant was decanted 
carefully. The microspheres were allowed to cool to room temperature, and washed 
several times in water. Finally microspheres were freeze-dried. Yields varied between 
50% and 78%. Microspheres were inspected by phase-contrast and scanning electron 
microscopy (SEM) using a Philips XL30 SEM system. 
 
Analysis of surface aldehyde groups  
The number of aldehyde groups on the surface of the microspheres was determined by 
quantifying the coupling of dinitrophenyl-hydrazine (DNPH) to free aldehyde groups. 
For this a 20 µg/mL solution of DNPH in ethanol was mixed with approximately 100 
mg spheres and the reaction was allowed to run for 20 hours. The absorbance of the 
remaining ethanol at 348 nm was determined. From this the amount of soluble DNPH 
left and subsequently the amount of DNPH coupled to the microspheres could be 
determined. The spheres with bound DNPH turned bright yellow, but this coloration 
was not suited for quantification. 
 
Coupling of fluorescently labelled albumin or collagen to microspheres  
100 mg of microspheres (all percentages of acrolein) were washed twice with 50 mM 
carbonate buffer pH 9.6. The washed spheres were incubated with 1) 10 mg/mL FITC-
BSA; or 2) 0.8 mg/mL FITC-Collagen I in 50 mM carbonate buffer pH 9.6 for 16 hours 
at room temperature. In the case of FITC-collagen, the protein solution was first heat 
treated at 80 ºC for 10 minutes and rapidly cooled to room temperature. After 3 hours of 
incubation, the microspheres were washed until no more significant fluorescence was 
present in the wash. First, the microspheres were analyzed by fluorescence microscopy 
using a Nikon Eclipse 3600, equipped with a Coolsnap CCD camera. Thereafter 
microspheres with FITC albumin were digested with trypsin (0.5 mg/mL in PBS with 
0.53 mM EDTA) for 16 hours at 37 ºC. The liberated protein was quantified by 
determining release fluorescence using a Gemini XS fluorometer, and comparison to a 
standard curve of trypsin digested FITC-BSA. Microspheres with covalently attached 
FITC-Collagen I were digested with collagenase (1 mg/mL in PBS pH 7.4) for 16 hours 
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at 37 ºC. Quantification of digested collagen was performed similarly to FITC-BSA 
from microspheres as described above. 
 
Coupling of Collagen I 
To 500 mg of washed microspheres, 0.8 mg/mL bovine collagen I in 50 mM carbonate 
buffer pH 9.6 was added. The collagen solution was heated to 80 ºC for 10 minutes 
prior to incubation with microspheres. After 16 hours incubation the spheres were 
treated with 10 mg/mL NaCNBH3 for at least 2 hours at room temperature. The 
microspheres were washed extensively in carbonate buffer and PBS and subsequently 
stored in PBS at 4 ºC until further use. 
 
Cytotoxicity of microspheres  
Mouse fibroblasts (3T3) were inoculated in 96-wells plates at a density of 1,000 
cells/well After incubation for 1 day at 37 ºC extracts of microspheres in culture 
medium were added. The cells were allowed to proliferate for 3 days and the number of 
viable cells was determined by addition of 0.5 mg/mL MTT in culture medium. After a 
further incubation of 1 hour, the medium was aspirated and the formed blue formazan 
crystals were dissolved in isopropanol, and the absorbance at 570 nm was determined. 
For a direct contact cytotoxicity assay, cells were grown in 24–wells plates up to 
approximately 50% confluency. Then microspheres shortly soaked in culture medium 
were added. After 5 days of incubation at 37 ºC photographs were taken using a 
standard digital camera on a Leica DM-IL microscope. 
 
Cell Adhesion to collagen coupled microspheres.  
3T3 cells were grown to confluency in 24-wells plates. Microspheres with or without 
covalently coupled collagen were shortly soaked in culture medium and added to the 
cell layers and incubated at 37 ºC for times indicated. In this set-up, cells have to 
actively migrate onto the spheres and attach to them. For quantification, microspheres 
were carefully removed from the cell layers (microscopic evaluation of the cell layer 
showed no significant damage of the remaining cell layer) and washed twice in culture 
medium. The last bit of medium was removed using a syringe equipped with a cut of 0.5 
mm needle, and the “dry” spheres were frozen at -80 ºC. The amount of attached cells 
was determined using the CyQuant reagent according to the manufacturer’s instructions. 
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Alternatively, cells were grown on coverslips (12 mm diameter) and microspheres were 
carefully placed on the semi-confluent layers. After 24 or 48 hours of incubation on the 
cell layers, the medium was aspirated and the coverslips could be removed from the 
culture dishes. The coverslips with microspheres lying on the cells were put on a 
microscope slide and put at an angle of approximately 45 degrees. Medium was flushed 
over the coverslips to study the adherence of the microspheres to the cells. The resulting 
coverslip were (i) photographed macroscopically, (ii) observed microscopically, and 
(iii) fixated in 2.5% glutaraldehyde in PBS for more than 1 hour at 4 ºC, dehydrated 
with an ethanol series, airdried, and prepared for observation with a scanning electron 
microscope (Philips XL30 SEM system). 
 
Results and discussion 
Radiopaque microspheres  
Microspheres containing the iodine-monomer 4IEMA and the aldehyde carrying 
acrolein were obtained without too many complications. Scanning electron microscopy 
shows nice microspheres with average sizes between 100-200 µm (Figure 1). 
 
 
Figure 1. SEM photographs of acrolein containing microspheres with 10% (A) and 20% (B) 
acrolein. 
 
The inclusion of iodine is responsible for the visibility of these spheres under standard 
X-ray condition. We have extensively reported on the X-ray visibility of iodine-
containing polymers and the stability of the radiopacity. Implantation in rats for 2 years 
[28], boiling of iodine-containing microspheres at 180 ºC for 30 minutes did not result 
Radiopaque microspheres containing acrolein 
 101 
in reduction of radiopacity [25]. With NMR we could confirm the presence of the 
iodine-containing monomer in the microspheres and therefore one can assume that the 
acrolein containing microspheres will be nicely X-ray visible (data not shown). To 
obtain microspheres that can be bio-functionalized, aldehyde groups were designed on 
the surface by addition of acrolein. 
These aldehyde groups can be easily modified with for instance proteins or peptides by 
a reaction with free amino groups that will yield covalent attachment via a Shiff base, 
which can be subsequently reduced to yield an amide bond [29]. The production of 
microspheres with high percentage acrolein (≥ 70%) was only successful when an 
increased percentage of the initiator BPO was used. This may be caused by the 
relatively good solubility of acrolein in water, meaning that when the polymerization 
with the standard 1% BPO proceeds too slow, a large part of the acrolein will dissolve. 
By increasing the initiator (BPO) concentration, the reaction velocity will increase, less 
acrolein will be lost in solution, and yields will increase to acceptable levels. 
Consequently it is reasonable to assume that the average chain length of these spheres 
will be shorter than in the low acrolein (< 50% acrolein) microspheres. This will 
however not pose any problems since microspheres are cross-linked with TEGDMA 
that carries two methacrylate functions.  
 
Table 2 Aldehyde content of the range of acrolein microspheres as determined by the coupling of 
dinitrophenylhydrazine. 
 
% acrolein in 
microspheres 
Dinitrophenylhydrazine binding 
(nmol/g spheres) 
0 0±0 
2 68.8±0.5 
5 100.8±5.4 
10 182.2±13.1 
20 303.5±32.0 
30 343.6±25.4 
50 406.5±16.3 
70 437.5±3.6 
100 435.9±5.6 
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To further analyse the surface of the microspheres, aldehyde groups on the surface of 
the microspheres were analyzed by reaction with dinitrophenyl-hydrazine (DNPH) [29].  
After this reaction the microspheres were stained bright yellow, but this staining could 
not be quantified (data not shown). Therefore the decrease of dissolved DNPH in the 
reaction was determined. The decrease of the DNPH concentration is directly 
proportional to the density of aldehyde groups on the surface. The data presented in 
Table 2 show that the density of the aldehyde groups increased with increasing acrolein 
content. For microspheres with high acrolein feed (> 50%), the amount of coupled 
DNPH, does not increase anymore. One explanation is that the aldehyde groups on the 
surface are so densely packed that steric hindrance avoids the coupling of additional 
DNPH to the surface. Therefore, addition of more than 50% acrolein to the 
polymerization reaction seems pointless, since no higher surface modification can be 
achieved. 
 
Cytotoxicity of microspheres  
Since the microspheres are intended for injection into tissue as a bulking agent, they 
should be non-toxic to cells in vitro and in vivo. The set of acrolein microspheres was 
tested for cytotoxicity by incubating 1) the extract of microspheres or 2) the 
microspheres directly with mouse fibroblasts (3T3). Microspheres containing less than 
50% acrolein were non-toxic (Figure 2A). Also when these spheres were incubated in 
direct contact with mouse fibroblasts, no toxicity could be determined (Figure 2B).  
 
 
Figure 2. (A) Cell viability of cells incubated with extracts from the range of microspheres. (B) 
cells cultures in direct contact with microspheres with 10, 20, 30, and 100% acrolein. Control 
incubations were without any material or with cytotoxic latex. 
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Microspheres with 70 or 100% acrolein released substances that were toxic to the 
mouse fibroblasts. These could be unreacted acrolein, which is known to be highly toxic 
(LD50 = 46 mg/kg), or BPO that was used in an increased concentration for the 
production of these spheres. The radiopaque microspheres that contain 50% acrolein or 
less are non toxic and potentially safe for in vivo use. Because the microspheres with 
more acrolein are toxic in vitro and additionally did not yield in increased binding sites, 
these microspheres will not be of use in the future. 
 
Coupling of fluorescently labelled proteins  
A frequent problem of currently used bulking agents is that they have a tendency to 
migrate away from the site of implantation [15-20]. This is caused by poor anchoring of 
the spheres in the surrounding tissue. To avoid migration and improve anchoring of the 
microspheres in tissue, attachment of protein, e.g., extra-cellular matrix protein like 
collagen, can be advantageous. First the attachment of FITC-labelled albumin was 
attempted. From Figure 3 can be seen that the binding succeeded and a strong increase 
in fluorescence on the surface could be observed by fluorescence microscopy. 
 
 
Figure 3. (A) Quantification of attachment of FITC labelled bovine serum albumin (BSA) to 
acrolein microspheres. (B) Fluorescence micrographs from microspheres with (top) and without 
(bottom) FITC-BSA. 
 
Treatment of these spheres with trypsin resulted in cleavage of the albumin and release 
of fluorescent protein fragments of the surface of the spheres. Quantification of the 
proteolysis products showed that an optimal composition of the spheres, for albumin 
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attachment, could be observed. Microspheres with 10-30% acrolein had most FITC-
labelled albumin on their surface. The fact that more acrolein, and thus higher density of 
aldehyde groups on the surface did not result in increased albumin binding may be 
somewhat surprising. This could be explained by the fact that multipoint attachment of 
albumin on the surface is more likely than attachment of additional protein from 
solution. The reaction of a soluble protein on the solid surface is less likely than the 
reaction of the free amino groups of an already coupled protein already in the vicinity of 
the aldehyde groups on the surfaces. Also the space for additional protein molecules on 
the surface may become too small, causing steric hindrance for additional albumin 
molecules. 
When studying the coupling of FITC-labelled collagen, a very similar result was 
obtained. The data presented in Figure 4 show a narrower distribution of covalent 
protein coupling to the different acrolein microspheres. But again the spheres with 10-
20% acrolein turned out to have the most suitable composition for protein attachment. 
Collagen was cleaved from the microspheres with collagenase, demonstrating that the 
bound collagen still had a more or less native conformation that could be recognized by 
this specific protease. Several experiments were attempted to couple active enzymes to 
the surface, e.g., alkaline phosphatase or thrombin.  
 
 
Figure 4. (A) Quantification of FITC labelled collagen type I to acrolein microspheres.(B) 
fluorescence micrographs of microspheres with FITC-collagen (top), after treatment with 
collagenase (middle), and the control spheres (bottom). 
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No significant amounts of active phosphatase or thrombin could be detected at the 
microsphere surface. This may be explained by coupling of multiple amino groups of 
lysine residues from each protein molecule to the surface of the microspheres. Because 
the aldehyde groups are stable in aqueous, binding of a second lysine residue to the 
surface is likely, more likely than the binding of an additional protein molecule. This 
will result in an immobilized protein that is catalytically inactive. So this may be why 
we have not been able to attach active protein to the acrolein microspheres. Decreasing 
the acrolein even further than in this study could improve the activity of attached 
protein, but the attachment to such spheres is far from optimal, as can be seen from the 
binding optimums for albumin and collagen (Figure 3 and 4). For use as bulking agents 
however, we do not need attachment of active protein but solely protein that enhances 
cell attachment and proliferation, e.g., collagen, laminin or fibronectin [30]. 
 
Cell attachment to microspheres with collagen 
The anchoring of microspheres in tissue may be obtained by the attachment of the 
extracellular matrix protein collagen I. This protein has been reported to enhance the 
attachment of cells to synthetic biomaterials [31,32]. This phenomenon has been 
extensively exploited in tissue engineering to avoid detachment of cells from polymeric 
scaffolds when growing cells under flow conditions. For this, non-labelled collagen I 
was attached to microspheres with 10, 20, and 30% acrolein. These were the 
microspheres with best protein binding characteristics.  
 
 
Figure 5. Number of cells on microspheres with 10, 20, or 30 % acrolein after 8 hours (A) or 24 
hours (B) incubation. 
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From Figure 5 can be seen that indeed cells attached rapidly and more efficiently to the 
collagen modified microspheres. In the used experimental set-up the cells have to 
migrate onto and subsequently attach to the surface of the spheres. This closely 
resembles the situation that can be expected shortly after implantation of these spheres 
in a patient. Already after 8 hours significant numbers of cells are already on the 
microspheres with collagen while the non-modified microspheres did not accommodate 
cells.  
 
 
Figure 6. (A) Photograph and (B) Micrograph of microspheres on a cell layer before and after 
flushing with medium. Note that the collagen modified microspheres remain attached to the cells. 
(C,D) SEM pictures of collagen modified microspheres on top of a cell monolayer, demonstrating 
cells that migrated onto the spheres in 24 hours. 
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The difference between modified and non-modified microspheres was even more 
pronounced after 24 hours, when the spheres with collagen were coated with a nice 
layer of cells. Subsequently the attachment of the collagen microspheres on the cell 
layer was demonstrated by the experiment depicted in Figure 6. Cells without collagen 
were almost directly flushed off the cell layer, while the collagen modified spheres 
remained attached to the cells, also after extensive flushing with medium. The 
microscopically analysis demonstrated that cells grew onto the microspheres (Figure 6 
C and D). No control microspheres were analyzed by SEM in this experiment because 
none of these spheres remained attached on the cell layer during the flushing with 
medium and all the washing and dehydration procedures that were necessary to prepare 
the samples for SEM analysis. 
The data presented here clearly demonstrate that the chosen strategy of covalently 
coupling collagen to microspheres will result in a rapid and efficient attachment of cells. 
In earlier reports from our group, we reported protein attachment to microspheres that 
carry carboxylic groups on their surface [25,26]. To these spheres, proteins were 
attached using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) chemistry. The disadvantage is that these toxic chemicals 
may persist in the spheres. Also it is more difficult to perform protein attachment to 
carboxylic groups, since reaction time, concentration of the reactants, and the density of 
surface groups are much more critical and more difficult to control. The attachment of 
proteins to the aldehyde groups is relatively simple since the only requirement is that 
protein has to be dissolved in a buffer of alkaline pH (> 9.0) and no additional reactants 
are required. The reaction time has not been determined exactly, but merely several 
hours are required for efficient protein attachment. The reduction of the formed Shiff 
base by borohydride is the only addition of a potential toxic chemical. The borohydride 
is easily washed away and can be degraded by heating, so no more borohydride will be 
left after the incubation. The MTT analysis clearly shows that the microspheres are non-
toxic. Also some pilot experiments with protein attachment without the borohydride 
treatment were performed and no significant difference was observed (data not shown). 
All the results demonstrate that microspheres containing acrolein are easy to produce 
and that attachment of protein to the surface is straightforward and can be performed 
under mild conditions. 
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Concluding remarks 
The here synthesized iodine-containing microspheres combine radiopacity and possible 
surface biofunctionalization. The currently used polymeric microspheres are radiolucent 
and also have a tendency to migrate throughout the patient after injection. Attachment 
of proteins to the acrolein containing radiopaque microspheres can be performed under 
easily controlled mild conditions. Covalent coupling of the extra-cellular matrix 
component collagen I strongly enhanced the interaction of the microspheres with a cell 
layer in vitro. The collagen-spheres attached strongly to a monolayer of fibroblasts 
grown on a glass cover slip. Furthermore, cells migrated rapidly onto these 
microspheres when compared to non-modified polymeric microspheres. A careful 
extrapolation of these results may indicate that the microspheres with coupled collagen 
will show improved anchoring in the tissue after injection. These bifunctional 
microspheres may therefore present a significant improvement in polymeric particles 
that can be used as filler or bulking agent. 
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Abstract 
Polymeric particles currently used for embolization procedures have the disadvantage 
that they are radiolucent, i.e., invisible on X-ray images, and consequently the 
interventional radiologist has to resort to angiography to (indirectly) monitor the fate of 
the particles. Here, we introduce intrinsically radiopaque hydrophilic microspheres. 
Since these microspheres can directly be visualised on X-ray images, using these 
microspheres for embolization purposes will allow super-precise location of the embolic 
material, both during and after the procedure. The microspheres, which are prepared by 
suspension polymerisation, are based on the radiopaque monomer 2-[4-iodobenzoyl]-
oxo-ethylmethacrylate and hydroxyethylmethacrylate and/or 1-vinyl-2-pyrrolidinone as 
hydrophilic component. It has been shown that for clinically relevant X-ray visibility 
the spheres should contain at least 20 wt% iodine. At this iodine content, 
copolymerisation with HEMA results in spheres that hardly imbibe water (EQ = 1.08). 
By replacing HEMA by NVP, the volume swelling ratio can be significantly increased 
(to 1.33).  
 
Introduction 
Artificial emboli are used by interventional radiologists in minimally invasive 
procedures to occlude vascular malformations (AVM’s) and tumour-feeding blood 
vessels [1-3]. Commercially, liquid or particulate emboli, both natural and synthetic, are 
used to obtain vascular occlusion [4]. The choice for a specific material depends on 
many factors, like the type of lesion to be treated and the kind of catheter to be used. 
The focus of this article is on a new type of synthetic particulate embolization material.  
Hydrogels, e.g., polyvinylalcohol (PVA), are a very commonly used example of this 
type of emboli. Because of their hydrophilic nature, PVA particles are soft and 
compressible, and as a result they perform better in vascular occlusions than rigid 
particles [5]. Originally, PVA particles were irregular in shape, but over the years 
preparation methods have improved, leading to the synthesis of spherical particles. The 
advantage of a sphere is that it is uniform in shape, which implies that the size is much 
better calibrated than that of a three-dimensional irregularly shaped particle. The 
combined benefit of particles that are both hydrophilic and spherical in shape is that 
they allow a simple transcatheteral introduction without aggregation of particles, and a 
geometrically better blocking of the vascular lumen is obtained [6,7].  
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A disadvantage of PVA microspheres and all other commercially available artificial 
particulate emboli is that they are radiolucent, i.e., they are invisible on X-ray images. 
However, to prevent incorrect positioning of the spheres, resulting in complications 
such as ‘reflux with non-target embolization’ and ‘through embolization’, permanent 
surveillance of the embolization procedure is necessary. A solution that is clinically 
applied is monitoring by angiography, which implies that the radiolucent spheres are 
dispersed in contrast medium [7]. This indirect method of visualisation has the 
disadvantage that in case of inhomogenous dispersion of the particles, the contrast 
medium passes more distally into the vascular bed than the particles and as such does 
not provide information about the position of the particles. Another disadvantage is that 
the contrast medium is cleared quickly from the place of injection, so postoperatively no 
information about the position of the particles can be obtained.  
Based on these shortcomings, the challenge is to prepare hydrophilic microspheres that 
are intrinsically radiopaque, which will allow exact location of the embolic material, not 
only during the embolization procedure, but also afterwards. 
The unique feature of intrinsic radiopacity has been introduced more than one decade 
ago [8-13]. Since then, several applications of these types of polymers have been 
suggested and studied [12-22]. Different syntheses of intrinsically radiopaque 
microspheres have been described in literature. For embolization purpose, both 
hydrophobic [20-22] and hydrophilic microspheres [12-14] have been proposed. For the 
latter, two types of microspheres are described: (i) polyhydroxyethylmethacrylate 
(PHEMA) microspheres for which the surface has been modified with an iodine-
containing radiopaque compound [12,13], (ii) porous radiopaque microspheres, 
prepared via copolymerisation of hydroxyethylmethacrylate (HEMA) and an iodine-
containing monomer [14]. The disadvantage of (i) is that desired properties like 
hydrophilicity and softness are largely lost due to the surface modification. The 
disadvantage of (ii) is that due the porosity of the microspheres, relatively high amounts 
of iodine are required to render the particles radiopaque and these results in the 
formation of some irregular particles and agglomerates during polymerisation [14]. 
Furthermore, the required high amount of iodine also diminishes the hydrophilic 
character of the material. 
Recently, we started the development of intrinsically radiopaque non-porous 
microspheres, which are based on the iodine-containing methacrylic monomer (2-[4-
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iodobenzoyl]-oxo-ethylmethacrylate (4IEMA)). This monomer was copolymerised with 
HEMA and/or 1-vinyl-2-pyrrolidinone (NVP) to render the microspheres hydrophilic. 
This article describes the preparation of this new type of intrinsically radiopaque 
microspheres and their most relevant physical-chemical properties, such as composition, 
size and size distribution, swelling capacity, cytocompatibility and X-ray contrast.  
 
Materials and Methods 
Preparation of radiopaque hydrogel microspheres 
All microspheres were based on the radiopaque iodine-containing monomer 2-[4-
iodobenzoyl]-oxo-ethylmethacrylate (4IEMA, Figure 1). As published previously, this 
monomer was prepared from 4-iodobenzoylchloride and distilled HEMA in a one-step 
esterification reaction [23].  
 
O
O
O
O
I
 
Figure 1. Structural formula of 4IEMA. 
 
To obtain hydrophilic microspheres, this hydrophobic monomer was reacted with 
HEMA, NVP or a combination of HEMA and NVP.  Both HEMA and NVP were 
purchased from Acros (Landsmeer, the Netherlands) and purified by distillation under 
reduced pressure before use.  
A range of microspheres with an iodine content of 10, 15 or 20 wt% has been prepared 
via suspension polymerisation, following a recipe of Jayakrishnan et al [24]. The 
dispersion medium, consisting of 70 mL distilled water, 14.64 g sodium chloride (NaCl) 
and 2.00 g magnesium chloride hexahydrate, was heated in a 250-mL 3-neck round 
bottom flask to 70 °C. At this temperature 0.78 g sodium hydroxide dissolved in 15 mL 
water was added dropwise under mechanical stirring (200 rpm), resulting in clouding of 
the solution by precipitation of magnesium hydroxide (Mg(OH)2), the suspension 
stabiliser. The dispersion medium thus contained 17 wt% NaCl and 0.67 wt% Mg(OH)2. 
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For the preparation of HEMA/4IEMA spheres with 20 wt% iodine, [NaCl] was lowered 
to 11.6 wt% and [Mg(OH)2] was increased to 1.2 wt%. 
After complete addition of the sodium hydroxide solution, the temperature was further 
raised to 75-80 °C. At this temperature, a homogeneous mixture of 20 g monomers and 
80 mg initiator (2,2'-azobis(isobutyronitrile)) was added dropwise. Subsequently, the 
temperature was increased to 85 °C and the reaction mixture was kept at this 
temperature for 4.5 h, while stirring was maintained at 200 rpm. In case of NVP-
containing microspheres, the reaction was further continued overnight at 55 °C. For 
spheres containing solely NVP as hydrophilic component, 3 mol% crosslinker 
(allylmethacrylate) was added to the homogeneous mixture of monomers.  
 
Table 1. Coding, composition, yield of synthesis and equilibrium volume swelling ratio (EQ) of 
radiopaque microspheres. 
 
Code (1) Monomer ratio (wt/wt) wt% iodine Yield 
Synthesis 
EQ (2) 
 
H100_10 HEMA/4IEMA 71.6/28.4 10 84% 1.27±0.03 
H100_15 HEMA/4IEMA 57.4/42.6 15 82% 1.18±0.03 
H100_20 HEMA/4IEMA 43.2/56.8 20 81% 1.08±0.01 
H50_N50_10 HEMA/NVP/4IEMA 35.8/35.8/28.4 10 84% 1.99±0.14 
H50_N50_15 HEMA/NVP/4IEMA 28.7/28.7/42.6 15 86% 1.33±0.02 
H50_N50_20 HEMA/NVP/4IEMA 21.6/21.6/56.8 20 86% 1.16±0.02 
N100_10 NVP/4IEMA 71.6/28.4 10 81% 2.16±0.07 
N100_15 NVP/4IEMA 57.4/42.6 15 82% 1.87±0.07 
N100_20 NVP/4IEMA 43.2/56.8 20 81% 1.33±0.03 
 
Note (1) Coding of the samples HxNy_z: x and y denote the weight percentage HEMA and NVP 
respectively of the hydrophilic part of the microspheres; z denotes the weight percentage iodine of 
the microspheres. (2) per composition 8 spheres were measured to determine EQ. 
 
In all cases, diluted hydrochloric acid was added to the reaction mixture after cooling to 
room temperature to dissolve the stabiliser. The spheres were washed five times with 
distilled water and dried under vacuum. 
Table 1 depicts the composition of the different spheres that have been prepared. 
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Size distribution  
Photomicrographs of the spheres were taken using a Nikon optical microscope. Per 
composition, the diameter of at least 500 spheres was measured to determine the 
number-averaged sphere size. Afterwards, the beads were sieved in fractions of well-
defined sizes (< 90 µm, 90 – 200 µm, 200 – 300 µm, 300 – 425 µm, 425 – 600 µm, 600 
– 800 µm, 800 – 1000 µm, > 1000 µm). 
 
Swelling  
The volume swelling ratio (Q) of the spheres was determined as follows: A single 
sphere was immersed in water and at fixed time points an image of the sphere was taken 
with the fluorescent microscope. Subsequently, the diameter of the sphere was 
measured and the volume was calculated, assuming perfect spherical geometry. (E)Q 
was calculated according to [25]:  
 
p
sw
V
VQ =       (Eq 1) 
 
where Vsw and Vp are the volume of the swollen and dry sphere respectively.  
 
Solid state NMR 
1H-decoupled 13C-NMR spectra were recorded on a Bruker DMX500 spectrometer with 
a 13C-NMR frequency of 125.13 MHz. A 4-mm magic-angle-spinning (MAS) probe 
head was used with sample rotation rates of 4-8 kHz. The radio-frequency power was 
adjusted to obtain 5 µs 90-degree pulses both for the 1H and 13C nuclei. 13C-NMR 
spectra were recorded by use of a Hahn-echo pulse sequence on swollen samples in 
CDCl3 with an interscan delay of 40-80 sec to obtain quantitative spectra for the 
copolymers and with an interscan delay of 5 sec to obtain qualitative spectra for both 
homopolymers.  
 
Cytotoxicity 
20,000 human microvascular endothelial cells (HMEC-1) were inoculated in each well 
of a 24-well plate. The cells were cultured at 37 °C/5% CO2 for 24 h before the 
microspheres were added. Microspheres were sterilised with UV light for 15 min and 
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subsequently added to the cells in such a way that estimated 20% coverage of the total 
area by spheres was achieved. Latex (Het Rubberhuis, Maastricht) was used as positive, 
toxic control and the negative control was a well with only cells and no spheres. After 3 
days of incubation, photographs of the cells were taken with a Leica DM-IL inverted 
microscope. 
 
In vitro X-ray visibility 
X-ray contrast of the spheres was determined on two different machines. The first was 
an Integris V5000, which is normally used in the hospital for angiography. The 
advantage of this machine is that the distance between the X-ray source and the detector 
can be varied, which increases the contrast of the X-ray image. For the current 
experiments, the machine was operated at 70-80 kV. The X-ray contrast of the spheres 
was also determined at a Philips BV Pulsera (C-bow), which is operated at 48 kV. This 
machine has a fixed (relatively) big distance (approx. 75 cm) between X-ray source and 
detector and is normally used for animal experiments.  
First, clusters of 5 spheres of defined size and iodine content were recorded on the 
Integris V5000. The next experiment was that 10 mg of spheres was placed in the soft 
tissue of a cadaveric chicken leg and images were recorded on both X-ray machines. 
The chicken leg was used as a model, to mimic a realistic situation, where surrounding 
tissue will also influence the X-ray visibility of the spheres.  
 
In vivo X-ray visibility 
A pilot study with a Yorkshire land race pig (30 kg) has been performed. This 
experiment was approved by the Maastricht University Experimental Animal 
Committee and the European and Dutch laws on animal experimentation were followed 
strictly. After anaesthetising by an intravenous injection of Pentothal, the pig was 
insufflated with a mixture of O2, N2O and isoflurane. A midline incision was made in 
the abdomen, the skin was opened and the fascia was carefully incised. A catheter was 
inserted in the aorta under the artery renali. Subsequently, the tip of the catheter was 
positioned in the renal artery and the skin and fascia were carefully closed again to 
ensure realistic absorption of X-ray by the surrounding tissue. Then the microspheres, 
dispersed in water, were injected via the catheter. During injection, the radiopacity of 
the spheres was tested with the C-bow. 
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Results and Discussion 
Synthesis of P(HEMA/4IEMA) microspheres 
A common technique for the preparation of microspheres is suspension polymerisation, 
with water as dispersion medium. Here, a concentrated salt solution is used as dispersed 
phase, to prevent dissolution of the hydrophilic monomers [24].  
In first instance, microspheres are prepared based on the radiopaque monomer 4IEMA 
and HEMA. Suspension polymerisation of the two monomers results for mixtures with 
28.4 or 42.6 wt% 4IEMA (i.e., 10 and 15 wt% iodine) in the formation of spherical 
particles and the yield of the reaction is always larger than 80%.  
 
 
Figure 2. HEMA/4IEMA microspheres containing 10 wt% iodine (H100_10): (a) optical 
micrograph, scale bar = 250 µm; (b) size distribution. 
 
Figure 2a depicts an example of such spheres (H100_10; see Table 1 for an explanation 
of the codes), while in Figure 2b the size distribution of these spheres is given. The 
average size of the spheres is 336 µm with a standard deviation of 132 µm. It is 
observed that with increasing 4IEMA content, the average sphere size increases 
(H100_15: average size 468 ± 130 µm). 
For spheres with 56.8 wt% 4IEMA (H100_20), the dispersion medium containing 17 
wt% NaCl and 0.67 wt% Mg(OH)2 even results  in the formation of agglomerates and 
big, non-spherical particles. Therefore, the [NaCl] is lowered to 11.6 wt% and the 
[Mg(OH)2] is increased to 1.2 wt%. Both changes induce smaller sphere sizes in case of 
PHEMA microspheres [24]. For H100_20, these reaction conditions result in the 
formation of spherical particles, with a large fraction > 600 µm in diameter.  For all 
compositions, a relatively broad size distribution of spheres is obtained. For use in 
embolization however, spheres of well-defined size are preferred, since this allows 
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selective embolization. Ultimately, embolization can be performed with a series of 
microspheres of well-defined size in such a way that first the capillaries at the periphery 
can be occluded, followed by occlusion of the larger feeding vessels. The broad size 
distribution obtained during suspension polymerisation gives the advantage that many 
different sizes of spheres are obtained. By sieving the spheres subsequently, narrow size 
distributions can be obtained. This method of sphere preparation thus results in a range 
of microspheres with different and well-defined sizes. 
 
Swelling of P(HEMA/4IEMA) microspheres 
Figure 3 shows a representative swelling curve for H100_10. Equilibrium in swelling is 
assumed when the diameter of the sphere maintains constant for at least 2 h. For this 
typical example, equilibration is reached in 2 h. It should be noted that the time to 
equilibrium swelling (EQ) is dependent on the initial sphere diameter, which varies for 
all experiments. Therefore, only EQ of the different spheres will be compared and the 
time to reach EQ is not taken into account. For H100_10, H100_15 and H100_20, EQ 
decreases from 1.27 to 1.18 and 1.08 respectively (see also Table 1). 
Figure 3. Volume swelling ratio Q of H100_10 (initial sphere diameter = 573 µm). 
 
Synthesis and swelling of P(HEMA/NVP/4IEMA) microspheres 
In an attempt to obtain higher EQs, also microspheres containing a combination of 
HEMA and NVP as hydrophilic component have been prepared. NVP, which is also 
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used already in biomedical applications, is more hydrophilic than HEMA and therefore 
microspheres based on a combination of both monomers are anticipated to be more 
hydrophilic.  
 
Figure 4. EQ dependence as function of the composition of the hydrophilic component of 
microspheres. 
 
Figure 4 depicts EQ as function of the composition of the hydrophilic component, i.e., 
the ratio NVP/HEMA, for spheres with 10 wt% iodine. From this figure it is clear that 
changing the hydrophilic component from pure HEMA to a mixture of HEMA and NVP 
significantly increases EQ. Also spheres with 15 and 20 wt% iodine are prepared and 
their equilibrium swelling ratio is compared tot that of spheres with 10 wt% Iodine in 
Table 1. From this table it is clear that for all iodine contents a significant increase in 
EQ is obtained by (partially) replacing HEMA by NVP. 
 
Solid state NMR of P(NVP/4IEMA) microspheres 
Previous work in our group on intrinsically radiopaque hydrogels for nucleus pulposus 
replacement has demonstrated that the reactivity of 4IEMA and HEMA is comparable, 
resulting in the formation of random copolymers. It has also been shown that 4IEMA is 
far more reactive than NVP (e.g., for the copolymerisation of 4IEMA with NVP we 
found r4IEMA = 5.4 and rNVP = 0.04) [19]. As a result, copolymerisation of NVP with 
4IEMA results in the formation of PVP oligomers at the end of the polymerisation 
reaction, which dissolve upon immersing the xerogel in water. By using a few mol% 
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allylmethacrylate, which couples vinyl to methacrylate monomers, as crosslinker, this 
problem could largely be overcome [26]. Based on this knowledge, we use 3 mol% 
allylmethacrylate for the preparation of NVP/4IEMA microspheres Magic–angle 
spinning 13C NMR has been performed on the materials swollen in CDCl3 to determine 
the ratio of the built-in monomers. First, spectra of the homopolymers PVP and 
P4IEMA are measured for qualitative information about peak positions (Figure 5).  
 
Figure 5. MAS 13C NMR Hahn-echo spectra. 
 
Reasoning that single, narrow peaks are preferably used for composition calculations, 
the ratio of the carbonylic peaks at 167 ppm (solely 4IEMA) and 177 ppm (both NVP 
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and 4IEMA) will be used to calculate the fraction built-in 4IEMA in the copolymers. 
Figure 5 also displays the Hahn-echo spectra of N100_15 and N100_20. The ratio of the 
peaks at 167 and 177 ppm is 0.25 and 0.38 respectively. These values reveal a mass% of 
built-in 4IEMA of 52.3 and 66.5 respectively. The mass% of 4IEMA in the monomer 
mixtures of both microspheres is 42.5 and 56.8 respectively. Assuming that all 4IEMA 
of the monomer mixture is built-in (due to its higher reactivity) and some NVP 
dissolved during synthesis and/or washing of the microspheres, it can be calculated that 
for both types of microspheres approx. 65% of the NVP in the monomer mixture is 
incorporated in the microspheres. This confirms our previous findings that some of the 
NVP dissolves in the water phase during synthesis and/or washing of the microspheres.  
 
Cytotoxicity 
To establish the cytotoxicity of the microspheres, endothelial cells are incubated with 
three different types of microspheres and after 3 days of incubation photographs are 
taken (Figure 6).  
 
 
Figure 6. Cytotoxicity of microspheres: direct contact with endothelial cells. 
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Around the surface of all microspheres no inhibition layer of cells can be observed; i.e., 
the microspheres do not effect cell proliferation. Also by comparing the morphology of 
the cells in presence of spheres to that of the control sample no adverse effect on the 
morphology of the cells can be observed. The cytocompatibility of these microspheres 
is corroborated by earlier studies of our group, where discs of comparable hydrogels 
have been implanted subcutaneous in mice [27]. These studies showed that the 
hydrogels were well tolerated and no signs of severe adverse reactions of the 
surrounding tissue were observed. 
 
In vitro X-ray contrast  
Reasoning that a high water content is good for compressibility, spheres with a high 
fraction of hydrophilic monomers would be the preferable choice for use in 
embolization. However, these spheres also have the lowest content of iodine, which 
implies that they will be the least visible on the X-ray image. So, a compromise between 
compressibility and X-ray visibility will have to be made. First, the X-ray visibility of 
single spheres is studied. By comparing the X-ray contrast of the different clusters of 
spheres as depicted in Figure 7a, it is clear that, as expected, the contrast increases with 
sphere size and iodine content. Subsequently, the X-ray visibility of the different 
radiopaque microspheres after injection in a chicken leg, purchased at a local 
supermarket, is studied. The chicken leg provides a cheap model which enables us to 
examine the particles under conditions that also allow imaging of soft tissue. Moreover, 
the contrast of the particles can be compared immediately to that of bone. Finally we 
use the chicken leg model to compare the X-ray images of the Integris V5000 system 
that is normally used for clinical angiography to that of the C-bow instrument (in our 
animal facility). For the images taken with the clinical X-ray machine (Integris V5000), 
clusters of spheres of all sizes and iodine content can be distinguished clearly, as is 
shown in Figure 7b and 7c, and the contrast of spheres with high iodine content (20 and 
15%) is superior to that of bone. 
When checking single spheres, which are lying slightly apart from the clusters, it can be 
concluded that for sphere sizes of 600 µm and larger, single spheres can be 
distinghuised for all three iodine content. For spheres in the range of 425-600 µm, it 
becomes more difficult to observe single spheres: only for H100_20, separate spheres 
are visible on the X-ray image. In the size-range of 300-425 µm, single spheres cannot 
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be distinghuised. By comparing the X-ray contrast of the spheres in the chicken leg to 
that of plain single spheres (Figure 7a), it can be concluded that the surrounding soft 
tissue of the chicken leg has not much influence on the contrast of the spheres.  
 
 
Figure 7. X-ray images of radiopaque microspheres: (a) single spheres, recorded at clinical 
conditions; (b),(c) 10 mg of spheres in a chicken leg, recorded at clinical conditions; (d) 10 mg of 
spheres in a chicken leg, recorded on the C-bow at 48 kV. 
 
Figure 7d demonstrates that on the X-ray images recorded with the C-bow, clusters of 
spheres can be distinguished, but for all sphere sizes single spheres are not visible. In 
other words, the resolution of the C-bow is lower than that of the Integris system. This 
is important to know since the in vivo experiments are evaluated with the C-bow 
instrument.  
 
 
 
New intrinsically radiopaque hydrophilic microspheres  
 125 
In vivo X-ray contrast  
Next, spheres of H100_20 are injected in the renal artery of a Yorkshire land pig. The 
injection is performed in 2 steps: First spheres in the size range 425-600 µm are injected 
and at a certain place in the artery they get stuck and as such block the blood supply to 
the tissue behind.  
Figure 8a shows the X-ray image (taken with the C-bow) of part of the kidney, where 
the spheres are assembled. The spheres can well be distinguished. Subsequently spheres 
with a diameter between 600 and 800 µm are injected in the same artery and they get 
blocked just behind the introduced occlusion. Figure 8b shows that the spheres line up, 
causing further occlusion of the artery. This preliminary experiment reveals that it is 
possible to induce blockage of an artery and follow this process in-situ by using 
intrinsically radiopaque microspheres. It is noted that these spheres can definitely be 
utilised in clinical conditions as well, where the resolution of the X-ray machine is even 
higher (vide supra).  
 
 
Figure 8. X-ray image of H100_20 spheres injected in a kidney of a pig, recorded on the C-bow 
at 48 kV: (a) spheres of 425-600 µm; (b) spheres of 600-800 µm. 
 
Discussion 
A variety of microspheres have been proposed for use as embolization material, but 
most of the spheres are not widely used or commercially available. The ones that are 
commercially available all lack radiopacity and clinically only indirect routes are used 
to overcome this problem (vide supra). The current research clearly demonstrates that 
the use of intrinsically radiopaque microspheres enables visualisation of the 
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embolization material itself and the X-ray visibility of single spheres increases with 
iodine-content and sphere size. In case of clusters (of equal weight) of spheres, the 
iodine content is the only determining factor for X-ray visibility.  
The question whether clusters of spheres or single spheres should be distinguishable is 
determined by the intended application. Also the size of spheres that are used is very 
much dependent on the type of lesion. In cases where distal embolization is desirable, 
e.g., the preoperative treatment of meningiomas, small spheres will be the most 
effective and in clinical practice mostly spheres in the range of 50-300 µm are used 
[7,28,29]. For more proximal embolization, as is e.g., the case in the treatment of 
uterine fibroids, larger particles (500-900 µm) are mostly applied [30].  
The first pilot experiments with a pig indicate that for clinically relevant X-ray visibility 
of individual spheres, the microspheres should at least contain 20 wt% iodine, though it 
should be remembered that the visibility is also very much dependent on the X-ray 
machine that is used.  
 
Conclusions 
Intrinsically radiopaque hydrophilic microspheres have been successfully prepared via 
suspension polymerisation. It has been shown that for clinically relevant X-ray visibility 
the spheres should contain at least 20 wt% iodine. Spheres from 425 µm and larger can 
then be distinguished as single spheres. At this iodine content, copolymerisation with 
HEMA results in spheres that hardly imbibe water (EQ = 1.08). By replacing HEMA by 
NVP, the water content of the spheres can be significantly increased to 1.33.  
The advantage of the new microspheres over commercially available embolization 
particles is that the fate of spheres can be monitored using X-ray fluoroscopy, which 
provides an important improvement over commercially available microspheres. It 
enables the interventional radiologist to determine precisely the site of injection and the 
amount of spheres that he/she wants to inject to obtain sufficient occlusion without the 
risk of migration as would be the case when too many spheres would be injected. A 
further advantage is that also post-operatively the position of the spheres can be 
determined radiographically. 
During the last decades, techniques for imaging have improved significantly (in 
particular CT), while the materials used for embolization have hardly refined. Here we 
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introduced a new, improved type of embolization material, which creates freedom for 
design and application: radiopacity, swelling and sphere size can all be varied. 
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Summary 
A variety of minimally invasive therapies was introduced during the last 2 decades. The 
most prominent example may be endovascular stenting, e.g., coronary or carotid 
arteries. Other developments are: (i) catheter-based specific embolization of solid 
tumors or aterio-venous malformations, or (ii), use of synthetic bulking agents to 
augment soft tissues, e.g., in cosmetic surgery or as a treatment of stress urinary 
incontinence (SUI). In fact, marked improvements in imaging methods, notably X-ray 
fluoroscopy and X-ray based computed tomography, have opened the ways to these new 
therapies. Besides, equipment and methods for catheterizations improved dramatically. 
This led, for instance, to novel guidewires with excellent steerability, and improved 
catheters with excellent properties such as flexibility, lubricity, etc. 
In 2003, at the onset of this research project, it seemed obvious that some of the new 
minimally invasive injection therapies were actually based on the use of archaic 
polymeric biomaterials. This was most certainly the case in embolotherapy which was 
(and in many cases still is) largely based on injection of irregular particles of poly (vinyl 
alcohol). Furthermore, it appeared that the biomaterial particles, used to treat SUI (such 
as microspheres from PTFE, silicone rubber, or carbon-coated zirconium dioxide) were 
far from ideal, as they showed either migration away from the site of injection, or 
excessive formation of granuloma. 
We reasoned that it should be possible to develop improved and more sophisticated 
microspheres for minimally invasive therapies, notably for SUI treatment and for 
different embolotherapies. First, we focused on radiopacity, i.e., microspheres were 
prepared from biocompatible and stable polymeric biomaterials that feature intrinsic 
radiopacity, due to incorporation of covalently bound iodine. This approach was in line 
with previous work from this laboratory, in which it was shown that iodine-containing 
poly(methacrylates) can be used in novel radiopaque implant materials, such as bone 
cements or biomimetic prostheses for the nucleus pulposus. Secondly, we focused on 
surface modification of the radiopaque microspheres, with the aim to either achieve 
improved anchorage in soft tissues (relevant for SUI treatment, since migration of 
injected bulking agent is unacceptable), or to impart bioactivity in the surface of the 
microspheres through immobilization of functional proteins. The thesis describes the 
preparation of new injectable microspheres with three functionalities: (i) they can be 
injected in soft tissues without inciting an inflammatory response, which is the basis for 
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soft-tissue augmentation, or they can be injected through a catheter in the arterial 
bloodstream leading to obstruction in a target blood vessel bed; (ii) the particles can be 
seen real-time on X-ray images, i.e., during injection but also afterwards; (iii) the 
particles can be decorated with functional proteins, such as collagen (which presumably 
will lead to improved anchoring of the particles in soft tissues), or thrombin, which 
turns on fibrin formation in blood almost immediately after injection of embolic 
particles. 
The data presented in chapter 2 demonstrate the possibility to create biocompatible 
microspheres that are intrinsically radiopaque. For this 2-[2’,3’,5’,-triiodobenzoyloxy] 
ethyl methacrylate (2,3,5-TIEMA) was copolymerized with methylmethacrylate 
(MMA) in bulk. Subsequently the copolymer was dissolved and added drop-wise to an 
aqueous solution containing detergent to create microspheres. These were shown to 
contain sufficient intrinsic radiopacity under standard clinical conditions in a chicken 
leg model. Also the spheres were shown to be injectable suspended in collagen and 
loaded in a syringe. A disadvantage of the solvent evaporation method used in this 
chapter may be that it is relatively inefficient for making microspheres that are larger 
than approx. 100 µm. It is however the best method to obtain spheres in the range of 10-
100 µm. 
The in vivo biocompatibility was studied by injection of the microspheres, suspended in 
collagen, into mice. The microspheres did not incite toxic or significant inflammatory 
responses. This result confirmed the data of an implant study in which rods of iodine-
containing copolymer were inserted subcutaneously into mice or rats. The microspheres 
however represent much more surface area and also the microspheres might migrate 
away from the site of injection. In chapter 3 it is shown that no obvious migration of the 
microspheres could be distinguished by X-ray 3 months after implantation. 
To fully avoid the problem of microsphere migration, the incorporation of spheres in the 
surrounding tissue would be the best strategy. For this, microspheres were prepared by 
suspension polymerization, so that larger spheres were obtained (chapter 4). These 
spheres were subsequently incubated under strong alkaline conditions at high 
temperatures. The surface ester groups slowly converted into carboxylic groups, which 
were used for chemical cross-linking of proteins. In chapter 4, cross-linking of an active 
enzyme, in this case alkaline phosphatase, is described. Also collagen could be linked to 
the surface of the microspheres. The possibility of linking proteins in their native, 
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active, conformation to the radiopaque microspheres demonstrated the bi-functionality 
of these spheres combining intrinsic X-ray visibility with surface bioactivity that can be 
tailored. In chapter 5 methacrylic acid (MAA) was added to the copolymer feed, so that 
a terpolymer containing 2-[4-iodobenzoyl]-oxo-ethylmethacrylate (4IEMA), MMA, 
MAA was obtained. The MAA content is of critical importance for the efficiency of 
protein coupling to the surface of these terpolymer microspheres. With low density of 
carboxylic groups, the coupling efficiency will be low because of low chance of a free 
amino group of the protein coming in close enough proximity of an activated carboxylic 
group on the sphere surface. In case of very high carboxylic density the chance of 
multiple point attachment of a single protein molecule to the surface is more likely than 
binding of a second protein molecule. Proteins that are bound to the surface by multiple 
links are most likely unable to change their conformation and are thus rendered inactive. 
It is therefore vital to closely control the monomer feed prior to the suspension 
polymerization and invest time into the optimization of microsphere composition.  
For application of radiopaque microspheres in embolization therapy, the 
functionalization of the surface with coagulation enzymes might lead to a more rapid 
and complete blockage of the artery (chapter 5). For this purpose thrombin, the central 
enzyme of the coagulation cascade, was linked to the microspheres. These thrombin-
spheres rapidly induced the formation of a fibrin clot and also accelerated additional 
generation of thrombin in the surrounding blood. Microspheres carrying active enzymes 
may have a range of possible applications in minimally invasive treatments. Also they 
may help in setting up models for occlusive diseases like stroke. In the near future 
microspheres carrying thrombin will be tested for their ability to induce stroke in a rat 
model, especially to induce strokes reliably and of a constant size and severity. Also for 
haemoptysis, i.e., severe bleedings after trauma or infection, these microspheres that 
induce rapid blood clotting may be of use to manage the bleeding and reduce blood loss. 
In chapter 6 microspheres are described that eliminate the need for cross-linking 
chemicals. The chemicals that are required for protein cross-linking (EDC and NHS) 
can be toxic since they may still be active upon activation. Although this risk is very 
small with the microspheres presented here, terpolymer microspheres were produced 
that contain surface aldehyde groups that react with free amino-groups (lysine residues) 
under mild alkaline conditions. The data clearly demonstrate that this strategy can work, 
however the linking of active enzymes was not successful yet. Cross-linking collagen I 
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to the surface greatly improved the interaction of cells with the surface of the spheres. 
These collagen coated microspheres are therefore well suited as bulking agent and filler, 
because the chance of migration is much reduced, since cells of the surrounding tissue 
will grow onto the spheres and cover these with extra-cellular matrix. The collagen 
linked to the microspheres will get entangled with collagen from the extra-cellular 
matrix, preventing migration of the spheres. 
The microspheres described in the chapters 2-6 are all hard and stiff. In chapter 7 the 
synthesis of hydrogel microspheres is described. These spheres are designed to take up 
water so that the spheres are compressible. This makes the microspheres especially well 
suited for injection into the blood stream via a catheter. Also swelling of the 
microspheres in situ will diminish the chance of the spheres dislodging. One could state 
that these microspheres first get stuck in the artery, block blood flow, swell and anchor 
themselves tightly into the vessel wall. The prospect of such hydrogel spheres with 
proteins attached to their surface is exciting. For instance collagen coated microspheres 
may result in rapid coagulation. Especially platelets can get activated on the surface of 
such spheres, inducing the normal formation of a blood clot, further stabilizing the 
block of the artery. 
This thesis research work shows that substantial technical improvements in injectable 
polymeric microspheres were realized. Further experimentation in large representative 
animal models is mandatory to precisely investigate the potential utility of such 
particles. It seems that the feature of intrinsic radiopacity is a valuable asset, in view of 
the existing X-ray based methods for (real-time) in vivo imaging. Moreover, it is now 
obvious that particles for use in different injection therapies can be decorated with 
active proteins. This enables us to translate basic knowledge in physiological 
mechanisms, such as blood coagulation, into improved therapeutical tools, which is the 
objective of what is currently known as translational medicine. 
Samenvatting  
 135 
Samenvatting 
Gedurende de afgelopen decennia zijn er verschillende nieuwe minimaal-invasieve 
operatie- en behandelmethoden ontwikkeld. Het meest in het oog springende voorbeeld 
is wel het plaatsen van endovasculaire stents in de kransslagader, via een kleine ingang 
in de bovenbeenslagader. Andere ontwikkelingen op dit gebied zijn: (i) specifieke 
embolisatie van tumoren of aterio-veneuze malformaties met behulp van catheterisatie 
technieken, of (ii) het verstevigen van zachte weefsels door injectie van opvulmiddelen 
in de cosmetische chirurgie (opspuiten van rimpels of acne littekens) of ter behandeling 
van stress incontinentie. De grote verbeteringen in imaging technieken zoals Röntgen 
diagnostiek en computertomografie (CT scan) hebben de opkomst van deze nieuwe, 
minimaal-invasieve methoden mogelijk gemaakt. Daarnaast heeft de sterke verbetering 
van instrumenten bijgedragen om catheterisatie technieken te optimaliseren. Dit heeft 
onder meer geleid tot betere voerdraden, en tot verbeterde catheters met uitstekende 
eigenschappen betreffende flexibiliteit, gladheid, enz. 
Toen in 2003 begonnen werd met dit onderzoeks-project, was het duidelijk dat sommige 
van de nieuwe minimaal-invasieve methoden nog steeds gebruik maken van archaische 
polymere biomaterialen. Dit was het meest duidelijk voor embolisatie-therapie waarbij 
destijds (en vaak nog steeds) onregelmatig gevormde poly(vinyl alcohol)-deeltjes 
werden geinjecteerd in patiënten. Bovendien bleek dat de deeltjes die gebruikt werden 
als opvulmiddel om bijvoorbeeld stress incontinentie te behandelen (zoals 
microbolletjes van Teflon (poly(tetrafluoretheen); PTFE), siliconen rubber, of met 
koolstof bedekte zirconium-dioxide bolletjes) verre van ideaal zijn, omdat ze na injectie 
kunnen migreren of granulomas induceren. 
Onze hypothese was dat het mogelijk moest zijn om betere en meer geavanceerde 
microbolletjes te ontwikkelen voor minimaal-invasieve methoden, zoals de behandeling 
van stress-incontinentie en verschillende vormen van embolotherapie. Allereerst 
richtten we ons op Röntgenzichtbaarheid. Dit betekent dat bolletjes werden gemaakt van 
polymeren die stabiel en biocompatibel zijn en tegelijk intrinsieke 
Röntgenzichtbaarheid bezitten, doordat er covalent gebonden jodium in het polymeer 
werd ingebouwd. Deze aanpak sloot naadloos aan bij eerder werk van onze 
onderzoeksgroep. Hierin was reeds aangetoond dat jodium-houdende polymethacrylaten 
gebruikt kunnen worden als nieuwe Röntgenzichtbare implanteerbare materialen zoals 
botcement. Een ander voorbeeld betreft materialen die dienen ter vervanging van de 
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nucleus pulposus, de zachte kern van de tussenwervelschijf. Vervolgens richtten we ons 
op de modificatie van het oppervlak van deze Röntgenzichtbare microbolletjes, met als 
doel: (1) betere verankering in zacht weefsel te verkrijgen, dit is van belang wanneer de 
bolletjes als opvulmiddel bij de behandeling van stress incontinentie worden gebruikt 
aangezien migratie van de bolletjes onacceptabel is, of (2) specifieke bio-activiteit op 
het oppervlak te verkrijgen door middel van het koppelen van actieve eiwitten. In dit 
proefschrift is de ontwikkeling beschreven van nieuwe, injecteerbare microbolletjes met 
drie verschillende eigenschappen: (i) ze kunnen geinjecteerd worden in zacht weefsel en 
worden daarin goed geaccepteerd. Dit is een vereiste om succesvolle versteviging van 
het zachte weefsel te verkrijgen. Ook kunnen de bolletjes gericht door een catheter 
ingebracht worden in de arteriële bloedstroom om vervolgens een slagader te blokkeren; 
(ii) ze zijn zichtbaar op Röntgen beelden, zowel tijdens het injecteren als naderhand; 
(iii) hun oppervlak kan worden geactiveerd door het koppelen van actieve en 
functionele eiwitten, zoals collageen (wat zou kunnen leiden tot een betere verankering 
van de bolletjes in zachte weefsels), of trombine, wat zorgt voor vorming van 
bloedstolsels bijna direct na injectie in de bloedbaan. 
De resultaten beschreven in hoofdstuk 2 laten zien dat het mogelijk is om 
biocompatibele microbolletjes te maken die intrinsiek Röntgenzichtbaar zijn. Hiervoor 
lieten wij het zelf gesynthetiseerde 2-[2’,3’,5’-triiodobenzoyl]oxoethyl methacrylaat 
(2,3,5-TIEMA) reageren met methylmethacrylaat (MMA) in een bulk polymerisatie 
reactie. Het resulterende polymeer werd opgelost in chloroform en druppelsgewijs 
toegevoegd aan een oplossing van een detergent (zeep) in water om bolletjes te vormen. 
Men zou als nadeel van deze “solvent-evaporation” (oplosmiddel-verdampings) 
techniek kunnen aanmerken dat het relatief inefficient is om met deze methode 
microbolletjes te maken groter dan 100 µm. Het is naar onze ervaring de beste techniek 
om microbolletjes te verkrijgen tussen 10 en 100 µm. De hier verkregen microbolletjes 
bleken voldoende intrinsieke Röntgenzichtbaarheid te bezitten. Dit kon worden 
geïllustreerd met behulp van een realistisch model. Bovendien was het mogelijk om de 
bolletjes met een collageen suspensie te mengen zodat injectie met een normale 
injectiespuit werd vergemakkelijkt.  
De in vivo biocompatibiliteit van microbolletjes, gesuspendeerd in collageen, werd 
bestudeerd door deze te injecteren in muizen. De bolletjes bleken geen significante 
onstekingsreactie te induceren. Dit resultaat bevestigde eerdere bevindingen betreffende 
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implantatie van jodium-houdende polymere biomaterialen in muizen en ratten. De 
microbolletjes representeren echter een veel groter oppervlak en tevens kunnen ze 
(potentieel) weg migreren van de plaats van injectie. In hoofdstuk 3 laten we zien dat er 
geen tekenen van migratie van de microbolletjes konden worden waargenomen, noch 
via een Röntgen onderzoek, noch via histologie. 
Om het probleem van mogelijke migratie van microbolletjes te ondervangen, is de beste 
strategie om deze aan het omringende weefsel te binden. Hiertoe werden bolletjes 
gemaakt met zogenaamde suspensie-polymerisatie, zodat grotere bolletjes werden 
verkregen (hoofdstuk 4). Deze bolletjes werden vervolgens behandeld met base (KOH) 
bij hoge temperatuur (180 ºC). Onder deze omstandigheden verzepen de ester groepen 
op het oppervlak tot COOH-groepen, welke voor het covalent koppelen van eiwitten 
kunnen worden gebruikt. In hoofdstuk 4 staat beschreven hoe een actief enzym, in dit 
geval het alkalische fosfatase, werd gekoppeld aan de microbolletjes. Ook werd het 
eiwit collageen covalent aan het oppervlak van de bolletjes gekoppeld. De mogelijkheid 
om actieve eiwitten in hun natieve en ook actieve conformatie aan het oppervlak van 
deze Röntgenzichtbare bolletjes te koppelen toont de bi-functionaliteit aan, namelijk een 
combinatie van Röntgenzichtbaarheid en bioactief oppervlak dat naar wens kan worden 
aangepast. In hoofdstuk 5 werd methacrylzuur (MAA) aan de polymerisatie-reactie 
toegevoegd, zodat een terpolymeer van 2-[4-iodobenzoyl]-oxo-ethylmethacrylaat (4-
IEMA), MMA, en MAA werd verkregen. Het gehalte aan MAA bleek van cruciaal 
belang voor de efficientie van eiwit koppeling aan het oppervlak van deze polymere 
bolletjes. In het geval van een lage dichtheid carboxyl groepen op het oppervlak (laag 
MAA gehalte in de polymerisatie reactie), bleek de eiwitkoppeling niet erg efficiënt 
vanwege de kleine kans dat een vrije aminogroep van het eiwit een geactiveerde 
carboxyl groep op het oppervlak dicht genoeg zal benaderen. In het geval van een (te) 
hoge dichtheid van carboxyl groepen op het oppervlak zal de kans op meer-punts 
koppeling van het eiwit toenemen. Wanneer een eiwit eenmaal aan het oppervlak is 
gekoppeld, wordt de vorming van een tweede koppeling veel waarschijnlijker. Eiwitten 
die op meerdere punten aan het oppervlak vast zitten, zullen zeer waarschijnlijk geen 
mogelijkheid hebben hun conformatie te veranderen en zijn dientengevolge inactief. Het 
is dus belangrijk om de relatieve hoeveelheden van de monomeren (speciaal die van 
MAA) in de polymerisatie nauwkeurig te bepalen. 
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De koppeling van thrombine op het oppervlak van Röntgenzichtbare microbolletjes kan 
gunstig zijn m.b.t. embolisatie-therapie. Om dit te bestuderen werd trombine, het 
centrale enzym in de bloedstolling, aan de bolletjes gekoppeld (Hoofdstuk 5). Deze 
trombine-bolletjes induceerden een snelle aanmaak van fibrine op het oppervlak en 
versnelden ook de aanmaak van trombine in het omringende bloed. Microbolletjes met 
actieve enzymen op hun oppervlak zouden een reeks van mogelijke toepassingen in 
minimaal-invasieve behandelingen kunnen krijgen. Ook kunnen dit type bolletjes nuttig 
zijn bij het ontwikkelen van goede modellen voor trombotische aandoeningen. In de 
nabije toekomst zullen de trombine-bolletjes worden getest om te kijken of ze een 
gecontroleerde beroerte in ratten kunnen induceren. Ook voor hevige bloedingen, 
bijvoorbeeld na trauma of bij bepaalde longinfecties (tuberculose), kunnen dit soort 
microbolletjes, zeer nuttig zijn om de bloeding snel en lokaal te stelpen. 
In hoofdstuk 6 zijn microbolletjes gemaakt met aldehyde groepen op het oppervlak. 
Deze aldehyde groepen kunnen reageren met vrije amino-groepen (bijv. van lysine 
residuen van een eiwit) onder milde basische condities. De resultaten laten duidelijk 
zien dat deze strategie succesvol kan zijn, hoewel het koppelen van actieve enzymen 
nog niet gelukt is. Het koppelen van collageen type I aan deze bolletjes bevorderde 
adhesie en groei van cellen. Deze collageen-bolletjes lijken zeer geschikt als opvul-
biomateriaal omdat de kans op migratie sterk verminderd wordt. Dit komt omdat de 
cellen van het omliggende weefsel over de bolletjes heen groeien en ze zo met 
extracellulaire matrix eiwitten zullen bedekken. Het collageen van de bolletjes zal zich 
verstrengelen met het collageen van de extracellulaire matrix van het weefsel, en zo 
migratie van bolletjes voorkomen. 
De microbolletjes die worden beschreven in de hoofdstukken 2-6 hebben gemeen dat ze 
hard en hydrofoob zijn. In hoofdstuk 7 is de synthese van volledig nieuwe radiopaque 
hydrogel microbolletjes beschreven. Deze bolletjes zijn speciaal ontwikkeld om in situ 
water op te nemen zodat ze zwellen en samendrukbaar, worden. Dit maakt ze dan 
uitermate geschikt voor injectie in de arteriële bloedbaan via een catheter. Bovendien 
zal opzwelling van de microbolletjes in situ er toe leiden dat ze beter vast komen te 
zitten in het bloedvat. Hydrogel bolletjes die tevens actieve eiwitten exponeren op het 
oppervlak zullen een hele nieuwe klasse van uitermate interressante microbolletjes gaan 
vormen. Microbolletjes met een oppervlak van collageen zouden bijvoorbeeld ook 
kunnen leiden tot versnelde stolling via activatie van bloedplaatjes. 
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Het werk beschreven in dit proefschrift laat zien dat aanmerkelijke verbeteringen aan 
injecteerbare polymere microbolletjes gemaakt konden worden. Verdere experimenten 
in representatieve proefdier modellen zijn nodig om te onderzoeken wat de precieze 
toepasbaarheid van deze Röntgenzichtbare microbolletjes is. Het lijkt erop dat 
Röntgenzichtbaarheid een belangrijke toevoeging is. Bovendien is nu duidelijk dat aan 
de bolletjes (actieve) eiwitten gekoppeld kunnen worden, afhankelijk van de specifieke 
toepassing. Dit maakt het mogelijk om de kennis van fysiologische mechanismen, zoals 
bloedstolling, te vertalen naar betere en meer bruikbare therapeutische oplossingen. Dit 
is de primaire doelstelling van wat tegenwoordig bekend staat als translationele 
geneeskunde. 
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Краткое обозрение  
Широкий спектр минимально-инвазийных методов лечения нашел свое 
применение в практической медицине в последние годы. Наиболее ярким 
примером служит эндоваскулярное стентирование, например коронарных или 
сонных артерий. Другими разработками в этой области являются: (а) 
специфическая эмболизация опухолей или артериовенозных мальформаций; или 
(б) использование синтетических веществ для заполнения мягких тканей, 
например, в косметической хирургии или в урологии, для лечения стрессового 
недержания мочи (СНМ). В значительной мере совершенствование методов 
визуализации, в особенности рентгенологической флюороскопии и рентгеновской 
компьютерной томографии (КТ), способствовало развитию указанных новых 
методов лечения. Кроме того, произошло значительное улучшение оснащения и 
методов катетеризации, что в свою очередь привело к появлению лучше 
управляемых новых катетеров, а так же к улучшению таких качеств, как 
эластичность, скольжение и т.д. 
В 2003 году, когда наш проект только начинался, часть новых минимально-
инвазийных инъекционных методик была фактически основана на использовании 
архаичных полимерных биоматериалов. Этот подход находил наиболее широкое 
применение в случае эмболотерапии, которая в значительной степени была (и 
зачастую есть) основана на инъекции ассиметричных частиц поливинилалкоголя. 
Кроме того, частицы биоматериала, которые использовались при лечении СНМ 
(такие, как микросферы из Тефлона (политетрафторэтиле́н, ПТФЭ), силикона или 
покрытые углеродом частицы диоксида циркония) были далеки от совершенства, 
т.к. наблюдалась либо их миграция с места инъекции, либо формирование 
гранулемы.  
Мы предположили возможность создания более совершенных микросфер для 
минимально-инвазийных методов лечения, в особенности для различных 
эмболотерапий или лечения СНМ. В первую очередь мы сконцентрировались на 
улучшении рентгеноконтрастности микросфер. Так, микросферы были 
изготовлены из биосопоставимых и устойчивых полимерных биоматериалов, 
которые обладают внутренней рентгеноконтрастностью, благодаря наличию 
ковалентно-связанного йода. Этот подход был основан на предшествующих 
разработках нашей лаборатории, которые показали что йод-содержащие 
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поли(метакрилаты) могут быть использованы в новом рентгеноконтрастном 
имплантантном материале, таком как костный цемент или биомиметические 
протезы. Далее мы модифицировали поверхность рентгеноконтрастных 
микросфер с целью достижения улучшенной фиксации в мягких тканях (т.к. 
например, при лечении СНМ недопустима миграция инъецированного 
заполняющего вещества с места инъекции); или, достижения биоактивности 
микросфер путем фиксации функциональных протеинов на их поверхности.  
В данной дисертации описано изготовление новых микросфер с тремя 
функциями: 1) они могут быть инъецированы в мягкие ткани с целью их (тканей) 
укрепления не вызывая воспаления; или они могут быть введены с помощью 
катетера, в просвет кровеносного сосуда для его облитерации; 2) частицы можно 
идентифицировать рентгеновским лучом во время инъекции и в дальнейшем; 3) 
поверхность частиц может содержать функциональные белки, такие как коллаген 
(который предположительно повлечет за собой улучшение фиксирования частиц в 
мягкой ткани), или тромбин, который мгновенно индуцирует образование тромба 
в просвете сосуда, подвергнутого эмболизации. 
Представленные во 2 главе данные, показывают возможность создания 
биосовместимых рентгеноконтрастных микросфер. Для этого была произведена 
полимеризация 2-[2’,3’,5’,- трийодобензоилокси]этил метакрилата (2,3,5-TЙЭMA) 
с метилметакрилатом (MMA) в массе. Микросферы были образованы путем 
капельного добавления предварительно растворенного сополимера к раствору 
детергента в воде. Рентгеноконтрастность микросфер в стандартных клинических 
условиях была показана экспериментально в реальной модели. Микросферы 
также могли быть инъецированы после смешения с коллагеном и перенесения в 
специальный шприц. Недостатком этого метода (метода выпаривания 
растворителя), может быть то, что он сравнительно неэффективен для создания 
микросфер, размер которых более 100 µм. Однако, этот метод является лучшим 
для получения сфер размером 10-100 µм. 
Биосовместимость микросфер in vivo была изучена после инъекции 
суспензированных в коллагене микросфер мышам. Микросферы не вызвали 
токсических или других значительных инфекционных реакций. Эти данные 
подтвердили результаты исследований, в которых йод-содержащие полимерные 
стержни были имплантированы подкожно крысам или мышам. Микросферы, 
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однако, имеют большую площадь поверхности и могут перемещаться с места 
инъекции. В главе 3 показано отсутствие миграции микросфер на рентгеновских 
снимках, сделанных 3 месяца после имплантации. 
Лучшим решением проблемы миграции микросфер будет их интегрирование в 
окружающие мягкие ткани. Для достижения этой цели, микросферы большего 
размера были изготовлены суспензионным методом полимеризации (глава 4) и 
далее обработаны в сильной щелочной среде при высокой температуре. 
Находящиеся на поверхности эфирные группы были медленно преобразованны в 
карбоксильные, которые, в свою очередь, образовали химическую связь с 
белками. В 4-ой главе описано связывание активного энзима с микросферами. 
Коллаген так же может соединяться с поверхностью микросфер. Возможность 
связывания протеинов в их природной активной форме с микросферами 
указывает на биофункциональность этих сфер в частности, на комбинацию 
рентгенноконтрастности и наличия активной поверхности. 
В 5-ой главе метакриловая кислота (MAК) была добавлена к сополимеру, что 
привело к образованию терполимера содержащего 2-[4-йодобензоил]-оксо-
этилметакрилат (4ЙЭMA), MMA, MAК. Наличие MAК играет важную роль в 
успешном связывании протеина с поверхностью сфер. При низкой плотности 
карбоксильных групп, эффективность связывания с протеином низкая, т.к. 
вероятность того, что свободная аминогруппа протеина приблизится достаточно 
близко к карбоксильной группе на поверхности сферы, очень мала. В случае 
слишком высокой плотности карбоксильных групп, многоразовое связывание 
одной молекулы протеина на поверхности более ожидаемо, чем связывание 
нескольких молекул протеина. Формирование множественных связей протеина с 
поверхностью микросферы приводит к фиксации структуры протеина и потере 
его активности. Потому определение точного состава полимера важно для 
получения оптимальных микросфер. 
Возможность связывания энзимов, инициирующих свёртывание крови, с 
поверхностью рентгенноконтрастных микросфер, может стать преимуществом в 
эмболотерапии, т.к. возможна более быстрая и полная блокада артерии (глава 5). 
Для этого тромбин, являющийся центральный энзим свёртывающей системы, был 
связан с поверхностью микросфер. Полученные тромбо-сферы ускоряют 
генерацию тромбина, а так же образование сгустка фибрина в крови. Микросферы 
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- носители активных энзимов могут иметь широкое применение в минимально-
инвазийных методиках. Так же они могут быть полезны для воссоздания 
экспериментальных моделей заболеваний, развивающихся в результате закупорки 
сосудов, например инсульта. В ближайшем будущем тромбин - содержащие 
микросферы будут проверены на способность вызывать контролируемый инсульт 
у крыс. Другим применением этих микросфер может стать их использование при 
гемоптизисе, или кровотечениях во время травмы или инфекций, для скорейшей 
остановки кровотечения и предотвращения значительной кровопотери. 
В главе 6 описаны микросферы, не нуждающиеся в специфичных химикалиях для 
связывания с протеинами. Для этого были созданы микросферы с альдегидными 
группами на поверхности, которые могут реагировать со свободными 
аминогруппами протеина в слабой щелочной среде. Полученные результаты 
демонстрируют успешность выбранной стратегии, хотя осуществить связь с 
активными энзимами пока не удалось. Связанный с поверхностью микросфер 
коллаген I улучшил взаимосвязь клеток с поверхностью сфер. Такие покрытые 
коллагеном микросферы могут быть успешно использованы как заполнители, т.к. 
шанс их миграции мал, ввиду того что, клетки окружающей ткани будут расти на 
поверхности сфер, и покроют их внеклеточным матриксом. Связанный с 
поверхностью микросфер коллаген переплетется с коллагеном внеклеточного 
матрикса и предотвратит миграцию микросфер. 
Описанные в главах 2-6 микросферы твердые и неэластичные. В 7-ой главе 
описан синтез так называемых гидрогелевых микросфер. Эти сферы, впитывая 
воду in situ, приобретают эластичность и сжимаемость. Эти свойства делают 
микросферы подходящими для инъекции через катетер в артериальное русло. 
Разбухание микросфер in situ также уменьшит шанс смещения сфер. 
Микросферы, попадая в артерию, блокируют поток крови, разбухают и 
фиксируют друг друга в просвете кровеносного сосуда. Перспектива, создания 
таких гидрогелевых микросфер с привязанными к их поверхности протеинами, 
захватывающа. Так, покрытые коллагеном микросферы могут вызвать активацию 
тромбоцитов, что вызовет формирование тромба, и дальнейшее блокирование 
артерии. 
В тезисах этой исследовательской работы показано достижение существенного 
технического улучшения полимерных микросфер. Дальнейшие более масштабные 
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эксперименты на животных точно исследуют потенциал использования таких 
частиц. Предположительно, внутренняя рентгеноконтрастность является 
ценным свойством этих микросфер, с учетом существующих 
рентгеноскопических методов изображения. Более того, очевидно, что частицы, 
используемые при различных инъекционных терапиях, могут связываться с 
активными протеинами. Это дает возможность, используя знания 
физиологических механизмов, таких как свертывание крови, улучшить доступные 
терапевтические инструменты, что является целью, так называемой, 
транслативной медицины. 
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mokle mimoxilva 
ukanaskneli 2 ocwleulis ganmavlobaSi farTod gamoiyeneboda 
minimalur-invaziuri Terapiebis mravalsaxeoba. yvelaze 
TvalsaCino magaliTad SeiZleba moviyvanoT endovaskularuli 
stentireba, magaliTad koronaruri an saZile arteriebis. sxva 
gamovlinebebia: 1) kaTeterze dafuZnebuli simsivnis specifikuri 
embolizia an arTeriovenuri malformacia; an 2) rbili qsovilis 
ganviTarebisTvis sinTetikuri Semvsebi nivTirebebis gamoyeneba, 
magaliTad, kosmetikur qirurgiaSi an Sardis Seukavlobis 
mkurnaloba (SSm). faqtiurad, vizualizaciis meTodebis 
gaumjobesebam, gansakuTrebiT rentdgenuli fluoroskopiis an 
rentdgenuli kompiuteruli tomografiis (kt), xeli Seuwyo am 
axali Terapiebis ganviTarebas. garda amisa mniSvnelovnad 
gaumjobesda kaTeterizaciis meTodebi. aman ki, safuZveli Cauyara 
magaliTad iseTi samedicino saSualebebis gamoyenebas, rogoricaa 
axali kaTeterebi saukeTeso marTvis SesaZleblobebiT, da sxva 
gaumjobesebuli tipis kaTeterebi, romelTac gaaCniaT iseTi 
Tvisebebi, rogoricaa elastiuroba, sriali da a.S. 
2003 wels am proeqtis kvlevis dasawyisSi, ukve naTeli iyo, rom 
axali minimalur-invaziuri ineqciuri Terapiis procesi faqtiurad 
dafuZnebuli iyo arqauli polimeruli biomasalis gamoyenebaze. 
am faqts aucileblad hqonda adgili emboloTerapiis SemTxvevaSi, 
romelic mniSvnelovnad damokidebuli iyo (da xSir SemTxvevebSi 
dResac aris) asimetriul, uwesrigo poli(vinilalkoholi) 
nawilakebis gamoyenebaze. garda amisa aRmoCnda, rom biomasalis 
nawilakebi, romelic gamoiyeneboda SSm-is mkurnalobisas 
(rogoricaa teflonis (politetrafToreTilenis) da silikonis 
mikrosferoebi, an naxSirbadiT dafaruli cirkonis dioqsidis 
nawilakebi) Sors iyo srulyofilebisagan, radgan isini 
aCvenebdnen an ineqciis adgilidan gadaadgilebas, migracias, an 
granulomas gadaWarbebul formacias, Camoyalibebas. 
Cven vamtkicebdiT, rom SesaZlebeli iyo ufro srulyofili da 
gaumjobesebuli mikrosferoebis ganviTareba minimalur-invaziuri 
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TerapisaTvis, gansakuTrebiT SSm–is mkurnalobisas an sxvadasxva 
emboloTerapiebisaTvis. pirvel rigSi, Cven xazs vusvamdiT 
rentgenokontrastulobas, magaliTad, mikrosferoebi momzadda 
bioSeTavsebadi da myari polimeruli biomasalidan, romelsac 
axasiaTebs Sida rentgenokontrastuloba, kovalenturi iodis 
Serevis gamo. aseTi midgoma SesabamisobaSi modioda wina 
samuSaosTan, romelic am  laboratoriaSi mimdinareobda, 
romelmac aCvena, rom iodis Semcveli nawilakebi SesaZloa 
gamoyenebuli iqnas axal rentgenokontrastul implantur 
masalaSi, rogoricaa Zvlis cementi, Semavsebeli nivTiereba, an 
biomimeturi protezebi. Semdeg Cven yuradReba gavamaxvileT 
rentgenokontrastuli mikrosferoebis zedapiris modifikaciaze, 
romlis mizani iyo rbil qsovilebSi gaumjobesebuli fiqsaciis 
miRweva (SSm-is mkurnalobisas, radgan miuRebelia ineqcirebuli 
Semavsebeli nivTierebis gadaadgileba, migracia), da an 
funqcionaluri proteinebis fiqsaciiT mikrosferoebis zedapirze 
bioaqtiurobis miRweva. 
mocemul disertaciaSi aRwerilia sami funqciis matarebeli axali 
ineqciis mikrosferoebis momzadeba: 1) maTi ineqcia SesaZlebelia 
rbil qsovilebSi. Mmikrosferoebi ar iwveven anTebas, da 
aZliereben rbil qsovils; an maTi ineqcia SesaZlebelia 
kaTeteriT, arteriul sisxlsadinarSi, romelic mimarTulia 
sisxlZarRvis Sris obstruqciisken; 2) nawilakebis danaxva 
SesaZlebelia rentgenuli sxiviT; ineqciis dros da SemdgomSic; 3) 
nawilakebi SesaZloa iyos datvirTuli funqcionaluri 
proteinebiT, rogoricaa kolageni (romelic savaraudod 
gamoiwvevs nawilakebis fiqsirebis  gaumjobesebas rbil 
qsovilebSi), an Trombini, romelic TiTqmis dauyovnebliv 
inducirebs Trombis Camoyalibebas sisxlZarRvsSi, embolizaciis 
dros. 
2 TavSi warmodgenili monacemebi aCvenebs bioSeTavsebadi 
mikrosferoebis Seqmnis SesaZleblobas, romlebsac axasiaTebs 
Sida rentgenokontrastuloba. amisaTvis, 2-[2’,3’,5’,-samiodo 
mokle mimoxilva  
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benzoiloqsi]eTil meTakrilati (2,3,5, - siema) iyo polimizirebuli 
meTilmetakrilatTan (mma) ZiriTad nivTierebaSi, masaSi. 
Sesabamisad, polimeri gaixsna da daemata wveTovani gziT wylis 
xsnars, romelic Seicavs detergents, mikrosferoebis 
Camosayalibeblad.Mmikrosferoebis rentgenulkontrastuloba 
klinikur pirobebSi iyo naCvenebi realur modelze Catarebul 
eqsperimentSi.  arsebulma sferoebma aseve aCvena, rom kolagenTan 
arevis da specialur SpricSi gadatanis Semdeg SesaZlebelia maTi 
ineqcireba. am TavSi mocemuli meTodis (gamxsnelis aorTqleba) 
uaryofiTi mxare SesaZloa iyos is, rom is SedarebiT 
arasakmarisia mikrosferoebis Sesaqmnelad, romelTa zomebia 
daaxloebiT 100 µm-ze meti. miuxedavad amisa, es aris saukeTeso 
meTodi  10-100 µm zomis sferoebis misaRebad. 
bioSeTavsebadoba, in vivo, Seswavlil iqna kolagenSi suspenzirebul 
mikrosferoebis TagvebSi ineqciis Semdeg. mikrosferoebma ar 
gamoiwvia toqsikuri an sxva saxis mniSvnelovani anTebiTi 
reaqciebi. am monacemebiT  dadasturda implanturi kvlevis 
Sedegebi, romlis drosac iod Semcveli polimeruli Reroebi iqna 
Seyvanili kanqveS TagvebSi an virTxebSi. magram mikrosferoebs 
gaaCniaT didi zedapiruli farTi da SgeuZliaT gadaadgileba 
ineqciis adgilidan. me-3 TavSi naCvenebia, rom rentgenul 
suraTebze ar aris dafiqsirebuli mikrosferoebis gadaadgileba 
TagvebSi implantaciidan 3 Tvis Semdeg.  
imisaTvis, rom srulad iqnas Tavidan acilebuli mikrosferoebis 
migraciis problema, saukeTeso saSualeba iqneba garSemo qsovilSi 
sferoebis inkorporacia. amisaTvis, SedarebiT didi mikrosferoebi 
iqna momzadebuli suspenziuri polimerizaciis gziT (Tavi 4).  
Semdeg, es mikrosferoebi iqnen damuSavebuli tutiT, maRal 
temperaturaze. zedapirze arsebuli eTeris jgufebi etapobrivad 
gardaiqmneba karboqsilis jgufebSi, romlebic daamyareben  qimiur 
kavSirs proteinebTan. me-4 TavSi aRwerilia aqtiuri enzimis 
dakavSireba mikrosferoebTan. kolageni aseve SesaZloa 
ukavSirdebodes mikrosferoebis zedapirs. aqtiuri proteinebis 
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dakavSirebis SesaZleblobam aCvena am sferoebis biofunqcia. 
mikrosferoebs gaaCniaT ori Tvisebebis kombinacia: zedapiris 
aqtiuroba da  Sida rentgenokontrastuloba.  
me-5 TavSi meTakrilis mJava (mam) daemata kopolimers, raTa 
miRebul iqnas terpolimeri, romelic Seicavs 2-[4-iodobenzoil]–
oqso-eTilmeTakrilats (4iema), mma-s, mam-s. mam aris gansakuTrebiT 
mniSvnelovani monomeri proteinis dawyvilebisaTvis  
mikrosferoebis zedapirze. karboqsilis jgufebis dabali 
simWidrovis SemTxvevaSi, dawyvilebis efeqturoba iqneba dabali, 
radgan arsebobs dabali albaToba imisa, rom proteinis 
Tavisufali amino jgufebi miuaxlovdeba sferos zedapirze myof 
karboqsilis jgufebs. karboqsilis jgufebis maRali simWidrovis 
SemTxvevaSi zedapirze, proteinis molekulis mravaljeradi mibma 
ufro mosalodnelia, vidre sxva proteinis molekulis 
dakavSireba. proteinebs, romlebsac aqvT mravaljeradi kavSirebi 
zedapirTan, struqtura aqvT dafiqsirebuli da amitomac ar arian 
aqtiurebi. miuxedavad amisa, mniSvnelovania mkacri kontroli 
polimeris Semandgenelobaze, imisaTvis rom miviRoT optimaluri 
Semadgenlobis mikrosferoebi.  
embolizaciis Terapiis dros upirateseba eqnebaT rentgeno 
kontrastul mikrosferoebs, romlis zedapirze iqneba 
dakavSirebuli iseTi enzimi, romelic inicirebs sisxlis 
Sededebas, radgan SesaZloa gamoiwvios arteriis ufro swrafi da 
sruli blokada (Tavi 5). amisaTvis Trombini, koagulaciis 
kaskadis centraluri enzimi, dakavSirebuli iyo mikrosferosTan. 
es Trombo-sferoebi swrafad iwveven fibrinis formacias da 
agreTve aCqareben sisxlSi Trombinis generacias. aqtiuri enzimis 
matarebel mikrosferoebs SesaZloa minimalur invaziur 
mkurnalobaSi gaaCndeT farTo gamoyenebis SesaZlebloba. aseve 
SeiZleba maTi gamoyeneba daavadebis eqperimentaluri modelebis 
SesaqmnelaT, magaliTad insultis. axlo momavalSi Trombinis 
matarebeli mikrosferoebi Semowmdeba virTxaze, Tu ramdenad 
SeuZliaT kontrolebadi insultis gamowveva. hemoptizis 
mokle mimoxilva  
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SemTxvevaSi, magaliTad,  travmis an infeqciis Sedegad sisxldena, 
iseTi mikrosferoebi, romlebic iwveven sisxlis swraf Sededebas, 
SesaZloa gamoyenebuli iyos sisxldenis SesaCereblad da sisxlis 
danakargis Sesamcireblad.  
me-6 TavSi aRwerilia is mikrosferoebi, romlebic aRmofxvrian 
qimiuri nivTierebebis aucileblobas, romlebic saWiroa 
proteinebTan dasakavSireblaT. qimiuri nivTierebebi, romlebic 
saWiroa proteinTan dasakavSireblaT (eds da nhs), SesaZloa iyos 
toqsikuri, radgan isini SesaZloa kvlav aqtiurebi darCnen. 
miuxedavad imisa, rom riskis faqtori mcirea warmodgenili 
mikrosferoebis SemTxvevaSi, warmoiqmneba polimeruli 
mikrosferoebi, romlebic Seicaven aldehidis jgufebs zedapirze, 
romelebic ki msubuqi tutis pirobebSi reaqciaSi Sevlen 
proteinis Tavisufal amino jgufebTan. miRebuli Sedegebi mkafiod 
miuTiTebs imaze, rom SesaZlebelia am strategiis gamoyeneba, 
Tumca jer kidev warmatebulad ar ganxorcielebula aqtiuri 
enzimis dakavSireba. Mmikrosferoebis zedapirze dakavSirebulma I 
tipis kolagenma mniSvnelovnad gaaumjobesa ujredebis 
urTierToba sferoebis zedapirTan. amitomac, aseTi mikrosferoebi 
SeiZleba gamokendes rogorc Semavsebeli nivTiereba, radgan 
mniSvnelovnad aris Semcirebuli migraciis Sansi; garSemo 
qsovilis ujredebi gamravldebian sferoebis zedapirze da 
dafaraven maT eqstra-ujredovani matriqsiT. mikrosferosTan 
dakavSirebuli kolageni daukavSirdeba kolagens eqstra-
ujredovani matriqsidan , da es ar dauSvebs sferoebis migracias.  
me-2 da me-6 TavebSi aRwerili mikrosferoebi magari da 
araelastiuria. me-7 TavSi aRwerilia, egreT wodebuli,  
hidrogeluri mikrosferoebis sinTezi. am sferoebs axasiaTebs  
wylis Sewovis unari in situ, da es aZlevs SesaZleblobas gaxden 
elastiuri da kumSvadi. es ki aZlevs SesaZleblobas 
mikrosferoebis kaTeteris saSualebiT sisxlsadinarSi 
ineqcierebas. Mmikrosferoebis gadideba in situ, amcirebs maTi 
migraciis SesaZleblobas. eseTi mikrosferoebi jer Sedian 
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arteriaSi, blokaven sisxlis dinebas, diddebian da axdenen 
fiqsacias mWidrod sisxlZarRvze. arsebobs perspeqtiva aseT 
hidrogelur sferoebze proteinebis dakavSireba. magaliTad, 
kolageniT dafarul mikrosferoebs SeuZliaT gamoiwvion 
Trombocitebis aqtivacia, rac gamoiwvevs Trombis formirebas da 
Semdgom arteriis blokirebas.  
am kvelevis TezisSi naCvenebia, rom ZiriTadi teqnikuri miRwevebi 
ineqciuri polimeruli sferoebSi ukve ganxorcielda. Semdgomi 
ufro masStaburi eqsperimentebi cxovelebze zustad gamoikvlevs 
aseTi nawilakebis gamoyenebis potencials. savaraudod Sida 
rentgenulkontrastuloba didaT mniSvnelovani faqtoria, 
rentgenoskopiis arsebuli meTodebis gaTvaliswinebiT. ufro 
metic, aSkaraa, rom sxvadasva ineqciis Terapiebis dros 
gamoyenebuli nawilakebi SesaZloa aqtiur proteinebs 
daukavSirdnen. es saSualebas mogvcmes gadavitanoT Cveni codna 
fiziologiur meqanizmebis, rogoricaa sisxlis koagulacia, 
Terapiuli saSualebebis gasaumjobeseblad, rac warmoadgens 
mizans imisa, rasac amJamad translatiur medicinas uwodeben.
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